

# Index

Note: Page numbers in boldface type indicate major discussions. A *t* following a page number indicates tabular material, and an *f* following a page number indicates a figure.

- A**
- Abacavir, 863*f*, **869**, 870*t*, **872**, 888  
 drug interactions with, 874*t*
- Abatacept, **643**, 656, **993**, 993*f*, 999
- Abbokinase, 617. *See also* Urokinase
- Abbreviated new drug application (ANDA), 75–76
- Abciximab, 613, 994, 617, 999
- Abdomen, poisoning effects on, 1029
- Abelcet  
 properties of, 850*t*
- Abilify, 519. *See also* Aripiprazole
- Abiraterone, **710**, 738
- Abortion  
 eicosanoids and, 324
- Abreva, 888. *See also* Docosanol
- Abscess(es)  
 amebic liver  
 chloroquine for, 917
- Absence seizures, 421
- Absorption of drugs. *See also specific drugs*  
 bioavailability effects on, 43  
 in the elderly, 1052  
 in infants and children, 1044, 1044*t*  
 percutaneous, 1061, 1062*f*  
 pharmacokinetic mechanisms of, 1149  
 as pharmacokinetic variable, 47–48
- Abstinence syndrome, 549
- Abuse  
 alcohol  
 prevalence of, 389  
 prevention of  
 drugs in, 400  
 drugs of, **565–580**. *See also specific drugs and Drug abuse*
- Acamprosate  
 in alcoholism management, 397
- Acarbose, 766  
 for diabetes mellitus, 759
- Acceptable daily intake (ADI), 1002
- Accolate, 328, 355. *See also* Zafirlukast
- Accumulation factors, 43
- Accumulation of drugs, 42–43, 42*f*
- Accupril, 190, 225. *See also* Quinapril
- ACE inhibitors. *See* Angiotensin-converting enzyme (ACE) inhibitors
- Acebutolol  
 as antihypertensive drug, 179  
 preparations available, 167, 189, 249
- Aceon, 190, 225. *See also* Perindopril
- Acephen, 656. *See also* Acetaminophen
- Acetaldehyde  
 metabolism of, 390–391, 390*f*
- Acetaminophen  
 half-life of  
 in neonates and adults, 1045*t*  
 ionization constants of, 11*t*  
 metabolism of  
 to hepatotoxic metabolites, 60–61, 61*f*  
 oral absorption of  
 in neonates *vs.* older children and adults, 1044*t*  
 overdose of, **1032**  
 pharmacokinetic parameters for, 39*t*
- Acetazolamide, 257, 270  
 for epilepsy, **420**  
 ionization constants of, 11*t*
- 5-Acetylaminosalicylic acid  
 structure of, 1101*f*
- Acetylation, 60*t*
- Acetylcholine (ACh), 99*f*, 124*f*, 467*f*, 112  
 activation of endothelial cell muscarinic receptors by, 103, 103*f*  
 in ANS, ENS, and NANC neurons, 80*f*, 81*f*, 83*f*, 84*t*  
 as CNS neurotransmitter, 366*t*, 369  
 effects of, 92*t*  
 properties of, 99, 100*t*
- Acetylcholine-blocking drugs. *See* Antimuscarinic drugs
- Acetylcholinesterase (AChE), 84
- Acetylcysteine  
 as poisoning antidote, 1033*t*
- Acetylsalicylic acid, 656. *See also* Aspirin
- N*-Acetyltransferases (NATs), 60
- Acid(s). *See also specific types*  
 secretion of  
 physiology of, **1081–1082**, 1082*f*  
 weak  
 defined, 10  
 ionization of, 10–12, 11*t*, 12*f*, 12*t*
- Acid-peptic diseases  
 drugs used for, **1081–1091**
- Acid reducers  
 ingredients in, 1118*t*
- Acid secretion  
 physiology of, **1081–1082**, 1082*f*
- Acidity  
 intragastric  
 drugs for reducing, **1081–1089**
- Acidosis  
 anion gap  
 drug-induced, 1030, 1030*t*  
 metabolic. *See* Metabolic acidosis
- Aciphex, 1111. *See also* Rabeprazole
- Acitretin  
 for psoriasis, **1071**
- Acne preparations, **1069–1071**  
 ingredients in, 1118*t*  
 topical antibiotics, **1064–1065**
- Aconite  
 risks associated with, 1127*t*
- Acromegaly, 665  
 dopamine agonists for, 673
- Actemra, 656, 999. *See also* Tocilizumab
- ACTH. *See also* Adrenocorticotropic hormone (ACTH)
- Acthar Gel, 678. *See also* Corticotropin
- Acthrel, 678. *See also* Corticorelin ovine triflutate
- Actigall, 1112. *See also* Ursodiol
- Actimmune, 999
- Action potential(s)  
 resting potential effects on, 231–233, 232*f*, 233*f*, 233*t*
- Activase, 617. *See also* Alteplase recombinant
- Activated charcoal  
 in decontamination of poisoned patient, 1032
- Activated partial thromboplastin time (aPTT), 605
- Active cell membrane, 230–231, 231*f*
- Activin, 726
- Actonel, 786. *See also* Risedronate sodium
- Actos, 766. *See also* Pioglitazone
- Acute coronary syndrome, 193  
 clinical pharmacology of, 207
- Acute heart failure  
 management of, 222  
 sympathomimetic drug effects on, 144
- Acute mountain sickness  
 carbonic anhydrase inhibitors for, 257–258
- Acute pulmonary edema  
 opioid analgesics for, 553
- Acute renal failure  
 loop diuretics for, 259  
 potassium-sparing drugs  
 and, 263

- Acyclovir, 863*f*, 888  
dosage of, 865*t*  
for HSV and VZV infections, **862–864**,  
863*f*, 864*f*  
pharmacokinetic and pharmacodynamic  
parameters for, 39*t*  
topical, **1067**
- Adagen, 999. *See also* Pegademase bovine
- Adalat, 190, 209. *See also* Nifedipine
- Adalimumab, **647–648**, 647*f*, 992  
for inflammatory bowel disease,  
1104–1106, 1105*t*  
preparations available, 656, 999, 1112  
for psoriasis, **1072**
- Adapalene  
for acne, 1070
- Adcirca, 209. *See also* Tadalafil
- Addiction  
animal models of, 566  
clinical pharmacology of, **578**  
defined, 565  
dopamine hypothesis of, 568  
dopamine level effects of, **565–566**,  
567*f*, 569*f*, 569*t*  
synaptic plasticity and, 571
- Addison's disease  
synthetic corticosteroids for, 703–704
- Adefovir, 863*f*, 888  
for HBV infection, 883*t*, **884**
- Adenocard, 250. *See also* Adenosine
- Adenosine  
for cardiac arrhythmias, **245–246**  
inhibitory effects of, 92*t*  
membrane actions of, 237*t*  
pharmacologic properties of, 238*t*  
in renal tubule transport, 256
- Adenosine A<sub>1</sub>-receptor antagonists, **258**
- Adenosine diphosphate (ADP)  
in coagulation, 601, 602*f*
- Adenosine triphosphate (ATP)  
in ANS, ENS, and NANC neurons, 80*f*,  
81*f*, 83*f*, 84*t*
- S-Adenosyl-L-methionine (SAME), 60
- ADH. *See* Antidiuretic hormone (ADH)
- ADHD  
sympathomimetic drugs for, 146
- Adherence  
in clinical trials, 73
- ADI. *See* Acceptable daily intake (ADI)
- Adipose tissue  
insulin effects on, 746, 747*t*
- Adjuvant chemotherapy, 950–951
- Adrenal androgens, **709**
- Adrenal cortex  
angiotensin II effects on, 298
- Adrenal steroid inhibitors, 712
- Adrenal suppression  
synthetic corticosteroids and, 707
- Adrenalin, 148, 355.  
*See also* Epinephrine
- Adrenergic nerves  
cotransmitters in, 87
- Adrenergic-neuron-blocking drugs  
as antihypertensive drugs, 175*t*,  
**177–178**
- Adrenergic receptors, 87, 89*t*
- Adrenergic transmission, 84–87, 85*f*, 86*f*
- Adrenoceptor(s), 87, 89*t*  
agonists of, **129–149**. *See also*  
Sympathomimetic drugs  
antagonists of, **151–168**  
alpha-receptor antagonists, **151–157**  
as antihypertensive drugs, **178**  
beta-receptor antagonists. *See also* Beta  
receptors, antagonists of  
basic pharmacology of, **157–161**  
beta. *See* Beta adrenoceptors
- Adrenoceptor-blocking actions  
of H<sub>1</sub>-receptor antagonists, 278
- Adrenocortical agents  
antagonists of, **709–711**.  
*See also specific drugs*  
structures of, 709*f*
- Adrenocortical hypo- and hyperfunction  
synthetic corticosteroids for, 704
- Adrenocortical insufficiency  
synthetic corticosteroids for, 703–704
- Adrenocorticosteroids, **697–709**. *See also*  
*specific drugs*  
ACTH *vs.*, 707  
mineralocorticoids, **708–709**  
synthetic corticosteroids, **703–708**
- Adrenocorticotrophic hormone (ACTH),  
661, 661*t*  
adrenocorticosteroids *vs.*, 707  
biosynthesis of  
major pathways in, 698, 698*f*  
diagnostic uses of, 662*t*
- Adrenomedullin, **308**
- Advair Diskus, 355. *See also* Salmeterol/  
fluticasone
- Adverse drug reactions (ADRs).  
*See also specific drugs*  
during drug development, 76–77  
in the elderly, **1057–1058**
- Advicor, 633
- Advil, 655. *See also* Ibuprofen
- AeroBid, 355. *See also* Flunisolide
- Aerosol corticosteroids, 355
- Aerospan, 355. *See also* Flunisolide
- African trypanosomiasis  
drugs used for, **930–934**,  
930*t*, 932*t*
- Afrin, 148. *See also* Oxymetazoline
- Aftate, 858. *See also* Tolnaftate
- Afterdepolarization(s)  
delayed, 233*f*, 234
- Afterload  
in cardiac performance,  
215, 215*f*
- Agammaglobulinemia  
X-linked, 984–985
- Age  
as factor in drug dosage in infants and  
children, 1047, 1049, 1049*t*  
as factor in drug metabolism, 66
- Aggrastat, 617. *See also* Tirofiban
- Aging. *See also* Elderly  
androgen production effects of, 736  
behavioral and lifestyle changes, 1053  
hepatic clearance of drugs and, 1052*t*  
pharmacologic changes associated with,  
**1051–1053**, 1052*f*, 1052*t*  
practical aspects of, **1058**  
phosphorylated enzyme complex of, 107  
physiologic function effects of, 1051,  
1052*f*
- Agomelatine, 283
- Agonist(s), 6–8, 7*f*, 8*f*  
binding molecule inhibitors, 6  
defined, 4  
full, 7, 8*f*, 19, 20*f*  
inverse, 8, 8*f*  
opioids with, 552  
partial, 6–7, 8*f*, 19–20, 20*f*  
receptor binding of  
concentration-effect curves and,  
16, 17*f*  
receptors in mediation of, 15
- AIDS, 985. *See also* HIV  
antimicrobial drugs in patients with, 909  
antiretroviral drugs in, 869
- Air pollutants, **1002–1005**, 1005*t*  
TLVs of, 1005*t*
- Airways  
lipoxygenase effects on, 323  
prostaglandins and thromboxanes effects  
on, 320
- Akathisia  
tardive, 496
- Akinesia  
end-of-dose, 487
- Akineton, 499. *See also* Biperidine
- Albendazole  
adverse effects of, 939  
clinical uses of, 938–939  
contraindications to, 939  
for helminthic infections, **937–939**, 938*t*  
pharmacology of, 937  
precautions with, 939
- Albenza, 935, 946. *See also* Albendazole
- Albumin  
concentration of  
in drug concentration measurements,  
49
- Albuterol, 343*f*, 355  
for asthma, 344  
ionization constants of, 11*t*
- Albuterol/ipratropium, 355
- Alcaine, 463. *See also* Proparacaine

- Alcohol(s), **389–401**. *See also* Ethanol  
 abuse of. *See also* Alcohol abuse;  
 Alcoholism  
 animal studies of, 392  
 as antiseptics/disinfectants, 893*t*, **894**  
 benzyl, **1068**  
 clinical pharmacology of, **395–397**  
 drug interactions with, 395, 1150*t*  
 durations of action of, 106*t*  
 neurotoxicity of, 393  
 in OTC products, 1123*t*  
 therapeutic uses for, 106*t*  
 tolerance to, 393
- Alcohol abuse, 569*t*, 575  
 acute intoxication  
 management of, **395**  
 prevalence of, 389  
 prevention of  
 drugs in, 400  
 treatment for, 575
- Alcohol dehydrogenase pathway,  
 390, 390*f*
- Alcoholism  
 prevalence of, 389  
 treatment of, **396–397**
- Aldactazide  
 dosage of, 262*t*
- Aldactone, 225, 270. *See also*  
 Spironolactone  
 dosage of, 262*t*
- Aldara, 889. *See also* Imiquimod
- Aldehydes  
 as antiseptics/disinfectants, 893*t*, **896**
- Aldicarb  
 toxicity rating for, 1008*t*
- Aldosterone, 697, **708**  
 antagonists of, 225  
 sites of action of, 252*f*
- Aldosteronism  
 synthetic corticosteroids for,  
 704–705
- Aldrin  
 toxicity rating for, 1006*t*
- Alefacept, **993**  
 for psoriasis, **1071**
- Alemtuzumab, 991
- Alendronate  
 for osteoporosis, 775, 783
- Alendronate sodium, 786
- Aleve, 656. *See also* Naproxen
- Alfenta, 562. *See also* Alfentanil
- Alfentanil, 557  
 pharmacokinetics of, 545*t*
- Alferon N, 889. *See also* Interferon alfa-n3
- Alfuzosin, 155
- Alinia, 935. *See also* Nitazoxanide
- Aliskiren, 300  
 in heart failure management, 219
- Alitretinoin, 1077  
 dermatologic uses of, 1078*t*
- Alkaloid(s)  
 belladonna, 127  
 vinca  
 for cancer, **962–964**, 963*t*
- Alkalosis  
 metabolic  
 carbonic anhydrase inhibitors for,  
 257, 257*t*  
 hypokalemic  
 thiazide diuretics and, 261
- Alkylamine(s), 279*t*
- Alkylamine derivative, 278*f*
- Alkylating agents. *See also specific drugs*  
 adverse effects of, 955, 955*f*, 956*t*  
 for cancer, **953–958**
- Alkylsulfonate, 954*f*
- Allegra, 292. *See also* Fexofenadine
- Allergic contact dermatitis  
 topical dermatologic medications and,  
 1063*t*
- Allergic drug reactions  
 to antipsychotic drugs, 512  
 autoimmune (type II), **998**  
 to cephalosporins, 800  
 to H<sub>1</sub>-receptor antagonists, 279–280  
 immediate (type I), **997**  
 desensitization to drugs, 997–998  
 treatment of, 997  
 immunologic, **997–998**  
 to insulin, 753  
 to loop diuretics, 260  
 serum sickness due to, **998**  
 to thiazide diuretics, 261  
 vascular (type III), **998**
- Allergic rhinoconjunctivitis, 349
- Allergy preparations  
 ingredients in, 1118*t*
- Allied health professionals  
 prescribing authority of, 1144–1145, 1144*t*
- Allopurinol, **653–654**, 962*f*  
 for angina pectoris, 206  
 drug interactions with, 654, 1150*t*  
 ionization constants of, 11*t*
- Allosteric modulators, 19
- Allylamines  
 topical, **856**, **1065**
- Almotriptan  
 pharmacokinetics of, 286*t*
- Aloe  
 in constipation management, 1093
- Alosetron  
 for irritable bowel syndrome, 1096
- Aloxil, 1111. *See also* Palonosetron
- Alpha<sub>1</sub>-acid glycoprotein  
 concentration of  
 in drug concentration measurements,  
 49
- Alpha adrenoceptors, 87, 89*t*  
 antagonists of  
 as antihypertensive drugs, 180
- Alpha<sub>1</sub> adrenoceptors  
 antagonists of, 189
- Alpha agonists  
 for open-angle glaucoma, 161*t*
- Alpha<sub>2</sub> antagonists  
 applications of, 157
- Alpha-glucosidase inhibitors  
 for diabetes mellitus, **759–760**, 759*t*  
 structures of, 759*t*
- Alpha receptor(s), 131, 131*t*, 132*f*, 137*t*
- Alpha<sub>1</sub> receptor(s)  
 activation of  
 cardiovascular effects of, 137, 138*t*,  
 139*f*, 140*f*
- Alpha<sub>2</sub> receptor(s)  
 activation of  
 cardiovascular effects of, 137
- Alpha receptor antagonists, **151–157**
- Alpha<sub>1</sub> responses  
 activation of, 130, 130*f*
- Alpha<sub>2</sub>-selective agonists, **141**
- Alphagan, 148. *See also* Brimonidine
- Alphanate, 617. *See also* Antihemophilic  
 factor
- AlphaNine SD, 617. *See also* Factor IX  
 complex, human
- Alprazolam  
 dosages of, 383*t*  
 hepatic clearance of  
 aging effects on, 1052*t*  
 pharmacokinetic properties of, 377*t*  
 for tremors, 494
- Alprenolol  
 ionization constants of, 11*t*
- Alprostadil, 315, 326  
 for erectile dysfunction, 199
- Altace, 190, 225. *See also* Ramipril
- Alteplase  
 pharmacology of, 612
- Alteplase recombinant, 617
- AlternaGEL, 1111. *See also* Aluminum  
 hydroxide gel
- Altretamine  
 clinical activity and toxicities of, 956*t*
- Aluminum hydroxide  
 as antacid, 1083
- Aluminum hydroxide gel, 1111
- Aluminum hydroxide/magnesium  
 hydroxide, 1111
- Alupent, 355. *See also* Metaproterenol
- Alveolar ventilation  
 of inhaled anesthetics, 430–432, 432*f*
- Alvimopan, 560  
 in constipation management, 1094  
 preparations available, 562, 1112
- Alzheimer's disease  
 antipsychotic drugs for, 509  
 in the elderly  
 drugs used for, 1054–1055,  
 1055*f*, 1055*t*

- Amantadine  
for influenza, **887**  
for parkinsonism, **491**
- Amaryl, 766. *See also* Glimepiride
- Amibenonium  
duration of action of, 106*t*  
therapeutic uses for, 106*t*
- Ambien, 387. *See also* Zolpidem
- AmBisome  
properties of, 850*t*
- Ambrisentan, 305
- Amebiasis  
drugs used for, **927–930**, 928*t*,  
929*f*  
types of, 927
- Amebic colitis  
drugs used for, 927
- Amebic liver abscess  
chloroquine for, 917
- Amerge, 292. *See also* Naratriptan
- Amevive, 999. *See also* Alefacept
- Amicar, 617. *See also* Aminocaproic acid
- Amidate, 446. *See also* Etomidate
- Amide(s), local anesthetics,  
structures of, 451*t*
- Amikacin, **826**  
dosage of, 840*t*  
pharmacokinetic parameters for,  
39*t*  
for tuberculosis, 840*t*, 844
- Amikin, 828. *See also* Amikacin
- Amiloride, **261–263**  
ionization constants of, 11*t*
- Amine(s)  
biogenic  
drugs binding to transporters of  
abuse of, **576–578**, 577*f*  
primary, secondary, etc 11
- Amino acids  
as CNS neurotransmitters, 366–369,  
366*t*–367*t*, 368*f*
- Amino group  
sympathomimetic drug substitution on,  
135
- p*-Aminobenzoic acid (PABA),  
832*f*
- Aminocaproic acid, 604  
for bleeding disorders, 604*f*, 616
- Aminocarb  
toxicity rating for, 1008*t*
- Aminoglutethimide, **709–710**
- Aminoglycosides, **821–827**
- Aminolevulinic acids, **1076**
- Aminopenicillins  
clinical uses of, 796
- Aminophylline  
for asthma, 345
- Aminopterin  
fetal effects of, 1042*t*
- 4-Aminoquinolones, 918*f*
- Aminosalicylate(s)  
for inflammatory bowel disease. *See*  
5-Aminosalicyclic acid  
5-Aminosalicyclic acid (5-ASA)  
(5-ASA)
- 5-Aminosalicyclic acid (5-ASA)  
adverse effects of, 1102–1103
- Azo compounds, 1101–1102,  
1101*f*  
chemistry and formulations of,  
1101–1102, 1101*f*  
clinical uses of, 1102  
dosage of, 840*t*  
for inflammatory bowel disease,  
**1101–1103**, 1101*f*, 1102*f*  
mesalamine compounds, 1102,  
1102*f*  
metabolism of, 1101–1102, 1101*f*,  
1102*f*  
pharmacodynamics of, 1102  
pharmacokinetics of, 1102  
for tuberculosis, 840*t*, 844
- Amiodarone  
for cardiac arrhythmias, **242–243**  
drug interactions with, 610*t*  
ionization constants of, 11*t*  
thyrotoxicosis due to, 693–694
- Amlodipine  
clinical pharmacology of, 202*t*  
clinical uses of, 205  
pharmacokinetics/dosage of, 175*t*
- Amitiza, 1112. *See also* Lubiprostone
- Amitriptyline  
dosage of, 535*t*  
pharmacodynamics of, 530*t*  
pharmacokinetics of, 529*t*
- Amnesia  
anesthesia and, 435
- Amobarbital, 387
- Amodiaquine  
clinical uses of, 917*t*  
for malaria, 920
- Amoxapine, 528*f*, 539  
pharmacology of, 527–530, 530*t*
- Amoxicillin  
dosage of, 795*t*  
pharmacokinetic parameters for,  
39*t*
- Amoxicillin/potassium clavulanate, 795*t*,  
807
- Amoxil, 807. *See also* Amoxicillin
- Amphetamines  
abuse of, 569*t*, 576–577, 577*f*  
effects, 136*f*, **142**  
fetal effects of, 1042*t*  
ionization constants of, 11*t*  
overdose of, **1032–1034**
- Amphotec  
properties of, 850*t*
- Amphotericin  
clinical uses of, 934
- Amphotericin (*Cont.*):  
pharmacokinetic parameters for,  
39*t*
- Amphotericin B, 850*f*, 858  
for systemic infections, **849–852**  
topical, **1066**
- Ampicillin  
clinical uses of, 796  
ionization constants of, 11*t*  
during lactation, 1048*t*  
oral absorption of  
in neonates *vs.* older children and  
adults, 1044*t*  
pharmacokinetic parameters for,  
39*t*
- Ampicillin/sulbactam sodium, 807
- Amrix, 481. *See also* Cyclobenzaprine
- AmVaz, 209
- Amyl nitrite, 197
- Amylin, 743, **763**
- Amylin analogs  
for diabetes mellitus, **760**
- Amyloid  $\beta$  synthesis  
inhibitors of  
for Alzheimer's disease, 1055*t*
- Amytal, 387. *See also* Amobarbital
- Anabolic steroids, **734–737**
- Anacetrapib, 631
- Anafranil, 539. *See also* Clomipramine
- Anakinra, 996, 999
- Analgesia/analgesics  
in the elderly, 1054  
ingredients in, 1119*t*  
opioid, **446**, **543–564**. *See also* Opioid  
analgesics  
patient-controlled, 554
- Anaphylactic shock  
sympathomimetic drugs for, 145
- Anaphylaxis  
sympathomimetic drugs for, 145
- Anaprox, 656. *See also* Naproxen
- Anaspaz, 127, 1111. *See also* Hyoscyamine
- Anastrozole, 733, 740
- Ancef, 807. *See also* Cefazolin
- Ancobon, 858. *See also* Flucytosine
- ANDA, 75–76
- Androgen(s), 726, **734–737**. *See also*  
Testosterone  
adrenal, **709**  
fetal effects of, 1042*t*  
Androgen suppression, **737**
- Androl-50, 740. *See also* Oxymetholone
- Anectine, 481. *See also* Succinylcholine
- Anemia(s). *See also specific types*  
agents used in, **581–599**. *See also specific*  
*drugs*  
folic acid/folates, **588–590**, 589*f*  
iron, **582–586**  
vitamin B<sub>12</sub>, 584*t*, **586–588**  
androgens in, 736

- Anemia(s). (*Cont.*):  
 defined, 582  
 iron deficiency  
 treatment of, 585–586, 586*t*  
 microcytic hypochromic, 582  
 nutritional  
 features of, 584, 584*t*  
 pernicious, 588
- Anesthesia/anesthetics  
 general, **429–447**. *See also specific drugs and General anesthetics*  
 inhaled, **430–438**. *See also Inhaled anesthetics*  
 intravenous, **438–446**. *See also specific drugs and Intravenous anesthetics*  
 local, **449–464**. *See also specific drugs and Local anesthesia/anesthetics*  
 H<sub>1</sub>-receptor antagonists in, 279  
 monitored care, 429, 430  
 neuromuscular blocking drugs with, 475  
 opioid analgesics in, 553–554  
 premedication before clonidine as, 146  
 sedative-hypnotic drugs as, 380  
 sites of action of, 435
- Angina pectoris  
 drugs used for. *See also specific drugs pharmacology of, 193–208*  
 vasodilators, **193–210**. *See also specific types and drugs*
- Angiomax, 617. *See also Bivalirudin*
- Angiotensin, **295–300**  
 agents blocking production or action of, 172  
 inhibitors of  
 as antihypertensive drugs, **183–185**  
 mechanism and sites of action of, 183–184
- Angiotensin-converting enzyme (ACE) inhibitors, 299  
 as antihypertensive drugs, **184–185**  
 fetal effects of, 1042*t*  
 in heart failure management, **219, 220**  
 pharmacokinetics/dosage of, 175*t*, 185
- Angiotensin I, 296*f*, 297
- Angiotensin II  
 actions of, **298**  
 excitatory effects of, 92*t*
- Angiotensin receptor(s)  
 mechanism of action of, **299**
- Angiotensin receptor blockers (ARBs), 299–300  
 as antihypertensive drugs, **185**  
 in heart failure management, **219, 220**
- Angiotensinase, 298
- Angiotensinogen, 296*f*, 297
- Anidulafungin, 855, 858
- Anion(s)  
 overdose of  
 loop diuretics for, 259
- Anion gap acidosis  
 drug-induced, 1030, 1030*t*
- Anion inhibitors, **689**
- Anisindione, 617
- Anistreplase, 612
- ANOs, 2
- ANS. *See* Autonomic nervous system (ANS)
- Ansaid, 655. *See also* Flurbiprofen
- Antabuse, 400. *See also* Disulfiram
- Antacids  
 for acid-peptic diseases, **1082–1083**  
 drug interactions with, 1150*t*
- Antagonism  
 among antimicrobial drugs, 910  
 drug  
 mechanisms of, 20  
 neutral, 7  
 physiologic, 20
- Antagonist(s), 6, 8*f*  
 adrenoceptor, **151–168**. *See also* Adrenoceptor(s), antagonists of  
 chemical, 20  
 defined, 4  
 competitive, 18–19, 18*f*  
 defined, 4  
 drugs acting as, 15–16  
 irreversible, 18*f*, 19  
 opioids with, 552  
 pure, 15–16  
 receptors in mediation of, 15
- Antagonist-precipitated withdrawal, 555
- Antara, 633. *See also* Fenofibrate
- Anterior pituitary hormones, **660–673**
- Anthracyclines  
 for cancer, **965–966**
- Anthraquinone derivatives  
 in constipation management, 1093
- Anti-amyloid antibodies  
 for Alzheimer's disease, 1055*t*
- Anti-amyloid vaccines  
 for Alzheimer's disease, 1055*t*
- Antiandrogens, **737–739**  
 receptor inhibitors, 738–739  
 steroid synthesis inhibitors, 737
- Antiarrhythmic drugs, **227–250**. *See also specific drugs*  
 for atrial fibrillation, 246  
 basic pharmacology of, **235–237**  
 benefits of, 247  
 beta-adrenoceptor antagonists, **242**  
 calcium channel blockers, **245**  
 in the elderly, 1056  
 mechanisms of action of, 235–237, 236*f*  
 neuromuscular blocking drugs with, 475  
 pharmacologic properties of, 238*t*  
 prolonging effective refractory period, **242–245**  
 risks associated with, 247
- Antibacterial drugs  
 topical, **1063–1065**
- Antibiotics. *See specific drugs and Antimicrobial drugs*
- Antibody, 978  
 antithymocyte, **989–990**  
 anti-amyloid  
 for Alzheimer's disease, 1055*t*  
 antilymphocyte, **989–990**  
 digitalis, 225  
 digoxin  
 as poisoning antidote, 1033*t*  
 functions of, 981, 982*f*  
 immunosuppressive, **989–991**  
 monoclonal. *See* Monoclonal antibodies (MABs)
- Anticholinergic drugs  
 for irritable bowel syndrome, **1096**  
 for nausea and vomiting, **1100**  
 overdose of, **1034**
- Anticholinergic syndrome, 1034
- Anticholinoceptor actions  
 of H<sub>1</sub>-receptor antagonists, 278
- Anticoagulants, **601–618**. *See also specific drugs*  
 coumarin, **608–611**  
 direct thrombin inhibitors, **607–608**  
 indirect thrombin inhibitors, **604–607, 605*f***  
 oral  
 drug interactions with, 1151*t*–1152*t*  
 oral direct factor XA inhibitors, **607**  
 warfarin, **608–611**
- Anticonvulsants  
 sedative-hypnotic drugs as, 381
- Antidepressant(s), **521–541**. *See also specific drugs*  
 drug interactions with, 536–537, 537*t*, 1152*t*  
 in the elderly, 1054  
 heterocyclic  
 drug interactions with, 1152*t*  
 overdose of, 536, **1034**
- SNRIs. *See* Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- SSRIs. *See* Selective serotonin reuptake inhibitors (SSRIs)
- subgroups of, 525–528, 526*f*–528*f*  
 summary table, 538  
 tetracyclic. *See* Tetracyclic antidepressants  
 tricyclic. *See* Tricyclic antidepressants (TCAs)  
 unicyclic. *See* Unicyclic antidepressants
- Antidepressant–CYP450 drug interactions, 537*t*
- Antidiabetic drugs  
 oral, **753–762**. *See also specific drugs and Diabetes mellitus, oral antidiabetic drugs for*

- Antidiarrheal agents, **1094–1095**. *See also specific drugs*  
 ingredients in, 1119*t*
- Antidiuretic hormone (ADH), **674–675**  
 agonists of, **264**  
 antagonists of, **264–265**  
 elevated  
 causes of, 264–265
- Antiemetic drugs, **1097–1100**.  
*See also specific drugs*  
 5-HT<sub>3</sub>-receptor antagonists, **1097–1098**  
 neurokinin receptor antagonists,  
**1099–1100**  
 pathophysiology of, 1097–1098, 1098*f*  
 phenothiazines, **1100**  
 substituted benzamides, **1100**
- Antiepileptic drugs (AEDs), **403–427**.  
*See also Antiseizure drugs*
- Antifolate drugs, **831–834, 958–960, 959t**. *See also specific drugs*  
 for cancer, **958–960, 959t**
- Antifungal drugs, **849–859, 1065–1067**.  
*See also specific drugs and indications*  
 drug interactions with, 1152*t*  
 topical, **856, 1065–1066**  
 ingredients in, 1120*t*  
 vaginal preparations  
 ingredients in, 1120*t*
- Antigen-presenting cells (APCs), 978
- Anthelmintic drugs  
 clinical pharmacology of, **937–947**  
 ingredients in, 1119*t*
- Antihemophilic factor, 617
- Antihepatitis drugs, **882–886**.  
*See also specific drugs*
- Antihistamines. *See also* H<sub>1</sub>-receptor  
 antagonists; H<sub>2</sub>-receptor  
 antagonists  
 dermatologic uses of, 1078*t*  
 in OTC products, 1123*t*  
 preparations available, 292
- Antihypertensive drugs, **169–191**.  
*See also specific drugs*  
 in the elderly, 1056
- Anti-IgE monoclonal antibodies  
 for asthma, 350, **352**
- Anti-inflammatory drugs, **1072–1074**.  
*See also specific drugs*  
 antimicrobial drugs, **1056–1057**  
 MABs as, **992–994, 993f**  
 topical  
 ingredients in, 1120*t*
- Anti-influenza drugs, **886–887**
- Anti-inhibitor coagulant complex, 617
- Anti-integrin therapy  
 for inflammatory bowel disease, **1106**
- Antilipid drugs  
 for Alzheimer's disease, 1055*t*
- Antilymphocyte antibodies, **989–990**
- Antimalarial drugs, **915–927**.  
*See also specific drugs*  
 dermatologic uses of, 1078*t*
- Antimetabolites. *See also specific drugs*  
 for cancer, **958–962**
- Antimicrobial drugs, **891–899**.  
*See also specific drugs*  
 bacteriostatic *vs.* bactericidal, 907, 907*t*  
 clinical uses of, **901–913**  
 combinations of, **908–910**  
 in the elderly, **1056**  
 introduction to, 789  
 for malaria, **926–927**  
 neuromuscular blocking drugs with, 475  
 prophylaxis with, **910–913, 911t, 912t**  
 topical  
 for acne, **1064–1065**  
 toxicity of  
 management of, **908–909, 908t**
- Antiminth, 946. *See also* Pyrantel pamoate
- Antimuscarinic drugs, **115–124**  
 clinical uses of, 347, 492  
 intoxication by  
 cholinomimetic drugs in management  
 of, 109  
 for parkinsonism, **491–492**
- Antimycobacterial drugs, **839–848**  
 for leprosy, **845–846**  
 for tuberculosis, **839–845**. *See also specific drugs and Tuberculosis, drugs used for*
- Antineoplastic agents, **1077**
- Antioxidants  
 for Alzheimer's disease, 1055*t*
- Antiplatelet drugs  
 basic pharmacology of, **612–614**
- Antiprotozoal drugs, **914–936**. *See also specific drugs and indications*
- Antipruritic drugs, **1076–1077**
- Antipsychotic drugs, **501–520**. *See also specific drugs*  
 in the elderly, 1054  
 overdose of, 513, 517, **1034**
- Antipyretics  
 ingredients in, 1119*t*
- Antiretroviral drugs, **869–882**. *See also specific drugs and indications*
- Antiseborrhea agents, **1077–1078, 1078t**  
 ingredients in, 1120*t*
- Antiseizure drugs, **403–427**. *See also specific drugs*
- Antisense oligonucleotides (ANOs), 2
- Antisepsis, 89*t*
- Antiseptic drugs, **896–897**
- Antispasmodics  
 for irritable bowel syndrome, **1096**
- Antithrombin, 603–604
- Antithrombin III, 617
- Antithymocyte antibodies, **989–990**
- Antithymocyte globulin, 999
- Antithyroid drugs, **681–696**.  
*See also specific drugs*
- Antitrichogenic agents, **1077**
- Antitumor antibiotics  
 for cancer, **965–966**
- Anti-tumor necrosis factor (TNF) therapy  
 for inflammatory bowel disease,  
**1104–1106, 1105t**
- Antitussives, **559**  
 ingredients in, 1121*t*
- Antivert, 292. *See also* Meclizine
- Antiviral drugs, **861–890**. *See also specific drugs and indications*  
 anti-influenza agents, **886–887**  
 for CMV infections, **866–869**  
 for HBV and HCV infections,  
**882–886**  
 for HSV and VZV infections, **862–866**  
 topical, **1067**
- Antizol, 400. *See also* Fomepizole
- Anturane, 656. *See also* Sulfipyrazone
- Anxiety  
 performance  
 beta-receptor antagonists for, 164
- Anxiety disorders  
 antidepressants for, 532–533  
 sedative-hypnotic drugs for, **382, 382t**
- Anzemet, 1111. *See also* Dolasetron
- Apixaban, 607
- Apocrine sweat glands  
 sympathomimetic drug effects on, 139
- Apokyn, 499. *See also* Apomorphine
- Apolipoprotein (apo) B-100, 619
- Apomorphine  
 for parkinsonism, **491**
- Apraclonidine  
 for ophthalmic disorders, 145  
 preparations available, 148
- Aprepitant  
 for nausea and vomiting, 1099
- Apresoline, 189. *See also* Hydralazine
- Apriso, 1102
- Aprotinin  
 for bleeding disorders, 617
- Aptivus, 889. *See also* Tipranavir
- aPTT, 605
- Aquachloral Supprettes, 387. *See also*  
 Chloral hydrate
- Aquaretics, **263–265**
- Aquatensen, 270. *See also* Methyclothiazide
- Aqueous diffusion, 9, 9*f*
- Arachidonic acid, **313, 314f–316f**  
 metabolism of  
 dietary manipulation of, **328**  
 release and metabolism of, 313, 314*f*
- Aralen, 935. *See also* Chloroquine
- Aramine, 148. *See also* Metaraminol
- Aranesp, 598. *See also* Darbepoetin alfa
- Arava, 656, 999. *See also* Leflunomide

- ARBs. *See* Angiotensin receptor blockers (ARBs)
- Arcalyst, 999. *See also* Rilonacept
- Arcitumomab, 992
- Area under the curve (AUC), 41
- Aredia, 786. *See also* Pamidronate sodium
- Arfonad, 127. *See also* Trimethaphan
- Arformoterol, 355
- Argatroban, 608, 617
- Arginine vasopressin, 673*f*
- Aricept, 112. *See also* Donepezil
- Arimidex, 740. *See also* Anastrozole
- Aripiprazole, 504*f*, **509–510**, 519
- Aristospan, 712. *See also* Triamcinolone hexacetonide
- Arixtra, 606. *See also* Fondaparinux
- Armodafinil, 148
- Armour, 695. *See also* Thyroid desiccated
- Aromasin, 740. *See also* Exemestane
- Aromatic (4)-hydroxylation, 64
- Aromatic hydrocarbons  
TLVs of, 1005*t*  
toxic exposure to, **1005–1006**
- Arrestin(s), 133–134
- Arrhythmia(s), **227–250**. *See also* Cardiac arrhythmias  
alcohol and, 394
- Arsenic, 1014*t*, **1017–1019**
- Arsine gas poisoning, 1019
- Artane, 499. *See also* Trihexyphenidyl
- Artemether, 920
- Artemether/lumefantrine, 935
- Artemisinin(s), 919*t*, **920–921**
- Arterial blood gases  
in poisoning assessment, 1030
- Arterial thrombosis, **614**
- Artesunate, 920
- Arthritis  
rheumatoid  
eicosanoids and, 328
- Articaine, 451*t*, **459–460**, 463
- Arzerra, 999. *See also* Ofatumumab
- 5-ASA. *See* 5-Aminosalicylic acid (5-ASA)
- Asacol, 1102, 1102*f*
- Asbestos  
as environmental pollutant,  
**1011**
- Ascariasis  
albendazole for, 938–939
- Asenapine, 519
- Asmanex Twisthaler, 355. *See also* Mometasone
- Asparaginase  
for cancer, **967–969**
- Aspirin, **638–640**  
as antiplatelet agent, 612  
ionization constants of, 11*t*  
during lactation, 1048*t*  
in OTC products, 1123*t*  
overdose of, **1034–1035**
- Aspirin (*Cont.*):  
pharmacokinetics of, 39*t*, 638,  
638*t*, 639*f*  
resistance to, 613
- Association-dissociation process, 10
- Asthma  
acute  
management of, **352–353**  
drugs used for, **339–357**. *See also*  
*specific drugs*  
sympathomimetic drugs, 145,  
**341–344**, 343*f*
- Atacand, 190, 225. *See also* Candesartan
- Atarax, 387. *See also* Hydroxyzine
- Atazanavir, 870*t*, **878**  
drug interactions with, 874*t*
- Atenolol, 158*f*, **157–163**,  
167, 189  
as antihypertensive drug, 175*t*, 179  
pharmacokinetic parameters for, 39*t*
- Atgam, 999. *See also* Lymphocyte immune globulin
- Athetosis, 483, 495
- Athletes  
androgen and anabolic steroid abuse in,  
736
- Ativan, 387, 400, 427, 446. *See also* Lorazepam
- Atomoxetine  
sympathomimetic drug effects, 143
- Atonic seizures, 421
- Atorvastatin, 633
- Atovaquone, 918*f*, 935  
for malaria, **924–925**
- Atovaquone-proguanil  
clinical uses of, 917*t*
- ATP  
inhibitory effects of, 92*t*
- Atracurium  
pharmacology of, 467–468, 470*t*
- Atrial fibrillation  
antiarrhythmic drug-use principles  
applied to, 246
- Atropine  
pharmacology of, **115–124**  
ionization constants of, 11*t*  
as poisoning antidote, 1033*t*  
preparations available, 127, 1111
- Atropine fever, 120
- Atrovent, 127, 355. *See also* Ipratropium
- Attention deficit hyperactivity disorder (ADHD)  
sympathomimetic drugs for, 146
- AUC (area under the curve), 41
- Augmentin, 807. *See also* Amoxicillin/potassium clavulanate
- Auranofin, 656
- Aurolate, 656. *See also* Gold sodium thiomalate
- Aurothioglucose, 656
- Autacoid(s), 273  
renal  
in renal tubule transport, 255–256
- Autoclaving, 897
- Autoimmune diseases  
immunosuppressive drugs for, 985*t*, **995**
- Autoimmunity, **983–984**
- Autologous stem cell transplantation  
myeloid growth factors in, 593, 593*f*
- Automatisms, 421
- Autonomic drugs, **79–168**
- Autonomic junctions  
anatomy of, 82
- Autonomic nervous system (ANS), **79–96**  
activity of  
systemic effects of, 90*t*  
anatomy of, **80–82**, 80*f*, 81*f*  
antipsychotic drugs effects on, 507*t*, 508,  
512  
functional organization of, **88–93**  
neurotransmitter chemistry of, **82–87**
- Autonomic pharmacology  
introduction to, **79–96**. *See also*  
Autonomic nervous system (ANS)
- Autonomic receptors, **87**, 89*t*  
types of, 89*t*
- Autonomic synapses  
anatomy of, 82
- Autonomic transmission  
drug effects of, 93, 94*t*
- Autoplex  
for bleeding disorders, 616
- Autoplex T, 617. *See also* Anti-inhibitor coagulant complex
- Autoreceptor(s), 92, 92*t*
- Autosomal dominant hypophosphatemia,  
**783**
- Avandamet, 766. *See also* Rosiglitazone plus metformin
- Avandaryl, 766. *See also* Rosiglitazone plus glimepiride
- Avandia, 766. *See also* Rosiglitazone
- Avapro, 190, 225. *See also* Irbesartan
- Avastin, 999. *See also* Bevacizumab
- Avelox, 838. *See also* Moxifloxacin
- Avodart, 740. *See also* Dutasteride
- Avonex, 999
- Axert, 292. *See also* Almotriptan
- Axid, 1111. *See also* Nizatidine
- Aygestin, 740. *See also* Norethindrone acetate
- Azactam, 807. *See also* Aztreonam
- Azathioprine, **643–644**  
adverse effects of, 644, 1104  
clinical uses of, 1103  
drug interactions with, 1104  
as immunosuppressive drug, 985*t*, **988**  
indications for, 644

- Azathioprine (*Cont.*):  
 for inflammatory bowel disease, **1103–1104**  
 mechanism of action of, 643, 1103
- Azelaic acid  
 for acne, **1070–1071**
- Azelastine, 292
- Azidothymidine (AZT). *See* Zidovudine
- Azilect, 499. *See also* Rasagiline
- Azilsartan, 190
- Azinphos-methyl  
 toxicity rating for, 1007*t*
- Azithromycin, **814**, 819
- Azmacort, 355. *See also* Triamcinolone
- Azo compounds, 1101–1102, 1101*f*
- Azole(s)  
 for systemic infections, **853–855**.  
*See also specific drugs*  
 topical, **856**, **1065–66**
- Azopt, 270. *See also* Brinzolamide
- Aztreonam, 801, 807
- Azulfidine, 656, 1112. *See also* Sulfasalazine
- B**
- B-48, 620
- B-100, 620
- Babesia* spp.  
 drugs used for, 931*t*
- Babesiosis  
 quinine for, 922
- Bacitracin, **805**  
 topical, **1063**
- Baclofen, **477**, **477f**, **478f**, 481  
 in addiction management, 578
- Bacterial cell wall synthesis, 792, 792*f*
- Bactrim, 837. *See also* Trimethoprim-sulfamethoxazole (TMP-SMZ)
- Bactroban, 898. *See also* Mupirocin
- BAL in Oil, 1025. *See also* Dimercaprol
- Balanced anesthesia, 429, 438
- Balantidium coli*  
 drugs used for, 931*t*
- Ballismus, 495
- Balsalazide, 1112
- Balsalazide sodium, 1101*f*
- Banthine, 127. *See also* Methantheline
- Banzel, 427. *See also* Rufinamide
- Baraclude, 889. *See also* Entecavir
- Barbiturate(s), **377**, **387**, **441**  
 abuse of, 575  
 biotransformation of, 377  
 chemistry of, 373–374  
 clinical uses of, 442  
 dosage of, 442  
 drug interactions with, 1153*t*  
 fetal effects of, 1042*t*  
 hepatic clearance of  
 aging effects on, 1052*t*  
 as intravenous anesthetic, **441–442**  
 neuropharmacology of, 379  
 tolerance and dependence of, 381
- Barbiturate nucleus, 375*f*
- Baroreceptor  
 renal  
 in renin release, 296, 297*f*
- Baroreflex  
 postural, 171, 171*f*
- Basal ganglia  
 circuitry of, 483, 484*f*
- Base(s)  
 weak  
 ionization of, 10–12, 11*t*,  
 12*f*, 12*t*
- Basiliximab, **993**, 999
- BCHE, 65
- BDNF. *See* Brain-derived neurotrophic factor (BDNF)
- Becaplermin  
 dermatologic uses of, 1078*t*
- Beclomethasone, 355
- Bedulin VH, 617. *See also* Factor IX complex, human
- Behavior(s)  
 antipsychotic drug effects on, 511  
 levodopa effects on, 487
- Behavioral effects  
 of aging, 1053
- Belladonna alkaloids, 127, 1111
- Benadryl, 292. *See also* Diphenhydramine
- Benazepril  
 pharmacokinetics/dosage of, 175*t*  
 preparations available, 190, 225
- Bendamustine  
 for cancer, 957  
 clinical activity and toxicities of, 956*t*
- Bendroflumethiazide, 270  
 dosage of, 261*t*
- Benefix, 617. *See also* Factor IX complex, human
- Benicar, 190, 225. *See also* Olmesartan
- Bentyl, 127, 1111. *See also* Dicyclomine
- Benylin DM, 563. *See also* Dextromethorphan
- Benzalkonium, 898
- Benzalkonium chloride, 896
- Benzamides  
 for nausea and vomiting, **1100**
- Benzathine penicillin  
 clinical uses of, 795  
 pharmacokinetics of, 794
- Benzene  
 TLVs of, 1005*t*  
 toxic exposure to, 1005–1006
- Benzene hexachlorides  
 toxicity rating for, 1006*t*
- Benzisoxazole  
 advantages and disadvantages of,  
 509*t*  
 chemical structure effects on potency  
 and toxicity of, 505*t*
- Benznidazole, clinical uses of, 934
- Benzocaine, 451*t*, **460**, 463
- Benzodiazepine(s), **373–387**  
 abuse of, 569*t*, 575  
 for alcohol abuse, 575  
 clinical uses of, 443  
 dosage of, 443  
 for epilepsy, **419–420**  
 as intravenous anesthetic, **442–443**  
 inverse agonists of, 379  
 for nausea and vomiting, **1100**  
 pharmacodynamics of, 378–381, 378*f*,  
 442
- Benzodiazepine antagonists, **381–382**
- Benzoic acid, 897
- Benzomorphans  
 with mixed receptor actions, 559
- Benzoyl peroxide  
 for acne, **1070**  
 preparations available, 898
- Benztropine, 117*f*, 492*t*, 499
- Benzyl alcohol, **1068**  
*o*-Benzyl-*p*-chlorophenol, 895
- Beryllium  
 as environmental pollutant, **1011**
- Beta adrenoceptor(s), 87, 89*t*  
 agonists of  
 in heart failure management, **218**  
 antagonists of  
 for angina pectoris, **205**  
 as antihypertensive drugs, **178–180**  
 for cardiac arrhythmias, **242**  
 cardiac effects of, 242  
 in heart failure management, **219**,  
**221**  
 for open-angle glaucoma, 161*t*  
 overdose of, **1035**  
 glucagon for, 763  
 preparations available, 189, 225, 249  
 rapid desensitization, resensitization, and  
 down-regulation of, 26, 27*f*
- Beta blockers. *See* Beta adrenoceptor(s),  
 antagonists of
- Beta carbon  
 sympathomimetic drug substitution on,  
 136
- Beta-lactam compounds, **790–797**  
 carbapenems, **801–802**  
 cephalosporins, **797–801**  
 cephamycins, **797–801**  
 monobactams, **801**  
 penicillins, **790–797**. *See also* Penicillin(s)
- Beta-lactamase assay  
 for infections with known etiology, 903
- Beta-lactamase inhibitors, **801**
- Beta receptor(s), 131–132, 131*t*, 132*f*, 137*t*  
 activation of  
 cardiovascular effects of, 137–138,  
 138*t*, 139*f*
- Beta-receptor antagonists  
 basic pharmacology of, **157–161**



- Beta-receptor antagonists (*Cont.*):  
 clinical pharmacology of, **162–164**, 163*f*  
 drug interactions with, 1153*t*  
 specific agents, 159*t*, 161–162  
 for variceal hemorrhage, **1108**
- Beta-selective agonists, 133*t*, **141**
- Betadine, 898. *See also* Povidone-iodine
- Betagan Liquifilm, 167. *See also*  
 Levobunolol
- Betamethasone  
 clinical uses and dosage of, 703*t*
- Betamethasone sodium phosphate, 712
- Betapace, 167, 249. *See also* Sotalol
- Betaseron, 999
- Betaxolol, 159*t*, 161, 167, 189  
 as antihypertensive drug, 179
- Bethanechol, 99*f*, 112  
 properties of, 99, 100*t*
- Bevacizumab, 991, 999  
 for cancer, **968**  
 clinical activity and toxicities of, 967*t*
- Bexarotene, 1077  
 dermatologic uses of, 1078*t*
- Bezold-Jarisch reflex, 283
- Bias  
 in clinical trials, 72–73
- Biaxin, 819. *See also* Clarithromycin
- Bicalutamide, 739, 740
- Bicarbonate  
 as poisoning antidote, 1033*t*
- Bicillin, 807. *See also* Penicillin G  
 benzathine
- Biguanides,  
 for diabetes mellitus, **757**
- Bile acid-binding resins  
 chemistry and pharmacokinetics of, 629  
 for diabetes mellitus, **760**  
 drug interactions with, 1153*t*  
 for hyperlipidemias, **629–630**  
 mechanism of action of, 624*f*, 629–630  
 therapeutic uses and dosage of, 630  
 toxicity of, 630
- Bile salt-binding resins  
 for diarrhea, **1095**
- Biliary tract  
 opioid analgesics effects on, 552
- Biltricide, 946. *See also* Praziquantel
- Bimatoprost, for glaucoma, 328, 1077
- Bioaccumulation  
 defined, 1003
- Bioavailability, 39*t*–40*t*, 43–44, 43*f*, 43*t*.  
*See also specific drugs*  
 absorption and, 43, 43*f*, 44  
 defined, 43  
 first-pass elimination and, 43–44
- Bioclate, 617. *See also* Antihemophilic  
 factor
- Biogenic amines  
 drugs binding to transporters of  
 abuse of, **576–578**, 577*f*
- Biologic agents  
 for psoriasis, **1071–1072**
- Biological License Application, 75
- Biomagnification  
 defined, 1003
- Biotransformation of drugs, **53–68**. *See also*  
 Drug metabolism; Metabolism  
 phase I reactions, 53–54, 54*f*  
 phase II reactions, 54, 54*f*; 59–60, 59*f*,  
 60*t*
- Biperiden, for parkinsonism, 492*t*
- Biperidine, 499
- Biphenyl(s)  
 coplanar, 1010  
 polychlorinated  
 as environmental pollutants, **1010**
- Bipolar (affective) disorder  
 antipsychotic drugs for, 508, **513–517**  
 lithium for, **513–518**. *See also* Lithium
- Bipyridines, in heart failure management,  
**218**
- Bipyridyl herbicides, **1010**
- Bisacodyl, 1112
- Bismuth compounds  
 for acid-peptic diseases, **1090–1091**
- Bisoprolol  
 as antihypertensive drug, 179  
 preparations available, 167, 189, 225  
 properties of, 159*t*
- Bisphosphonates  
 in bone mineral homeostasis, **776**
- Bithionol  
 for helminthic infections, 938*t*, **939**
- Bitolterol, 355
- Bivalirudin, 607–608, 617
- Black cohosh  
 risks associated with, 1127*t*
- Black widow spider bite  
 passive immunization for, 1168*t*
- Blackwater fever, 922
- Bleeding  
 heparin and, 605–606  
 mucosal  
 stress-related  
 proton pump inhibitors in  
 prevention of, 1088  
 uterine  
 estrogen and, 722
- Bleeding disorders  
 aprotinin in, 617  
 drugs used for, **614–617**, 615*t*  
 fibrinolytic inhibitors in, 604*f*, 616  
 plasma fractions in, 615–616, 615*t*  
 recombinant factor VIIA in, 603*f*, 616  
 serine protease inhibitors in, 617  
 vitamin K for, 614–615
- Bleomycin  
 for cancer, **966**  
 clinical activity and toxicities of, 963*t*
- Blocadren, 189. *See also* Timolol
- Blood alcohol concentration (BAC)  
 clinical effects of  
 in nontolerant persons, 391, 391*t*
- Blood cells  
 lipoxigenase and, 323
- Blood clotting  
 initiation of, 602–604, 603*f*
- Blood coagulation, **601–602**  
 disorders of  
 drugs used for, **601–618**. *See also*  
*specific drugs and* Anticoagulants  
 estrogen effects on, 720
- Blood coagulation cascade, 602, 603*f*, 603*t*
- Blood gases  
 arterial  
 in poisoning assessment, 1030
- Blood pressure  
 regulation of, **169–171**, 170*f*, 170*t*, 171*f*
- Blood schizonticides, 915
- Blood vessels  
 autonomic nerve activity effects on, 90*t*
- BMI  
 calculation of, 664
- Boceprevir  
 for HCV infection, 886
- Body mass index (BMI)  
 calculation of, 664
- Bond(s) drug-receptor, **4**
- Bone(s)  
 Paget's disease of, **784**  
 PTH, FGF23, and vitamin D effects on,  
 774*t*  
 tetracyclines effects on, 812
- Bone marrow transplantation  
 immunosuppressive drugs in, **994–995**  
 passive immunization for, 1168*t*
- Bone metabolism  
 prostaglandins effects on, 322
- Bone mineral homeostasis, **769–785**  
 FGF23 in, 770, 770*f*, 771*f*; **773**  
 hormonal interactions controlling, 771*f*  
 hormonal regulators of  
 principal, **770–774**  
 secondary, **774–775**  
 mechanisms contributing to, 770*f*  
 nonhormonal agents affecting, **776–778**,  
 776*f*  
 parathyroid hormone and, 770  
 vitamin D and, 772
- Bone mineral-regulating hormones  
 disorders involving, **780–785**
- Boniva, 786. *See also* Ibandronate sodium
- Borage  
 risks associated with, 1127*t*
- Bortezomib  
 for multiple myeloma, 971
- Bosentan, 305, 305*f*, 255  
 in heart failure management, 219
- Botanical pesticides, **1008**, 1009*f*
- Botanical substances, **1126–1134**

- Botox, 481. *See also* Botulinum toxin, type A
- Botulinum toxin, 84, **479**, **481**
- Botulism
- passive immunization for, 1168*t*
- Brain
- cellular organization of, **364–366**, 365*f*
  - hierarchical systems in, 365, 365*f*
  - nonspecific/diffuse neuronal systems in, 365–366
- Brain cancer
- chemotherapeutic drugs for, **974**
- Brain-derived neurotrophic factor (BDNF)
- in major depression, 522–523, 522*t*
- Brain natriuretic peptide (BNP)
- in heart failure management, 219
- Bravelle, 678. *See also* Urofollitropin
- Breast(s)
- oral contraceptives effects on, 727
- Breast cancer
- chemotherapeutic drugs for, **971–972**
- Brethine, 355. *See also* Terbutaline
- BreviBloc, 167, 189, 249. *See also* Esmolol
- Brevital, 446. *See also* Methohexital
- Brimonidine, for ophthalmic disorders, 145, 148
- Brinzolamide, 270
- Bromfenac, 655
- Bromocriptine, 672
- for parkinsonism, 489, 499
- Bromocriptine mesylate, 678
- Brompheniramine
- dosage of, 279*t*, 292
- Bronchiolar smooth muscle
- autonomic nerve activity effects on, 90*t*
  - histamine effects on, 276
- Bronchodilation
- sympathomimetic drugs and, 137*t*, 138
- Bronchodilators
- for asthma, **351**
- Brovano, 355. *See also* Arformoterol
- Brovex, 292. *See also* Brompheniramine
- Brugia* spp.
- diethylcarbamazine citrate for, 940
- Bucindolol, 162
- Bucladin-S Softabs, 292. *See also* Buclizine
- Buclizine, 292
- Budesonide
- for inflammatory bowel disease, 1103
  - preparations available, 355, 1112
- Bulk-forming laxatives, **1093**, 1112
- Bumetanide
- dosage of, 259*t*, 270
- Bumex, 270. *See also* Bumetanide
- Bupivacaine, 451*t*, **460**, 463
- ionization constants of, 11*t*
  - pharmacokinetic properties of, 452*t*
  - toxicity of
    - reversal of, 458
- Buprenex, 562. *See also* Buprenorphine
- Buprenorphine, 558–559, 562
- pharmacokinetics of, 545*t*
- Bupropion, **527–531**, 539
- dosage of, 535*t*
  - in nicotine addiction management, 575
  - overdose of, 1034
- Burimamide, 276–277
- BuSpar, 387. *See also* Buspirone
- Buspirone, 283–285, 374, 376, 387
- Busulfan
- clinical activity and toxicities of, 956*t*
  - fetal effects of, 1042*t*
- Butenafine
- preparations available, 858
  - from prescription to OTC status, 1116*t*
  - topical, **1065**
- Butoconazole, 858
- from prescription to OTC status, 1116*t*
- Butorphanol, 559, 562
- pharmacokinetics of, 545*t*
- Butoxamine, **162**
- Butyrophenone(s)antipsychotics, 503*f*, 504–505, 505*t*
- advantages and disadvantages of, 509*t*
  - chemical structure effects on potency and toxicity of, 505*t*
  - for nausea and vomiting, **1100**
- Butyrylcholinesterase (BCHE), 65
- Byetta, 766. *See also* Exenatide
- Bystolic, 167, 189, 225. *See also* Nebivolol
- C**
- Cabazitaxel
- for cancer, 963*t*, 964
- Cabergoline, 672, 678
- Calcineurin inhibitors
- as immunosuppressive drugs, 985*t*, **986**
- Calcitonin
- in bone mineral homeostasis, **774–775**
- Cadmium
- as environmental pollutant, **1011–1012**
- Cadmium fume fever, 1012
- Cafergot, 292. *See also* Ergotamine mixtures
- Caffeine, **344–345**
- during lactation, 1048*t*
  - in OTC products, 1123*t*
- Cal-Sup, 786. *See also* Calcium carbonate
- Calan, 190, 209, 249. *See also* Verapamil
- Calciferol, 786. *See also* Ergocalciferol
- Calcimimetics
- in bone mineral homeostasis, 777
- Calcionate, 786. *See also* Calcium glubionate
- Calcipotriene
- for psoriasis, **1071**
- Calciquad, 786. *See also* Calcium glubionate
- Calcitonin
- for hypercalcemia, 778, 786
- Calcitonin gene-related peptide (CGRP), **308**
- in ANS, ENS, and NANC neurons, 81*f*, 84*t*
  - in migraine, 285
- Calcitonin-Salmon, 786
- Calcitriol, 786
- for psoriasis, **1071**
- Calcium
- abnormal levels of
    - in bone mineral homeostasis, **778–780**  - contractile proteins sensitivity to, 212
  - digitalis with, 218
  - for hypocalcemia, 779–780
  - as poisoning antidote, 1033*t*
  - as second messengers, 28–29, 28*f*
  - stored in and released from sarcoplasmic reticulum, 212
  - trigger
    - amount of, 212
- Calcium salts, 786
- Calcium carbonate as antacid, 1083
- Calcium channel(s)
- voltage-activated
    - properties of, 201*t*
- Calcium channel blockers. *See also specific drugs*
- for angina pectoris, **201–205**
  - as antihypertensive drug, **183**
  - for cardiac arrhythmias, **245**
  - in control of smooth muscle contraction, 194, 195*f*
  - drug interactions with, 1154*t*
  - overdose of, **1035**
- Calcium Disodium Versenate, 1025. *See also* Edetate calcium
- Calcium ion, 25
- cAMP, 25
- Campath, 999. *See also* Alemtuzumab
- Campral, 400. *See also* Acamprosate calcium
- Camptothecins
- for cancer, 963*t*, **964–965**
- Canakinumab, 996, 999
- Canasa, 1102, 1102*f*
- Cancer(s). *See also specific types and sites*
- alcohol effects on, 395
  - causes of, **949–950**
  - cell cycle and, 951, 952*f*
  - estrogen and, 722
  - garlic effects on, 1129
  - insulin and, 753
  - oral contraceptives and, 730
  - prostaglandins effects on, 322
  - treatment modalities for, **950–951**. *See also* Cancer chemotherapy
- Cancer chemotherapy, **949–976**. *See also specific drugs and types of cancer*

- Cancer chemotherapy (*Cont.*):  
 alkylating agents, **953–958**  
 antimetabolites, **958–962**  
 antitumor antibiotics, **965–966**  
 cell cycle kinetics and, **951–953**, 951*f*,  
 952*f*, 952*t*  
 cell cycle–nonspecific drugs, 951, 952*t*  
 cell cycle–specific drugs, 951, 952*t*  
 drug combinations in, 951–953  
 drug resistance in, 953  
 milk thistle effects on, 1132  
 nausea and vomiting due to  
 5-HT<sub>3</sub>-receptor antagonists for, 1099
- Candidas, 858. *See also* Caspofungin
- Candesartan, 190, 225
- Cannabinoids  
 abuse of, 569*t*, 572–573  
 for nausea and vomiting, **1100**
- Cantil, 127. *See also* Mepenzolate
- Capacity-limited elimination, 39*t*–40*t*,  
 41–42
- Capacity-limited protein binding  
 in drug concentration measurements, 49
- Capastat Sulfate, 848. *See also* Capreomycin
- Capecitabine  
 for cancer, **960**  
 clinical activity and toxicities of, 959*t*
- Capoten, 190, 225. *See also* Captopril
- Capreomycin  
 for tuberculosis, 840*t*, 844
- Capromab pendetide, 992
- Captopril, 190, 225, 299  
 as antihypertensive drug, 184–185  
 dosage of, 175*t*, 185  
 pharmacokinetics of, 39*t*, 175*t*, 185
- Carafate, 1111. *See also* Sucralfate
- Carbachol, 99*f*, 112  
 properties of, 99, 100*t*
- Carbamate(s)  
 durations of action of, 106*t*  
 therapeutic uses for, 106*t*
- Carbamate pesticides, **1008**, 1008*t*
- Carbamazepine, 409–410, 427, **517**, 519  
 for bipolar disorder, 517  
 drug interactions with, 410, 1154*t*  
 fetal effects of, 1042*t*  
 pharmacokinetics of, 39*t*, 410  
 for seizures, **409–410**  
 therapeutic levels/dosage of, 410
- Carbapenem(s), 791*f*, **801–802**,  
 807–808  
 pharmacokinetics and dosage of, 798*t*,  
 801–802
- Carbaryl, structure of, 105*f*  
 toxicity rating for, 1008*t*
- Carbenicillin  
 clinical uses of, 796
- Carbenoxolone  
 hepatic clearance of  
 aging effects on, 1052*t*
- Carbidopa, 485, 499
- Carbidopa/levodopa, 499
- Carbidopa/levodopa/entacapone, 499
- Carbimazole  
 structure of, 688*f*
- Carbinoxamine, 292  
 dosage of, 279*t*
- Carbocaine, 463. *See also* Mepivacaine
- Carbofuran  
 toxicity rating for, 1008*t*
- Carbohydrate(s)  
 impaired tolerance for  
 thiazide diuretics and, 261  
 metabolism of  
 oral contraceptives effects on, 728
- Carbon monoxide, TLVs of, 1005*t*
- Carbon monoxide poisoning, **1003–1004**,  
**1035**, 1036*t*
- Carbon tetrachloride, TLVs of, 1005*t*
- Carbonic anhydrase inhibitors, **256–258**,  
 257*t*  
 for open-angle glaucoma, 161*t*
- Carboplatin  
 clinical activity and toxicities of, 956*t*
- Carboprost, 328
- Carboprost tromethamine, 324, 325*f*
- Cardene, 190, 209. *See also* Nicardipine
- Cardiac arrhythmias  
 beta-receptor antagonists for,  
 162, 163*f*  
 drugs used for, **227–250**. *See also*  
 Antiarrhythmic drugs  
 mechanisms of, **233–235**,  
 233*f*–236*f*  
 disturbances of impulse conduction,  
 234–235, 234*f*–236*f*  
 disturbances of impulse formation,  
 233*f*, 234  
 nonpharmacologic therapy of, 228
- Cardiac disease. *See* Heart disease
- Cardiac muscle  
 calcium channel blockers effects on,  
 203–204
- Cardiac output  
 in heart failure, 212–213  
 inhaled anesthetics effects on, 433
- Cardiac resynchronization therapy  
 in chronic heart failure management,  
 221
- Cardiac rhythm  
 normal  
 electrophysiology of, **227–233**
- Cardiac stress test  
 dobutamine in, 144
- Cardiogenic shock  
 sympathomimetic drugs for, 144
- Cardiomyopathy  
 alcohol and, 393–394
- Cardioquin, 249. *See also* Quinidine  
 polygalacturonate
- Cardiovascular disorders  
 antimuscarinic drugs for, 121  
 beta-receptor antagonists for, 163  
 sympathomimetic drugs for, 144–145
- Cardiovascular drugs  
 in the elderly, **1056**
- Cardiovascular system, *see* specific drugs
- Cardizem, 189, 209, 250. *See also*  
 Diltiazem
- Cardura, 167, 189. *See also* Doxazosin
- Carisoprodol, 481
- Carmustine, 954*f*  
 clinical activity and toxicities of, 956*t*
- Carperitide  
 in heart failure management, 219
- Carteolol, 159*t*, 161  
 as antihypertensive drug, 179
- Cartrol, 189. *See also* Carteolol
- Carvedilol, 159*t*, 162  
 as antihypertensive drug, 179  
 preparations available, 167, 189, 225  
 racemate of, 5, 5*t*
- Cascara  
 in constipation management, 1093
- Cascara sagrada, 1112
- Casodex, 740. *See also* Bicalutamide
- Caspofungin, 855, 858
- Cataflam, 655. *See also* Diclofenac
- Catapres, 189. *See also* Clonidine
- Catechol, 136*f*
- Catechol-*O*-methyltransferase (COMT)  
 in catecholamine metabolism, 87, 88*f*
- Catechol-*O*-methyltransferase (COMT)  
 inhibitors  
 for parkinsonism, **490–491**
- Catecholamine(s)  
 biosynthesis of, 84–86, 86*f*  
 endogenous, 138*t*, 140–141
- Catecholamine reuptake inhibitors  
 sympathomimetic drug effects on, **143**
- Cathartics  
 activated, 1032  
 in constipation management, **1093**
- Causal prophylactic drugs, 915
- Ceclor, 807. *See also* Cefaclor
- Cedax, 807. *See also* Ceftriaxone
- Cefaclor, 807, 797*f*
- Cefadroxil, 797*f*, 807  
 pharmacokinetics and dosage of, 797,  
 798*t*
- Cefazolin, 797*f*, 807  
 pharmacokinetics and dosage of, 798*t*,  
 799
- Cefdinir, 797*f*, 807
- Cefditoren, 807
- Cefepime, 797*f*, 807  
 pharmacokinetics and dosage of, 798*t*,  
 800
- Cefixime, 807
- Cefizox, 807. *See also* Ceftriaxone

- Cefmetazole, 807
- Cefotan, 807. *See also* Cefotetan
- Cefotaxime, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*, 800
- Cefotetan, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*
- Cefoxitin, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*
- Cefpodoxime, 797*f*
- Cefprozil, 797*f*; 807
- Ceftaroline, 797*f*; 800
- Ceftaroline fosamil  
pharmacokinetics and dosage of, 798*t*, 800
- Ceftazidime, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*, 800
- Ceftibuten, 797*f*; 807
- Ceftin, 807. *See also* Cefuroxime
- Ceftizoxime, 797*f*; 807
- Ceftriaxone, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*, 800
- Cefuroxime, 797*f*; 807  
pharmacokinetics and dosage of, 798*t*
- Cefzil, 807. *See also* Cefprozil
- Celebrex, 655. *See also* Celecoxib
- Celecoxib, 638*t*, **640**, 655
- Celestone, 712. *See also* Betamethasone
- Celestone Phosphate, 712. *See also* Betamethasone sodium phosphate
- Celexa, 539. *See also* Citalopram
- Celiprolol, properties of, 159*t*
- Celivarone, 242
- Cell cycle kinetics  
in cancer chemotherapy, **951–953**, 951*f*, 952*f*, 952*t*
- Cell growth  
angiotensin II effects on, 298
- Cell-mediated immunity, 978
- Cell proliferation  
prevention of  
immunosuppressive drugs for, 985*t*
- CellCept, 999. *See also* Mycophenolate mofetil
- Celontin, 427. *See also* Methsuximide
- Cenestin, 740. *See also* Esterified estrogens
- Central integration  
in functional organization of autonomic activity, 81*f*; 89
- Central nervous system (CNS)  
alcohol effects on, 391, 391*t*  
angiotensin II effects on, 298  
antimuscarinic drug effects on, 116, 118  
antipsychotic drugs effects on, 507*t*, 508  
barbiturates effects on, 441  
benzodiazepines effects on, 442
- Central nervous system (*Cont.*):  
dexmedetomidine effects on, 445  
digitalis effects on, 217  
direct-acting cholinomimetic drug effects on, 102*t*, 104  
disorders of  
antimuscarinic drugs for, 120–121  
cholinomimetic drugs for, 109  
sympathomimetic drugs for, 146  
drugs acting in, **359–580**. *See also* Central nervous system (CNS) drugs  
ergot alkaloids effects on, 288–289  
etomidate effects on, 443  
ganglion-blocking drug effects on, 124  
ginkgo effects on, 1130  
indirect-acting cholinomimetic drug effects on, 107  
ketamine effects on, 444  
local anesthetics effects on, 457–458  
methylxanthines effects on, 345  
morphine effects on, 549–551, 551*t*  
nitric oxide effects on, 336  
oral contraceptives effects on, 727  
propofol effects on, 440  
prostaglandins and thromboxanes effects on, 321  
sympathomimetic drug effects on, 140
- Central nervous system (CNS) drugs, **359–580**. *See also specific types and drugs*  
in the elderly, **1053–1055**  
pharmacology of, **359–371**  
in cellular organization of brain, **364–366**, 365*f*  
central neurotransmitters in, **366–371**, 366*t*–367*t*  
identification of, **364**  
ion channels in, **360–361**, 362*f*  
methods for study of, 359–360, 361*f*  
neurotransmitter receptors in, **360–361**, 362*f*  
synapses and synaptic potentials in, **361–363**, 362*f*, 363*f*  
sites of action of, **363–364**, 364*f*
- Central neurotransmitters  
identification of  
CNS drugs and, **364**
- Central precocious puberty  
gonadotropins in, 670–671
- Cephalexin, dosage of, 797, 798*t*  
pharmacodynamics of, 797, 798*t*
- Cephalosporin(s), **797–801**. *See also specific drugs*  
active against methicillin-resistant staphylococci, 800  
adverse effects of, **800–801**  
chemistry of, 797, 797*f*  
toxicity of, 800–801
- Cephalothin, pharmacokinetics 39*t*
- Cephamycins, **797–801**
- Cephradine, pharmacokinetics and dosage of, 797
- Cephulac, 1112. *See also* Lactulose
- Cerebral vasospasm  
following subarachnoid hemorrhage  
calcium channel blockers effects on, 204
- Cerebrospinal fluid (CSF)  
antimicrobial drugs in, 908, 909*t*
- Cerebrovascular disease  
oral contraceptives and, 729
- Cerebyx, 427. *See also* Fosphenytoin
- Certolizumab, **648**  
for inflammatory bowel disease, 1104–1106, 1105*t*  
preparations available, 656, 999, 1112
- Certolizumab pegol, 992
- Cervidil, 328. *See also* Dinoprostone
- Cesamet, 1112. *See also* Nabilone
- Cestodes  
drugs used for, 938*t*
- Cetirizine, 292  
dosage of, 279*t*  
from prescription to OTC status, 1116*t*
- Cetrorelix, 671, 678
- Cetrotide, 678. *See also* Cetrorelix acetate
- Cetuximab, 991  
for cancer, **967–968**
- Cevimeline, 112
- cGMP  
as second messengers, 29
- Channel(s)  
ligand-gated, 23–24, 24*f*; 362*f*  
voltage-gated, 23–24, 24*f*; 362*f*
- Chantix, 112. *See also* Varenicline
- Chaparral  
risks associated with, 1127*t*
- Charcoal  
activated  
in decontamination of poisoned patient, 1032
- ChAT, 82, 83*f*
- Chelators  
pharmacology of, **1021–1025**. *See also specific drugs*
- Chemet, 1025. *See also* Succimer
- Chemical(s)  
toxic exposure to, **1003–1005**, 1005*t*
- Chemical antagonists, 20  
defined, 4
- Chemical contraception  
in men, **739**
- Chemoattractant cytokines, 977–978
- Chemokines, 977–978
- Chemoreceptor reflex, 283
- Chemotherapeutic drugs, **789–1000**.  
*See also specific drugs, types of cancer, and* Cancer chemotherapy

- Children. *See* Pediatric patients
- Chirality, 4–5
- Chirocaine, 463. *See also* Levobupivacaine
- Chlor-Trimeton, 292. *See also*  
Chlorpheniramine
- Chloral hydrate, 375*f*, 387  
during lactation, 1048*t*
- Chlorambucil  
clinical activity and toxicities of, 956*t*
- Chloramine T  
as antiseptic/disinfectant, 895
- Chloramphenicol, **816–817**, 819  
drug interactions with, 1154*t*  
during lactation, 1048*t*  
pharmacokinetics of, 39*t*, 816
- Chlordane  
toxicity rating for, 1006*t*
- Chlordiazepoxide  
dosages of, 383*t*  
hepatic clearance of  
aging effects on, 1052*t*  
ionization constants of, 11*t*  
pharmacokinetics of, 39*t*, 377*t*
- Chlorfenvinphos  
toxicity rating for, 1007*t*
- Chlorhexidine  
as antiseptic/disinfectant, 893*t*, **894–895**
- Chloride channel activator  
in constipation management, **1094**  
for irritable bowel syndrome, **1097**
- Chloride channel GABA receptor complex,  
378*f*, 380
- Chlorine  
as antiseptic/disinfectant, 893*t*, 895
- Chlorine dioxide  
as antiseptic/disinfectant, 893*t*, 895
- Chlormethiazole  
hepatic clearance of  
aging effects on, 1052*t*
- Chloroform  
TLVs of, 1005*t*
- Chloromycetin, 819. *See also*  
Chloramphenicol
- Chlorophenoxy herbicides, **1008–1009**,  
1009*f*
- Chloroprocaine, **460**, 463
- Chloroquine, **644**, **916–920**, 917*t*, 918*f*,  
919*t*, 920, 935  
ionization constants of, 11*t*  
for malaria, **916–920**, 917*t*, 918*f*, 919*t*  
pharmacokinetics of, 39*t*, 644, 916, 918*f*
- Chlorothiazide, 261*t*, 270  
ionization constants of, 11*t*  
during lactation, 1048*t*
- Chlorotrianisene, 718*f*, 719*t*
- Chlorpheniramine, 278*f*, 279*t*, 292  
ionization constants of, 11*t*
- Chlorpromazine, 155, 503*f*, 519  
advantages and disadvantages of,  
509*t*–510*t*
- Chlorpromazine (*Cont.*):  
ionization constants of, 11*t*  
during lactation, 1048*t*
- Chlorpropamide, 755*t*, 766  
for diabetes mellitus, 754, 755*t*  
fetal effects of, 1042*t*  
ionization constants of, 11*t*  
pharmacokinetic parameters for, 39*t*
- Chlorthalidone, 261*t*, 270
- Chlorzoxazone, 481
- Cholecalciferol, 786
- Cholecystokinin (CCK)  
in ANS, ENS, and NANC  
neurons, 84*t*
- Cholesterol, 619
- Cholesteryl ester(s), 619
- Cholesteryl ester transfer protein (CETP)  
inhibitors  
for hyperlipidemias, 631
- Cholestyramine, **629–630**, 633  
for diarrhea, 1095
- Choline acetyltransferase (ChAT),  
82, 83*f*
- Choline esters  
properties of, 99, 100*t*
- Choline salicylate, 655
- Choline transporter, 82, 83*f*
- Cholinergic fibers, 80*f*, 82
- Cholinergic nerves  
cotransmitters in, 87
- Cholinergic poisoning  
antimuscarinic drugs for, 122–123
- Cholinergic receptors, 87, 89*t*
- Cholinergic transmission, 82–84, 83*f*, 84*t*
- Cholinesterase inhibitors, 105*f*, **110–112**  
for Alzheimer's disease, 1055*t*  
overdose of, **1035–1036**
- Cholinesterase regenerator(s), 127
- Cholinesterase regenerator compounds  
antimuscarinic drugs for, 123
- Cholinoceptor, 84  
characteristics of, 98*t*  
subtypes of, 98*t*
- Cholinoceptor-activating drugs, **97–113**.  
*See also* Cholinomimetic drugs
- Cholinoceptor-blocking drugs, **115–128**.  
*See also* Cholinoreceptor  
antagonists
- Cholinomimetic drugs, **97–113**  
clinical pharmacology of, **108–110**  
clinical uses of, **108–110**  
direct-acting, **99–105**  
in gastrointestinal motility stimulation,  
**1092**  
groups of, 97, 98*f*  
indirect-acting, **105–107**  
mode of action of, 99  
for open-angle glaucoma, 161*t*  
spectrum of action of, **97–98**, 98*t*  
toxicity of, 109–110
- Cholinoreceptor antagonists, **115–128**  
ganglion-blocking drugs, **124–125**  
muscarinic receptor–blocking drugs,  
**115–120**. *See also*  
Antimuscarinic drugs
- Chorea  
described, 483  
forms of, 495
- Choriogonadotropin alfa, 667  
preparations available, 678
- Chorionic gonadotropin, 678
- Chronic kidney disease,  
vitamin D for, 781–782
- Chronic lymphocytic leukemia (CLL)  
passive immunization for, 1168*t*
- Chronic obstructive pulmonary disease  
(COPD)  
antimuscarinic drugs for, 121  
treatment of, **353**
- Chronic orthostatic hypotension  
sympathomimetic drugs for, 144
- Chronotropic effect  
positive, 138
- Chronulac, 1112. *See also* Lactulose
- Chrousos syndrome  
synthetic corticosteroids for, 704
- Chylomicron(s), 620
- Chylomicronemia  
primary, 623  
drugs used for, 622*t*
- Cialis, 209. *See also* Tadalafil
- Ciclesonide, 348
- Ciclopirox olamine  
topical, **1065**
- Cidex, 898. *See also* Glutaraldehyde
- Cidex OPA, 898. *See also* Ortho-  
phthalaldehyde (OPA)
- Cidofovir, 863*f*, 867*t*, 888  
for CMV infections, **868–869**
- Cigarette smoking  
coronary disease related to, 619
- Cilastatin, 802
- Cilostazol, 209, 617  
as antiplatelet agent, 614  
for intermittent claudication, 207
- Cimetidine, 1083*t*, 1111  
drug interactions with, 610*t*, 1155*t*  
pharmacokinetics, 39*t*  
from prescription to OTC status,  
1116*t*
- Cimzia, 999, 1112. *See also* Certolizumab
- Cinacalcet, 780, 786
- Cinchonism, 922
- Cipro, 837. *See also* Ciprofloxacin
- Ciprofloxacin  
clinical uses of, 836  
ionization constants of, 11*t*  
pharmacokinetics of, 39*t*, 836, 836*t*
- Circus movement, 234, 234*f*
- Cirrhosis, hepatic, diuretics for, **267**

- Cisapride, 286  
in constipation management, 1094
- Cisatracurium, **468–470**, 481
- Cisplatin  
clinical activity and toxicities of, 956*t*  
drug interactions with, 1155*t*
- Citalopram  
dosage of, 535*t*  
pharmacokinetics of, 529*t*
- Citanest, 463. *See also* Prilocaine
- Citracal, 786. *See also* Calcium citrate
- Citrucel, 1112. *See also* Methylcellulose
- Cladribine  
for cancer, **962**  
clinical activity and toxicities of, 959*t*
- Clarinet, 292. *See also* Desloratadine
- Clarithromycin, **814**, 819
- Claritin, 292. *See also* Loratadine
- Classic angina, 193
- Claudication, intermittent treatment of, 207
- Clavulanic acid, 801*f*
- Clearance, 38–42, 39*t*–41*t*, 1027–1028  
capacity-limited elimination and, 39*t*–40*t*, 41–42  
defined, 38  
drug accumulation and  
time course of, 42–43, 42*f*  
in drug concentration measurements, 49, 50  
in the elderly, 1052*f*, 1052*t*, 1053  
flow-dependent elimination and, 39*t*–40*t*, 42  
in infants and children, 1045–1046  
models of, 38, 41*f*  
pharmacokinetic mechanisms of, 1161  
as pharmacokinetic variable, 48
- Clemastine, 292  
from prescription to OTC status, 1116*t*
- Cleocin, 819, 935. *See also* Clindamycin; Lincomycin
- Clevidipine, 189, 209
- Cleviprex, 189, 209. *See also* Clevidipine
- Clidinium, 127
- Clindamycin, **815**, 815*f*  
for acne, 1064
- Clinical trials, **72–77**  
controlled, 2  
types of evidence in, 73
- Clinoril, 656. *See also* Sulindac
- Clobazam, for epilepsy, 420  
hepatic clearance of  
aging effects on, 1052*t*
- Clofazimine, dosage of, 840*t*  
for leprosy, **846**
- Clomid, 740. *See also* Clomiphene
- Clomiphene, 731, 732*f*, **733–734**, 740
- Clomipramine, 527*f*, 539  
dosage of, 535*t*  
fetal effects of, 1042*t*
- Clomipramine (*Cont.*):  
pharmacodynamics of, 530*t*  
pharmacokinetics of, 529*t*
- Clonazepam, 387, 427  
for epilepsy, 420
- Clonidine, **176**, 176*f*, 189  
for hypertension, 146, **176–177**  
ionization constants of, 11*t*  
pharmacokinetics of, 39*t*, 175*t*, 177  
as premedication before anesthesia, 146  
for tics, 495
- Clonorchiasis  
praziquantel for, 944
- Clopidogrel, 617  
as antiplatelet agent, 613
- Clorzepate, 387  
dosages of, 383*t*  
pharmacokinetic properties of, 377*t*
- Clorzepate dipotassium  
for epilepsy, 420, 427
- Clotrimazole, 853*f*, 858  
from prescription to OTC status, 1116*t*
- Cloxacillin, dosage of, 795*t*
- Clozapine, 504*f*, 519  
advantages and disadvantages of, 509*t*  
dosage of, 510*t*
- Clozaril, 519. *See also* Clozapine
- CMV infections. *See* Cytomegalovirus (CMV) infections
- CNS. *See* Central nervous system (CNS)
- Co-Lyte, 1112. *See also* Polyethylene glycol electrolyte solution
- Coagulation  
disorders of  
drugs used for, **601–618**, 615*t*.  
*See also specific drugs and*  
Anticoagulants  
mechanisms of, **601–602**, 602*f*
- Coagulation factor VIIa recombinant, 617
- Coartem, 935. *See also* Artemether/ lumefantrine  
for malaria, 919*t*
- Cocaine, 451*t*, **460**, 463  
abuse of, 569*t*, 576  
fetal effects of, 1042*t*  
ionization constants of, 11*t*  
sympathomimetic drug effects of, 143
- Cockcroft-Gault formula, 1053
- Codeine, 558, 559, 562, 563  
ionization constants of, 11*t*  
during lactation, 1048*t*  
pharmacokinetics of, 545*t*
- Codeine/acetaminophen, 562
- Codeine/aspirin, 562
- Coenzyme Q10, **1134–1135**
- Cogentin, 499. *See also* Benztropine
- Cognex, 112. *See also* Tacrine
- Cognitive remediation  
antipsychotic drugs in, 513
- Colace, 1112. *See also* Docusate
- Colazal, 1112. *See also* Balsalazide
- Colchicine, 656  
drug interactions with, 1155*t*
- Colcrys, 656. *See also* Colchicine
- “Cold” preparations  
ingredients in, 1118*t*
- Colesevelam, **629–630**, 633  
for diabetes mellitus, 760  
for diarrhea, 1095
- Colestid, 633. *See also* Colestipol
- Colestipol, **629–630**  
for diarrhea, 1095
- Colistimethate sodium, 898
- Colitis  
amebic  
drugs used for, 927
- Collecting tubule system  
in renal tubule transport, 252*t*, 254–255, 254*f*
- Colorectal cancer  
chemotherapeutic drugs for, 972
- Coltsfoot  
risks associated with, 1127*t*
- Coly-mycin M, 898. *See also* Colistimethate sodium
- Coma  
hyperosmolar  
nonketotic, 744  
myxedema, 691
- Combantrin, 946. *See also* Pyrantel pamoate
- Combivent, 355. *See also* Albuterol/ ipratropium
- Comfrey  
risks associated with, 1127*t*
- Compazine, 1112. *See also* Prochlorperazine
- Complement  
in innate immunity, 979*f*
- Complex partial seizures, 421
- Compliance  
in clinical trials, 73  
in prescribing drugs, **1143–1144**
- Compound(s)  
with estrogenic activity, 718, 718*f*
- Compound F, **698–702**. *See also* Cortisol
- COMT inhibitors  
for parkinsonism, **490–491**
- Comtan, 499. *See also* Entacapone
- Concentration, target, 45
- Concentration-dependent killing, 823, 907
- Concentration-effect curves  
receptor binding of agonists and, 16, 17*f*
- Concentration gradient  
as factor in pharmacologic response to dermatologic drugs, 1061
- Congenital adrenal hyperplasia  
synthetic corticosteroids for, 704
- Congestive heart failure  
sympathomimetic drugs in, 225

- Conivaptan, 264, 270, 675, 678  
in acute heart failure management, 222
- Conjugated estrogens  
dosage of, 731*t*
- Conscious sedation, 430
- Consciousness  
anesthesia and, 435
- Constitutive activity, 7
- Contact dermatitis  
topical dermatologic medications and, 1063*t*  
topical dermatologic medications and, 1063*t*
- Contact hypersensitivity, 983
- Contact urticaria  
topical dermatologic medications and, 1063*t*
- Context-sensitive half-time, 440
- Continuous subcutaneous insulin infusion (CSII) devices, 750–751
- Contraception  
chemical  
in men, 739  
hormonal, 725*t*, 726–731  
“morning after,” 731
- Contraceptives  
emergency  
ingredients in, 1121*t*  
implantable, 725*f*  
oral, 725*f*  
postcoital, 731, 731*t*
- Contractile proteins  
sensitivity to calcium, 212
- Contractility  
in cardiac performance, 215, 215*f*
- Controlled clinical trial, 2
- Controlled ovarian hyperstimulation, 667, 668*f*  
gonadotropins in, 670
- Controlled substances  
classification of, 1145–1146, 1145*t*
- Converting enzyme, 297–298, 298*f*
- Convulsion(s)  
neuromuscular blocking  
drugs for, 476
- COPD. *See* Chronic obstructive pulmonary disease (COPD)
- Coplanar biphenyls, 1010
- Cordarone, 249. *See also* Amiodarone
- Coreg, 167, 189, 225. *See also* Carvedilol
- Corgard, 167, 189. *See also* Nadolol
- Corlopam, 148, 189. *See also* Fenoldopam
- Coronary artery disease  
alcohol and, 394  
myxedema and, 690–691  
smoking and, 619
- Coronary blood flow  
determinants of, 194
- Cortef, 712. *See also* Hydrocortisone
- Cortenema, 1112. *See also* Hydrocortisone
- Cortex  
circuitry of, 483, 484*f*
- Corticotropin, 678
- Corticotropin-releasing hormone (CRH), 661, 661*f*  
clinical uses of, 661*t*
- Cortifoam, 1112. *See also* Hydrocortisone
- Cortisol, 697, 698–702
- Cortisone, 712  
clinical uses and dosage of, 703*t*
- Cortone Acetate, 712. *See also* Cortisone
- Cortrosyn, 678. *See also* Cosyntropin
- Corvert, 249. *See also* Dronedarone
- Cosyntropin, 678
- Cotransmitter(s)  
in cholinergic and adrenergic nerves, 84*t*, 87
- Cotransmitter substances, 82
- Cough suppression. *See also* Antitussives  
opioid analgesics in, 551, 553
- Coumadin, 617. *See also* Warfarin
- Coumarin anticoagulants, 608–611
- Coupling  
receptor-effector  
spare receptors and, 16–18, 17*f*
- COX-2 inhibitors  
selective, 640
- COX inhibitors  
nonselective, 640–642
- Cozaar, 190, 225. *See also* Losartan
- Creon, 1111. *See also* Pancrelipase
- Crestor, 633. *See also* Rosuvastatin
- CRH. *See* Corticotropin-releasing hormone (CRH)
- Crixivan, 889. *See also* Indinavir
- Cromolyn  
for asthma, 348–349, 352  
ionization constants of, 11*t*  
from prescription to OTC status, 1116*t*
- Crotamiton, 1068
- Cryoablation  
for cardiac arrhythmias, 228
- Cryoprecipitate  
for bleeding disorders, 616
- Cryptosporidium* spp.  
drugs used for, 931*t*
- Cubicin, 808. *See also* Daptomycin
- Cuprimine, 499, 656, 1025. *See also* Penicillamine
- Cushing’s syndrome  
synthetic corticosteroids for, 704
- Cyanide  
poisoning by, 1036, 1036*t*
- Cyanocobalamin, 586
- Cyclic adenosine monophosphate (cAMP)  
as second messenger, 25, 26, 28, 28*f*
- Cyclic guanosine monophosphate (cGMP)  
as second messenger, 29
- Cyclizine, 292  
dosage of, 279*t*  
ionization constants of, 11*t*
- Cyclobenzaprine, 481
- Cyclodienes  
toxicity rating for, 1006*t*
- Cyclogyl, 127. *See also* Cyclopentolate
- Cyclooxygenase(s), 314–316, 315*f*
- Cyclopentolate, 127
- Cyclophilin, 986
- Cyclophosphamide, 644  
clinical activity and toxicities of, 956*t*  
fetal effects of, 1042*t*  
as immunosuppressive drugs, 985*t*, 988–989  
metabolism of, 955*f*  
structure of, 954*f*
- Cycloplegia, 118, 119*f*
- Cycloserine, 805, 808, 848  
dosage of, 840*t*  
for tuberculosis, 840*t*, 844
- Cyclospasm, 93, 95*f*
- Cyclospora cayetanensis*  
drugs used for, 931*t*
- Cyclosporine, 644, 999  
dermatologic uses of, 1078*t*  
drug interactions with, 1156*t*  
as immunosuppressive drug, 985*t*, 986  
pharmacokinetics of, 39*t*, 644
- Cyklokapron, 617. *See also* Tranexamic acid
- Cymbalta, 539. *See also* Duloxetine
- CYP. *See* Cytochrome P450 (CYP)
- Cyproheptadine, 279, 286  
dosage of, 279*t*  
preparations available. *See also* Cyclizine
- Cyproterone, 738
- Cyproterone acetate, 738
- Cystospaz-M, 127. *See also* Hyoscyamine
- Cytarabine  
for cancer, 960–961  
clinical activity and toxicities of, 959*t*  
fetal effects of, 1042*t*  
as immunosuppressive drug, 989
- Cytisine  
in nicotine addiction management, 574
- Cytochrome P450 (CYP), 55–64  
in enzyme induction, 57–59, 58*t*  
in enzyme inhibition, 58*t*, 59
- Cytochrome P450 (CYP)–antidepressant  
drug interactions, 537*t*

- Cytochrome P450 (CYP) cycle  
in drug oxidation, 55, 55*f*
- Cytochrome P450 (CYP)–dependent oxidations, 56*t*–57*t*
- Cytochrome P450 (CYP)–independent oxidations, 57*t*
- Cytochrome P450–derived metabolites  
prostaglandins and thromboxanes effects on, 322–323
- Cytokine(s)  
chemoattractant, 977–978  
in immunomodulation therapy, **995–996**, 995*t*–996*t*
- Cytokine inhibitors  
in immunomodulation therapy, **996–997**
- Cytokine receptors, 23, 24*f*
- Cytomegalovirus (CMV) infections  
drugs used for, **866–869**  
passive immunization for, 1168*t*
- Cytomel, 695. *See also* Liothyronine
- Cytosine arabinoside, 960*f*
- Cytosine deoxyriboside, 960*f*
- Cytotec, 328, 1111. *See also* Misoprostol
- Cytotoxic agents  
as immunosuppressive drugs, 985*t*, **988–989**
- Cytovene, 889. *See also* Ganciclovir
- D**
- Dabigatran etexilate mesylate, 608
- Dacarbazine  
for cancer, 957  
clinical activity and toxicities of, 956*t*
- Daclizumab, 999
- DAG. *See* Diacylglycerol (DAG)
- Dalbavancin, **803**
- Dalcetrapib, 631
- Dalmane, 387. *See also* Flurazepam
- Dalteparin, 617
- Danaparoid, 617
- Danazol, **732–733**
- Danocrine, 740. *See also* Danazol
- Dantrium, 481. *See also* Dantrolene
- Dantrolene, **479**
- Dapsone, **846**  
for acne, 1064–1065  
dermatologic uses of, 1078*t*  
for leprosy, 846
- Daptomycin, **803–804**, 808
- Daranide, 270. *See also* Dichlorphenamide
- Daraprim, 837, 935. *See also* Pyrimethamine
- Darbepoetin alfa, 598
- Darifenacin  
for urinary disorders, 122, 122*t*
- Darunavir, 870*t*, **879**  
drug interactions with, 874*t*
- Dasatinib  
for cancer, **966–967**, 967*t*
- Daunorubicin  
for cancer, 963*t*, 965  
clinical activity and toxicities of, 963*t*
- Daypro, 656. *See also* Oxaprozin
- DDT  
toxicity rating for, 1006*t*
- Dealkylation  
oxidative, 56*t*
- Deamination, 56*t*
- Debrisoquin-sparteine oxidation, 63
- Decadron, 712. *See also* Dexamethasone
- Decadron-LA, 712. *See also* Dexamethasone acetate
- Decadron Phosphate, 712. *See also* Dexamethasone sodium phosphate
- Declomycin, 270, 819. *See also* Demeclocycline
- Decongestants  
ingredients in, 1121*t*
- Decontamination  
defined, 894*t*  
of poisoned patients, 1031–1032
- Deep sedation, 430
- Deferasirox, 598, **1024**, **1025**  
for iron poisoning, 586
- Deferoxamine, **1024**  
for iron poisoning, 586  
as poisoning antidote, 1033*t*
- Degarelix, 671, 678
- Degree of sparseness, receptors, 18
- Dehydration  
osmotic diuretics and, 264
- Dehydroemetine  
for amebiasis, **930**
- Delatestryl, 740. *See also* Testosterone enanthate in oil
- Delavirdine, 870*t*, **876–877**, 888
- Delayed afterdepolarizations (DADs), 216, 218*f*, 233*f*, 234
- Delirium tremens, 393
- Delsym, 563. *See also* Dextromethorphan
- Delta-Cortef, 712. *See also* Prednisolone
- Delta-D, 786. *See also* Cholecalciferol
- Demadex, 270. *See also* Toremide
- Demecarium  
duration of action of, 106*t*  
preparations available, 112  
therapeutic uses for, 106*t*
- Demeclocycline, 812, 270, 819
- Demerol, 562. *See also* Meperidine
- Demser, 167. *See also* Metirosine
- Denavir, 889. *See also* Penciclovir
- Denervation supersensitivity, 92
- Denileukin diftitox, 999
- dermatologic uses of, 1078*t*
- Denosumab, 771, 786, 994, 999  
in bone mineral homeostasis, **776–777**  
for osteoporosis, 775, 783
- Deoxycorticosterone, **708–709**
- Deoxycytidine analogs  
for cancer, **960–961**
- Depade, 561. *See also* Naltrexone
- Depakene, 427, 519. *See also* Valproic acid/valproate
- Depakote, 519. *See also* Divalproex
- Depen, 499, 656, 1025. *See also* Penicillamine
- Dependence  
addiction *vs.*, 565  
clinical pharmacology of, **578**  
defined, 565
- Depo-Estradiol, 740. *See also* Estradiol cypionate in oil
- Depo-testosterone, 740. *See also* Testosterone cypionate
- Depolarization(s)  
delayed after, 216, 218*f*, 233*f*  
early after, 233*f*  
premature, 216, 218*f*
- Depo-Medrol, 712. *See also* Methylprednisolone acetate
- Depression  
antidepressants for. *See* Antidepressant(s)  
major, 521–522. *See also* Major depressive disorder  
oral contraceptives and, 730  
pathophysiology of  
hypotheses integration in, 525  
neuroendocrine factors in, 524–525  
psychotic  
antipsychotic drugs for, 509  
recurrent endogenous  
lithium for, 516  
St. John's wort for, 1132–1133  
unipolar  
lithium for, 516
- Dermatitis  
contact  
allergic, photoallergic  
topical dermatologic medications and, 1063*t*
- Dermatologic drugs, **1061–1079**  
for acne, **1069–1071**  
affecting pigmentation, **1068–1069**  
anti-inflammatory drugs, **1072–1074**  
antibacterial drugs, **1063–1065**  
antifungal drugs, **1065–1067**  
antineoplastic agents, **1077**  
antipruritic agents, **1076–1077**  
antiseborrhea agents, **1077–1078**, 1078*t*  
antiviral drugs, **1067**  
ectoparasitocides, **1068**  
immunomodulators, **1067**  
keratolytic and destructive agents, **1074–1076**  
for psoriasis, **1071–1072**  
reactions to, **1061–1063**, 1063*t*  
sunscreens, **1069**



- Dermatologic drugs (*Cont.*):  
 trichogenic and antitrichogenic agents, **1077**  
 vehicles for, **1061–1062**  
 as factor in pharmacologic response to dermatologic drugs, 1061
- Dermopathy  
 thyroid disease–related, 693
- Desensitization  
 heterologous, of receptors, 133  
 homologous, of receptors, 133  
 to drugs, 997–998
- Desferal, 598, 1025. *See also* Deferoxamine
- Desflurane, 432*f*, 446  
 pharmacologic properties of, 433*t*
- Desoxycorticosterone acetate  
 clinical uses and dosage of, 703*t*
- Desipramine  
 chemistry of, 526, 527*f*  
 dosage of, 535*t*  
 pharmacodynamics of, 530*t*
- Desirudin, 617
- Desloratadine, 292
- Desmethyl diazepam, 374*f*  
 hepatic clearance of  
 aging effects on, 1052*t*
- Desmopressin, 616, 674, 678
- Desogestrel, 719*f*  
 properties of, 723*t*
- Desoxyn, 148. *See also* Methamphetamine
- Desulfuration, 56*t*–57*t*
- Desvenlafaxine  
 dosage of, 535*t*
- Desyrel, 539. *See also* Trazodone
- Detrol, 127. *See also* Tolterodine
- Development, fetal  
 critical periods of, 1041*f*
- Dexamethasone, 712  
 clinical uses and dosage of, 703*t*
- Dexamethasone suppression test, 705
- Dexchlorpheniramine, 292
- Dexedrine, 148. *See also* Dextroamphetamine
- Dexfenfluramine, 285
- Dexilant, 1111. *See also* Dexlansoprazole
- Dexlansoprazole  
 pharmacokinetics of, 1086*t*
- Dexmedetomidine, 141, 148, 446  
 as intravenous anesthetic, **445–446**  
 for sedation, 146
- Dexmethylphenidate, 148
- Dexrazoxane  
 in cancer therapy, 966
- Dextroamphetamine, 148
- Dextromethorphan, 559
- Diaβeta, 766. *See also* Glyburide
- Diabetes insipidus  
 diuretics for, **268**  
 nephrogenic  
 ADH antagonists and, 265  
 lithium effects on, 516–517
- Diabetes mellitus  
 defined, 743  
 drugs used for, 764–765  
 glucagon in, 743, **762–763**. *See also* Glucagon  
 glycemic control in  
 benefits of, 751, 752  
 insulin for, 743, **744–745**. *See also* Insulin  
 oral antidiabetic drugs for, **753–762**.  
*See also specific drugs*  
 alpha-glucosidase inhibitors, **759–760**, 759*t*  
 amylin analog, **760**  
 biguanides, **757**  
 bile acid sequestrants, **760**  
 combination therapy with, **761–762**  
 DPP-4 inhibitors, **761**  
 GLP-1 receptor antagonists, **760–761**  
 insulin secretagogues, **754–756**  
 meglitinide, 756, 756*t*  
 D-phenylalanine derivative, 756, 756*t*  
 sulfonylureas, **754–756**, 755*t*  
 thiazolidinediones, **757–759**  
 type 1 (insulin-dependent), 743–744  
 combination therapy for, **762**  
 type 2 (noninsulin-dependent), 744  
 combination therapy for, 761–762  
 type 3, 744  
 type 4 (gestational), 744
- Diabetic ketoacidosis, 744  
 insulin for, 751–752
- Diabinese, 766. *See also* Chlorpropamide
- Diacetylmonoxime, 123*f*  
 for cholinergic poisoning, 123
- Diacomit, 427. *See also* Stiripentol
- Diacylglycerol (DAG), 131, 131*t*, 132*f*, 137*t*  
 as second messengers, 28–29, 28*f*
- Dialysis  
 peritoneal  
 in decontamination of poisoned patient, 1032
- Diamox, 270. *See also* Acetazolamide
- Diarrhea  
 drugs used for, **1094–1095**. *See also specific agents and* Antidiarrheal agents  
 opioid analgesics for, 553
- Diastat, 481. *See also* Diazepam
- Diastolic heart failure, 211
- Diazepam, **476**  
 dosages of, 383*t*  
 for epilepsy, 420  
 fetal effects of, 1042*t*  
 half-life of  
 in neonates and adults, 1045*t*  
 hepatic clearance of  
 aging effects on, 1052*t*  
 ionization constants of, 11*t*
- Diazepam (*Cont.*):  
 during lactation, 1048*t*  
 oral absorption of  
 in neonates *vs.* older children and adults, 1044*t*  
 pharmacokinetics of, 39*t*, 377*t*  
 pharmacologic properties of, 378, 439*t*  
 preparations available, 387, 400, 427, 446, 481
- Diazinon  
 toxicity rating for, 1007*t*
- Diazoxide, 182*f*, 189  
 as antihypertensive drug, **182–183**
- Dibenamine  
 cardiovascular effects of, 153*f*
- Dibenzo-*p*-dioxins  
 polychlorinated, 1010
- Dibenzodiazepine  
 advantages and disadvantages of, 509*t*  
 chemical structure effects on potency and toxicity of, 505*t*
- Dibenzofurans  
 polychlorinated, 1010
- Dibenzothiazepine  
 advantages and disadvantages of, 509*t*  
 chemical structure effects on potency and toxicity of, 505*t*
- Dibenzoxazepine  
 advantages and disadvantages of, 509*t*
- Dibenzylidine  
 Phenoxybenzamine
- Dibucaine, 463
- Dichlorodiphenyltrichloroethane (DDT), 1009*f*  
 toxicity rating for, 1006*t*
- 2,4-Dichlorophenoxyacetic acid, 1008–1009
- Dichlorphenamide, 270  
 dosage of, 257*t*
- Dichlorvos  
 toxicity rating for, 1007*t*
- Diclofenac, **640**  
 properties of, 638*t*
- Dicloxacillin  
 dosage of, 795*t*
- Dicumarol, structure of, 609*f*  
 during lactation, 1048*t*
- Dicyclomine, 117*f*, 127, 1111  
 for irritable bowel syndrome, 1096
- Didanosine, 863*f*, 870*t*, **872**, 888  
 drug interactions with, 874*t*
- Didronel, 786. *See also* Etidronate disodium
- Dieldrin  
 toxicity rating for, 1006*t*
- Dientamoeba fragilis*  
 drugs used for, 931*t*
- Diet  
 in drug metabolism, 65–66  
 in hyperlipidemia, 625

- Dietary Supplement and Non-Prescription Drug Consumer Protection Act, 1126
- Dietary Supplement Health and Education Act (DSHEA), 74*t*, 1125–1126
- Dietary supplements, **1125–1138**. *See also specific types*
- Diethylcarbamazine, for helminthic infections, 938*t*, **939–940**
- Diethylstilbestrol, 718*f*, 740  
dosage of, 731*t*  
fetal effects of, 1042*t*
- Difenoxin, 558, 1112
- Diffuse neuronal systems  
of CNS, 365–366
- Diffusible second messenger, 361, 362*f*
- Diffusion  
aqueous, 9, 9*f*  
lipid, 9, 9*f*
- Diflucan, 858. *See also* Fluconazole
- Diflunisal, **641**, 655  
properties of, 638*t*
- Digestive enzymes, 1111
- Digibind, 225
- DigiFab, 225
- Digitalis  
in heart failure management, **215–218**, 221
- Digitalis antibody, 225
- Digitalis glycosides  
drug interactions with, 1156*t*
- Digoxin  
in chronic heart failure management, 215–218, 221  
half-life of  
in neonates and adults, 1045*t*  
during lactation, 1048*t*  
oral absorption of  
in neonates *vs.* older children and adults, 1044*t*  
overdose of, **1036–1037**  
pharmacokinetics, 39*t*
- Digoxin antibodies, as poisoning antidote, 1033*t*
- Digoxin immune fab, 225
- Dihydroartemisinin, 920
- Dihydrocarbostyryl  
advantages and disadvantages of, 509*t*  
chemical structure effects on potency and toxicity of, 505*t*
- Dihydrocodeine, 558
- Dihydroergotamine, 155, 292
- Dihydroindolone  
advantages and disadvantages of, 509*t*  
chemical structure effects on potency and toxicity of, 505*t*
- Dihydropyridine(s), 202*t*
- Dihydroxyphenylalanine, 485*f*
- Diiodotyrosine (DIT), 682
- Dilacor, 250. *See also* Diltiazem
- Dilantin, 427. *See also* Phenytoin
- Dilaudid, 562. *See also* Hydromorphone
- Diloxanide furoate  
for amebiasis, **929–930**
- Diltiazem  
for angina, **202*t***  
for cardiac arrhythmias, **245**  
clinical pharmacology of, 202*t*  
membrane actions of, 237*t*  
pharmacokinetics/dosage of, 175*t*  
pharmacologic properties of, 238*t*  
preparations available, 189, 209, 250
- Dimaval, 1025. *See also* Unithiol
- Dimenhydrinate, 278*f*, 292  
dosage of, 279*t*  
for nausea and vomiting, 1100
- Dimercaprol, **1021–1022**, 1022*f*, 1025  
indications and toxicity of, 1022
- Dimercaptopropanesulfonic acid.  
*See* Unithiol
- 2,3-Dimercaptopropanol.  
*See* Dimercaprol
- Dimercaptosuccinic acid. *See* Succimer
- Dimetan  
toxicity rating for, 1008*t*
- Dimethisterone, 719*f*  
properties of, 723*t*
- Dimethoate  
toxicity rating for, 1007*t*
- D-Dimethylcysteine. *See* Penicillamine
- Dimetilan  
toxicity rating for, 1008*t*
- Dinoprostone, 324, 325*f*, 328
- Diovan, 190, 225. *See also* Valsartan
- Dioxins, 1009
- Dipentum, 1112. *See also* Olsalazine
- Dipeptidyl peptidase-4 (DPP-4) inhibitors  
for diabetes mellitus, **761**
- Diphenhydramine, 278*f*, 292  
dosage of, 279*t*  
ionization constants of, 11*t*  
for nausea and vomiting, 1100
- Diphenoxylate, 558, 1112  
for diarrhea, 1094–1095  
ionization constants of, 11*t*
- Diphenylmethane derivatives  
in constipation management, 1093
- Diphtheria  
passive immunization for, 1168*t*
- Diphtheria tetanus acellular pertussis (DTaP) vaccine, 1164*t*
- Diphyllobothriasis  
praziquantel for, 944
- Diphyllobothrium latum*  
niclosamide for, 942
- Diprivan, 446. *See also* Propofol
- Dipyridamole, 617  
as antiplatelet agent, 613–614
- Direct thrombin inhibitors, **607–608**.  
*See also specific drugs*  
oral, **608**  
parenteral, **607–608**
- Direct vasodilators, 172
- Disalcid, 656. *See also* Salsalate
- Disease-modifying antirheumatic drugs (DMARDs), **643–650**, 656  
in inflammation reduction, 636
- Disinfectants, **893–896**, 898
- Disinfection  
defined, 894*t*
- Disopyramide  
for cardiac arrhythmias, **239–240**
- Disseminated intravascular coagulation (DIC), 604
- Dissociation constants ( $K_D$ )  
of enantiomers, 5, 5*t*
- Distal convoluted tubule  
in renal tubule transport, 252*t*, 254, 254*f*
- Distribution of drugs. *See* Volume of distribution
- Disulfiram  
in alcoholism management, 397, 400  
drug interactions with, 610*t*, 1156*t*
- Ditropan, 127. *See also* Oxybutynin
- Diurese, 270. *See also* Trichlormethiazide
- Diuresis forced for poisoned patient, 1032  
saline  
for hypercalcemia, 778
- Diuretic(s), **251–271**. *See also specific drugs*  
adenosine  $A_1$ -receptor antagonists, **258**  
as antihypertensive drugs, **172–174**, 174*f*  
basic pharmacology of, **256–265**  
clinical pharmacology of, **265–268**  
for diabetes insipidus, **268**  
for edematous states, **265–267**  
in heart failure management, 219, **265–266**  
hemodynamic effects of, 173  
toxicity of, 174, 258–263  
use of, 173–174
- Diuril, 270. *See also* Chlorothiazide
- Divalproex, 519
- DMARDs. *See* Disease-modifying antirheumatic drugs (DMARDs)
- DNA gyrase inhibitors, **834–836**. *See also specific drugs*
- Doan's Pills, 655. *See also* Magnesium salicylate
- Dobutamine, 141, 142*f*, 148, 225  
in cardiac stress test, 144  
in heart failure management, 218
- Dobutrex, 148. *See also* Dobutamine
- Docetaxel  
for cancer, 963*t*, 964

- Docosanol  
dosage of, 865*t*  
for HSV and VZV infections, **866**
- Docusate, 1093, 1112
- Dofetilide  
for cardiac arrhythmias, **237–244**
- Dolasetron, 1097*f*, 1111  
for nausea and vomiting, 1098–1099
- Dolobid, 655. *See also* Diflunisal
- Dolophine, 562. *See also* Methadone
- Domperidone  
in gastrointestinal motility stimulation, **1092**
- Donepezil, 112  
for Alzheimer's disease, 1055
- Dopamine, 136*f*, 138*t*, **141**, 148, 225, 661, 661*t*  
addictive drugs effects on, **565–566**, 567*f*, 569*f*, 569*t*  
in ANS, ENS, and NANC neurons, 84*t*  
as CNS neurotransmitter, 366*t*, 370  
inhibitory effects of, 92*t*
- Dopamine agonists, **143–144**, 278, **488–490**, **672–673**  
for parkinsonism, **488–490**, 488*f*
- Dopamine hypothesis  
of addiction, 568  
of schizophrenia, 502
- Dopamine receptor(s), 87, 89*t*, 131, 132, 137*t*  
activation of  
cardiovascular effects of, 138  
antagonists of, 506  
antipsychotic drugs and, 506–507, 506*f*
- Dopamine transporter, 576
- Dopaminergic systems  
antipsychotic drugs and, 506
- Dopar, 499. *See also* Levodopa
- Doral, 387. *See also* Quazepam
- Doribax, 807. *See also* Doripenem
- Doripenem  
pharmacokinetics and dosage of, 798*t*, 801–802
- Dorzolamide, 270
- Dose, **16–18**  
reducing interval between cancer treatment cycles, 953
- Dose axis, 30, 30*f*
- Dose-effect curves  
graded, 16–18  
quantal, 31–32, 31*f*
- Dose escalation, 953
- Dose-response curves, **16–18**  
for sedative-hypnotic drugs, 374*f*  
shape of, 30*f*, 31
- Dose-response relationship, **30–34**, 30*f*, 31*f*
- Dosing schedule  
as factor in pharmacologic response to dermatologic drugs, 1061
- Dostinex, 678. *See also* Cabergoline
- Double-blind design, 72
- Down-regulation  
receptor, 23
- Doxazosin, **154**, 167, 189
- Doxepin, **1076**  
dosage of, 535*t*  
pharmacodynamics of, 530*t*
- Doxercalciferol, 786
- Doxorubicin  
for cancer, 963*t*, 965
- Doxycycline, **810–813**, 819, 935  
antiparasitic uses of, 917*t*  
for helminthic infections, 938*t*, 940  
in malaria prevention in travelers, 919*t*
- DPP-4 inhibitors. *See* Dipeptidyl peptidase-4 (DPP-4) inhibitors
- Dramamine, 292. *See also* Dimenhydrinate
- Drisdol, 786. *See also* Ergocalciferol
- Dromotropic effect, positive, 138
- Dronabinol, 1111 abuse of, 572
- Dronedarone, 242, 249  
for cardiac arrhythmias, **243**  
membrane actions of, 237*t*
- Droperidol, 446  
for nausea and vomiting, 1100
- Drospirenone, 711
- Drospirenone/ethinyl estradiol  
dermatologic uses of, 1078*t*
- Drug(s). *See also specific types, indications, and agents*  
of abuse, **565–580**. *See also specific drugs and* Drug abuse  
with actions on smooth muscle, **273–357**  
autonomic, **79–168**  
autonomic transmission effects of, 93, 94*t*  
biotransformation of, **53–68**. *See also* Biotransformation of drugs  
CNS-related, **359–580**. *See also* Central nervous system (CNS) drugs  
development of, **69–77**. *See also* Drug development  
discovery of, **70–71**, 70*f*  
efficacy of, 30*f*, 31  
excretion of. *See* Clearance  
ionization constants of, 11*t*  
labeled and off-label uses of  
legal issues related to, 1146  
legislation pertaining to  
in USA, 73, 74*t*  
lipid:aqueous partition coefficient of, 9, 9*f*  
nature of, **3–6**, 5*f*, 5*t*  
orphan  
development of, 77  
permeation of  
mechanisms of, 9–10, 9*f*
- Drug(s) (*Cont.*):  
physical nature of, 4  
potency of, 30–31, 30*f*  
rational design of, 6  
reactivity of, 4  
shape of, 4–5, 5*f*, 5*t*  
size of, 4
- Drug abuse, **565–580**. *See also specific drugs and* Addiction  
nonaddictive, 571  
tolerance in, 566–567  
withdrawal in, 567
- Drug accumulation, 42–43, 42*f*
- Drug action  
duration of, 8  
signaling mechanisms and, **21–29**, 21*f*–28*f*, 26*t*  
time course of, **37–51**
- Drug antagonism  
mechanisms of, 7–8, 20
- Drug concentration  
drug response and  
relationship between, **16–20**, 17*f*, 18*f*, 20*f*  
measurements of  
interpretation of, **49–50**
- Drug conjugates, 59, 60*t*
- Drug development, **69–77**  
clinical trials in, **72–77**. *See also* Clinical trials  
orphan drugs in, 77  
pharmaceutical industry in, 69–70  
preclinical safety and toxicity testing in, 71–72, 71*t*  
for rare diseases, 77  
receptor classes and, 22*f*, **29–30**  
translational research in, 76
- Drug disposition  
biotransformation of drugs in, 53–54, 54*f*
- Drug distribution  
models of, 38, 41*f*  
physical volumes of body compartments in, 38, 41*t*
- Drug dose  
clinical response and  
relationship between, **30–34**, 30*f*, 31*f*. *See also* Dose-response relationship  
individualization of  
pharmacokinetics and  
pharmacodynamics in, **47–49**  
rational  
time course of drug action related to, **37–51**  
regimen for  
target concentration approach to  
designing of, **45–47**, 47*f*
- Drug-drug interactions  
during drug metabolism, 66–67, 66*t*, 67*t*

- Drug groups, 12–13
- Drug holidays, 488
- Drug interactions, **1149–1162**,  
1150*t*–1161*t*. *See also*  
*specific drugs*  
combined toxicity, 1161–1162  
pharmacodynamic mechanisms of, 1161  
pharmacokinetic mechanisms of, 1149,  
1161  
predictability of, **1149–1162**  
Drug metabolism, **61–68**  
diseases affecting, 67–68, 67*t*  
in the elderly, 1052–1053, 1052*t*  
fetal  
during pregnancy, 1040  
in infants and children, 1045, 1045*t*  
pharmacokinetic mechanisms of, 1149,  
1161  
placental  
during pregnancy, 1040  
to toxic products, 60–61, 61*f*
- Drug overdose. *See also specific drugs*  
hemodialysis in, 1031, 1031*t*, 1032
- Drug penetration  
regional variation in  
as factor in pharmacologic response to  
dermatologic drugs, 1061
- Drug receptor(s), 2. *See specific types and*  
Receptor(s)
- Drug-receptor bonds, 4
- Drug resistance  
in cancer chemotherapy, 953
- Drug response  
drug concentration and  
relationship between, **16–20**, 17*f*, 18*f*,  
20*f*  
idiosyncratic, 32  
variations in, 32–33
- Drug screening, 70–71
- Drug tolerance, 32, 66, 566–567
- Drug “trapping”  
through pH-partitioning phenomenon,  
11, 12*t*
- Drug withdrawal, 567
- Drug-body interactions, **6–12**, 7*f*–9*f*,  
10*t*–12*t*, 12*f*
- Drug-receptor interactions  
types of, 6, 7*f*
- DSHEA. *See* Dietary Supplement Health  
and Education Act (DSHEA)
- Duetact, 766. *See also* Pioglitazone plus  
glimepiride
- Dulcolax, 1112. *See also* Bisacodyl
- Duloxetine, 526*f*, 539  
dosage of, 535*t*  
pharmacokinetics of, 528, 529*t*  
sympathomimetic drug effects on, 143
- Duocaine, 463. *See also* Lidocaine and  
bupivacaine
- DuoNeb, 355. *See also* Albuterol/ipratropium
- Duricef, 807. *See also* Cefadroxil
- Dutasteride, 738, 740
- Dyazide  
dosage of, 262*t*
- Dyclone, 463. *See also* Dyclonine
- Dyclonine, 463
- Dylix, 355. *See also* Dyphylline
- DynaCirc, 190, 209. *See also* Isradipine
- Dynorphin(s), 543–544, 544*t*  
CREB-mediated up-regulation  
during withdrawal from dependence,  
568, 570*f*
- Dyphylline, 355
- Dyrenium, 270. *See also* Triamterene  
dosage of, 262*t*
- Dysbetalipoproteinemia  
familial, 623–624  
drugs used for, 622*t*
- Dyskinesia(s)  
dopamine receptor agonists and, 489  
drug-induced, 495–496  
levodopa and, 487  
tardive, 496  
antipsychotic drugs and, 511
- Dyslipidemia(s)  
drugs used in, **619–633**. *See also*  
*specific disorders, e.g.,*  
Hyperlipidemia(s)
- Dysmenorrhea  
eicosanoids and, 326
- Dysmorphogenesis, 1041–1043  
antipsychotic drugs and, 512
- Dyspepsia  
nonulcer. *See* Nonulcer dyspepsia
- Dystonia(s), 495  
described, 483  
tardive, 496
- E**
- E-prescribing, **1143**
- Early afterdepolarizations (EADs), 233*f*,  
234
- Easprin, 655. *See also* Aspirin
- Eating disorders  
antidepressants for, 533
- Ecallantide, 302
- Echinacea, **1126–1128**
- Echinocandins, 849  
for systemic infections, **855**
- Echothiophate, 106*f*, 112  
durations of action of, 106*t*  
therapeutic uses for, 106*t*
- Econazole, 858
- Ecotoxicology, 1002
- Ecstasy  
abuse of, 569*t*, 577–578
- Ectoparasiticides, **1068**
- Eculizumab, 994
- Edarbi, 190. *See also* Azilsartan
- Edecrin, 270. *See also* Ethacrynic acid
- Edema  
idiopathic  
diuretics for, **267**  
lithium and, 517  
pulmonary, acute,  
opioid analgesics for, 553
- Edematous states  
diuretics for, **265–267**
- Edetate calcium disodium, 1021*f*, **1023**  
indications and toxicity of, 1023
- Edrophonium, **105–107**, **112**  
durations of action of, 106*t*
- Efavirenz, 870*t*, **877**, 888  
drug interactions with, 874*t*
- Effector(s)  
of G proteins, 25, 26*t*
- Effector mechanism, 6
- Effector pathways  
beneficial and toxic drug effects related  
to, 34
- Effexor, 539. *See also* Venlafaxine
- Efficacy  
intrinsic, 7
- Effient, 617. *See also* Prasugrel
- Effort angina, 193  
clinical pharmacology of, 206–207, 206*f*,  
207*t*  
nitrate effects in, 200
- Eflornithine, 935, **1077**  
clinical uses of, 933–934
- EGF receptor  
mechanism of activation of, 22, 23*f*
- Eicosanoid(s). *See also* Leukotriene(s);  
Prostaglandin(s)  
basic pharmacology of, **317–324**  
clinical pharmacology of, **324–328**
- Eicosanoid receptors, 319–320, 319*t*
- Elavil, 539. *See also* Amitriptyline
- Eldepryl, 499. *See also* Selegiline
- Elderly. *See also* Aging  
ADRs in, **1057–1058**  
anti-inflammatory drugs in, **1056–1057**  
antimicrobial drugs in, **1056**  
cardiovascular drugs in, **1056**  
CNS drugs in, **1053–1055**. *See also*  
Central nervous system (CNS)  
drugs, in the elderly  
ophthalmic drugs in, **1057**
- Electrocardiography (ECG)  
in poisoning assessment, 1030–1031,  
1031*f*
- Electroencephalography (EEG)  
antipsychotic drugs effects on, 508
- Electrolyte(s)  
lithium effects on, 514  
in poisoning assessment, 1030, 1030*t*
- Electrolyte balance  
alcohol effects on, 394
- Electrostatic bonding, 4
- Elestat, 292. *See also* Epinastine

- Eletriptan, 286*t*, 292
- Eligard, 678. *See also* Leuprolide acetate
- Elimination of drugs. *See also* Clearance  
capacity-limited, 39*t*–40*t*, 41–42  
flow-dependent, 39*t*–40*t*, 42  
models of, 38, 41*f*
- Elixirs  
in pediatric patients, 1046
- Elixophyllin, 355. *See also* Theophylline
- Eltrombopag, 595, 598
- Emadine, 292. *See also* Emedastine
- Emedastine, 292
- Emend, 1111. *See also* Aprepitant
- Emergency contraceptives  
ingredients in, 1121*t*
- Emesis  
in decontamination of poisoned patient,  
1031–1032
- Emetine  
for amebiasis, **930**
- EMLA (eutectic mixture of local  
anesthetics), **461**
- Empiric therapy, antimicrobials,  
**902–906**
- Empirin Compound, 562. *See also*  
Codeine/aspirin
- Emtricitabine, 863*f*; 870*t*, **872–874**, 888
- Enablex, 127. *See also* Darofemacom
- Enalapril, 190, 225, 299  
as antihypertensive drug, 184, 190  
pharmacokinetics, 39*t*
- Enantiomers, 5, 5*f*, 5*t*
- Enbrel, 656, 999. *See also* Etanercept
- End-of-dose akinesia, 487
- Endocannabinoids  
as CNS neurotransmitter, 367*t*, 371
- Endocrine disorders  
diagnosis of  
glucagon in, 763
- Endocrine disruptors  
as environmental pollutants, **1011**
- Endocrine drugs, **659–787**. *See also specific  
types, drugs, and indications*
- Endocrine glands  
kinins effects on, 301
- Endocrine pancreas, **743–744**
- Endocrine system  
alcohol effects on, 394  
antipsychotic drugs effects on, 507*t*, 508,  
512  
beta-receptor antagonists effects on, 160  
etomidate effects on, 444  
garlic effects on, 1129  
oral contraceptives effects on, 727  
properties in common with nervous  
system, 80
- Endocytosis, 9–10, 9*f*
- Endogenous catecholamines, 138*t*,  
140–141
- Endogenous opioid peptides, 543–544, 544*t*
- Endometriosis  
gonadotropins in, 670
- Endomorphin-1, 544
- Endomorphin-2, 544
- Endoperoxides  
structures of, 918*f*
- Endorphin(s), 543–544, 544*t*
- Endothelial-derived relaxing factor  
(EDRF), 103, 331
- Endothelin(s), **304–306**
- Endothelium-derived hyperpolarizing  
factors, 317
- Endotracheal intubation, 476
- Enduron, 270. *See also* Methyclothiazide
- Entecavir, 863*f*
- Enflurane, 432*f*, 446  
pharmacologic properties of, 433*t*
- Enfuvirtide, 870*t*, **881**, 888
- Enjuvia, 740. *See also* Esterified estrogens
- Enkephalin(s), 543–544, 544*t*  
in ANS, ENS, and NANC neurons, 84*t*  
inhibitory effects of, 92*t*
- Enoxaparin, 617
- ENS. *See* Enteric nervous system (ENS)
- Entacapone  
for parkinsonism, 488*f*, 490, 499
- Entecavir  
for HBV infection, 883*t*, **884**, 889
- Entereg, 562, 1112. *See also* Alvimopan
- Enteric infections  
proton pump inhibitors and, 1088–1089
- Enteric nervous system (ENS), 81–82,  
81*f*, 84*t*  
physiology of, **1091–1092**, 1092*f*  
transmitter substances found in, 84*t*
- Enteric oxaluria, **785**
- Enterochromaffin-like (ECL) cells, 81*f*,  
1082, 1082*f*
- Enteroglucagon, 762
- Entocort, 1112. *See also* Budesonide
- Entry inhibitors, 870*t*–871*t*, **881–882**.  
*See also specific drugs*
- Environmental factors  
cancer related to, 949  
in drug metabolism, 65–66
- Environmental pollutants, **1010–1011**  
asbestos, **1011**  
endocrine disruptors, **1011**  
metals, **1011–1012**  
polychlorinated biphenyls, **1010**
- Environmental toxicology, **1001–1003**
- Enzyme(s), 16, 1111  
converting, 297–298, 298*f*  
digestive  
human liver P450, **55–59**. *See also*  
Human liver P450 enzymes  
lithium effects on, 514, 515*t*  
transmembrane  
ligand-regulated, 22–23, 23*f*  
Ziegler's, 65
- Enzyme induction  
P450 in, 57–59, 58*t*
- Enzyme inhibition, 58*t*, 59
- Ephedra  
risks associated with, 1127*t*
- Ephedrine, 136*f*, 148, 355  
for asthma, 343–344  
ionization constants of, 11*t*  
sympathomimetic drug effects of, 136*f*,  
**141–142**
- Epidermal growth factor (EGF) receptor  
mechanism of activation of, 22, 23*f*
- Epilepsy  
drug development for, 403–404, 405*f*,  
406*f*  
drugs used for, **419–420**, **422–423**  
prevalence of, 403  
VNS for, 404
- Epinastine, 292
- Epinephrine, 138*t*, **140–141**  
for anaphylactic shock, 145  
for asthma, 343  
cardiovascular responses to, 138*t*  
excitatory effects of, 92*t*  
ionization constants of, 11*t*
- Epinephrine reversal, 152
- Epipodophyllotoxins  
for cancer, 963*t*, **964**
- Epirubicin  
for cancer, 965
- Eplerenone, 711, 225, 270
- Epoetin alfa, 598
- Epoetin beta, 598
- Epogen. *See also* Epoetin alfa
- Epoprostenol, 328, 325*f*
- Epoxidation, 56*t*
- Epoxide hydrolases, 60
- Epoxygenase products, 317
- Eprosartan, 190, 225
- Epsom Salt, 1112. *See also* Magnesium  
hydroxide
- Eptifibatide, 613, 617
- Equalactin, 1112. *See also* Polycarbophil
- Equanil, 387. *See also* Meprobamate
- Eraxis, 858. *See also* Anidulafungin
- Erbix, 999. *See also* Cetuximab
- Erectile dysfunction  
drugs used for, 199  
alpha-receptor antagonists, 156–157
- Erethism, 1020
- Ergocalciferol, 786
- Ergomar, 292. *See also* Ergotamine tartrate
- Ergonovine, 292
- Ergosterol, 850
- Ergot alkaloids, **287–290**
- Ergot poisoning, 287
- Ergotamine, 155  
ionization constants of, 11*t*
- Ergotamine mixtures, 292
- Ergotamine tartrate, 292

- Ergotism, 287  
 Ergotrate, 292. *See also* Ergonovine  
 Erlotinib  
   for cancer, **968**  
   clinical activity and toxicities of, 967*t*  
 Epogen, 598  
 Ertapenem  
   pharmacokinetics and dosage of, 798*t*,  
     801–802  
 Erythromycin, **813–814**  
   for acne, 1064  
   in gastrointestinal motility stimulation,  
     1092  
   pharmacokinetics of, 39*t*, 813  
 Erythropoietin, **591–592**  
 Escitalopram, 529*t*  
   dosage of, 535*t*, 539  
 Eserine, 112. *See also* Physostigmine  
 Esidrix, 270. *See also* Hydrochlorothiazide  
 Eskalith. *See also* Lithium carbonate  
 Eslicarbazepine, 427  
   for seizures, **411**  
 Esmolol, **162**, 167, 189, 249  
   as antihypertensive drug, 180  
   cardiac effects of, 242  
   membrane actions of, 237*t*  
   pharmacologic properties of, 238*t*  
   as poisoning antidote, 1033*t*  
   properties of, 159*t*  
 Esomeprazole, 1111  
   pharmacokinetics of, 1086*t*  
 Essential tremor, 493–494  
 Estazolam, preparations available, 387  
 Ester(s),  
   choline, properties of, 99, 100*t*  
 Esterified estrogens, 740  
 Estrace, 740. *See also* Estradiol  
 Estraderm, 740. *See also* Estradiol transdermal  
 Estradiol, 716*f*, 717–718, 717*f*  
 Estradiol cypionate  
   dosage of, 719*t*  
 Estriol, 716*f*, 717–718, 717*f*  
 Estrogen(s), **716–723**, 740  
   blood coagulation effects of, 720  
   in bone mineral homeostasis, **775**  
   drug interactions with, 1157*t*  
 Estrogen inhibitors, **731–734**  
 Estrogen replacement therapy  
   for osteoporosis, 775  
 Estrogen response elements (EREs), 719  
 Estrone, 716*f*, 717–718, 717*f*, 740  
 Estropipate  
   dosage of, 719*t*  
 Eszopiclone, 374  
   biotransformation of, 378  
   pharmacokinetic properties of, 377*t*  
 Etanercept, **647**, 656, 992, 999  
   for psoriasis, **1071–1072**  
 Ethacrynic acid, 259*f*, 270  
   dosage of, 259*t*  
 Ethambutol,  
   for tuberculosis, 840*t*, **842**  
 Ethanol. *See also* Alcohol(s)  
   as antiseptic/disinfectant, 893*t*, **894**  
   pharmacology of, **390–397**  
   fetal effects of, 1042*t*  
   during lactation, 1048*t*  
   metabolism of, 390, 390*f*  
   overdose of, **1037**  
   pharmacokinetics of, 390–391, 390*f*  
   as poisoning antidote, 1033*t*  
 Ethanolamines (antihistamines)  
   dosage of, 279*t*  
 Ethinyl estradiol, dosage of, 719*t*, 731*t*  
 17-Ethinyl testosterone derivatives  
   properties of, 723*t*  
 Ethionamide, 843*f*, 848  
   dosage of, 840*t*  
   for tuberculosis, 840*t*, 843–844  
 Ethosuximide  
   for seizures, **417–418**, **422–423**  
 Ethotoin  
   for seizures, **409**  
 Ethrane, 446. *See also* Enflurane  
 Ethylene glycol  
   in alcoholism, 398  
   poisoning by, **1037**  
 Ethylene oxide, 897  
 Ethylenediaminetetraacetic acid. *See*  
   Edate calcium disodium  
 Ethyleneimonium intermediate,  
   152, 152*f*  
 Ethynodiol diacetate  
   properties of, 723*t*  
 Etidocaine, **460**  
 Etidronate, 776*f*  
 Etidronate disodium, 786  
 Etodolac, **641**, 655  
   properties of, 638*t*  
 Etomidate, 438*f*, 446  
   as intravenous anesthetic, 439*t*, **443–444**  
 Etoposide  
   clinical activity and toxicities of, 963*t*  
 Etravirine, 870*t*, **877**, 889  
   drug interactions with, 874*t*  
 Etretnate  
   fetal effects of, 1042*t*  
 Eulexin, 740. *See also* Flutamide  
 Euphoria  
   opioid analgesics and, 550  
 Evista, 740. *See also* Raloxifene  
 Evoxic, 112. *See also* Cevimeline  
 Excitatory postsynaptic potential (EPSP),  
   92, 93*f*, 362–363  
 Exelderm, 858. *See also* Sulconazole  
 Exelon, 112. *See also* Rivastigmine  
 Exemestane, 733, 740  
 Exenatide  
   for diabetes mellitus, 760  
 Exjade, 598, 1025. *See also* Deferasirox  
 Exocrine glands  
   kinins effects on, 301  
 Exocytosis, 9–10, 9*f*  
 Ex-Lax, 1112. *See also* Senna  
 Expectorants  
   ingredients in, 1121*t*  
 Experimental pharmacology, 2  
 Experimental physiology, 2  
 Extavia, 999  
 Extensive metabolizers, 64  
 Extracellular volume expansion  
   osmotic diuretics and, 264  
 Extraction ratio, 44  
 Extrinsic factor, 586  
 Eye(s). *See also* Ophthalmic disorders;  
   Ophthalmologic disorders  
   anterior chamber of  
     structures of, 95*f*  
   antimuscarinic drug effects on, 118, 119*f*  
   antipsychotic drugs effects on, 512  
   autonomic nerve activity effects on, 90*t*  
   beta-receptor antagonists effects on, 160,  
     161*t*  
   cholinomimetic drug effects on  
     direct-acting, 102, 102*t*  
     indirect-acting, 107  
   disorders of  
     cholinomimetic drugs for, 108  
   ganglion-blocking drug effects on, 125  
   pharmacology of, 93, 95*f*  
   poisoning effects on, 1029  
   prostaglandins effects on, 322  
   serotonin effects on, 284  
   sympathomimetic drug effects on, 138  
 Ezetimibe  
   for hyperlipidemias, **630–631**  
 Ezogabine (retigabine), 415  
**F**  
 Factive, 838. *See also* Gemifloxacin  
 Factor IX complex, human, 617  
 Factrel, 678. *See also* Gonadorelin  
   hydrochloride  
 Fadrozole, 733  
 Famciclovir, 865*t*  
   for HSV and VZV infections, **866**  
   topical, **1067**  
 Familial combined hyperlipoproteinemia,  
   623, 624  
   drugs used for, 622*t*  
 Familial dysbetalipoproteinemia,  
   623–624  
   drugs used for, 622*t*  
 Familial hypercholesterolemia, 624, 624*f*  
   drugs used for, 622*t*  
 Familial hypertriglyceridemia, 623  
   drugs used for, 622*t*  
 Familial ligand-defective apo B  
   drugs used for, 622*t*  
 Familial ligand-defective apo B-100, 624

- Famotidine, 1083  
 from prescription to OTC status, 1116*t*
- Famvir, 889. *See also* Etravirine
- Fansidar, 837, 925–926, 935. *See also* Pyrimethamine/sulfadoxine
- Fareston, 740. *See also* Toremifene
- Faslodex, 740. *See also* Fulvestrant
- Fasudil  
 for angina pectoris, 206
- Fatty acids  
 omega-3, 633
- FDA  
 in clinical trials, 73–74, 74*t*  
 review of OTC drug ingredients by, 1115–1124
- Febuxostat  
 for gout, **654**  
 preparations available, 656
- Federal Food, Drug, and Cosmetic Act of 1938, 73, 74*t*
- FEIBA (factor eight inhibitor bypassing activity)  
 for bleeding disorders, 616
- Feiba VH Immuno, 617. *See also* Anti-inhibitor coagulant complex
- Felbamate, for seizures, **412–413**, 427
- Felbatol, 427. *See also* Felbamate
- Feldene, 656. *See also* Piroxicam
- Felodipine  
 clinical pharmacology of, 202*t*, 190, 209
- Female infertility  
 GnRH agonists for, 669–670
- Female maturation  
 estrogen effects on, 719–720
- Female reproductive system  
 eicosanoid effects on, 324–326  
 melatonin effects on, 1136  
 prostaglandins and thromboxanes effects on, 321
- Femara, 740. *See also* Letrozole
- Fenitrothion  
 toxicity rating for, 1007*t*
- Fenofibrate, 628*f*, 633  
 in drug combinations, 631  
 for hyperlipidemias, **628–629**
- Fenoldopam  
 as antihypertensive drug, **183**, 189  
 sympathomimetic drug effects of, 144, 148
- Fenoprofen  
 properties of, 638*t*
- Fentanyl, 557, 557*f*, 562, 563  
 pharmacokinetics of, 545*t*
- Ferric hexacyanoferrate. *See* Prussian blue
- Ferrioxamine, 1022*f*
- Fesoterodine  
 for urinary disorders, 122, 122*t*
- Fetal alcohol syndrome, 394
- Fetal drug metabolism  
 during pregnancy, 1040
- Fetal hydantoin syndrome, 424
- Fetus  
 adverse drug effects on, 1042*t*–1043*t*  
 lung maturation in  
 corticosteroids in stimulation of, 705  
 predictable toxic drug actions in, 1041  
 teratogenic drug action effects on, 1042*t*–1043*t*  
 therapeutic drug actions in  
 during pregnancy, 1040–1041
- Fever  
 atropine, 120  
 Blackwater, 922  
 cadmium fume, 1012  
 prostaglandins and, 321
- Fexmid, 481. *See also* Cyclobenzaprine
- Fexofenadine dosage of, 279*t*
- FGF23. *See* Fibroblast growth factor 23 (FGF23)
- Fiber-Lax, 1112. *See also* Polycarbophil
- FiberCon, 1112. *See also* Polycarbophil
- Fibrates  
 in drug combinations, 631  
 for hyperlipidemias, **628–629**, 629*f*
- Fibric acid derivatives. *See* Fibrates
- Fibrinolysis, 604, 604*f*
- Fibrinolytic drugs  
 basic pharmacology of, **611–612**
- Fibrinolytic inhibitors  
 for bleeding disorders, 604*f*, 616
- Fibroblast growth factor 23 (FGF23)  
 in bone mineral homeostasis, **770–774**
- Fibroids  
 uterine  
 gonadotropins in, 670
- Fick's law of diffusion, 10
- Fidaxomicin, **892**
- Filgrastim, 598
- Finasteride, 738, **1077**
- Firmagon, 678. *See also* Degarelix
- First-pass effect, 44, 54  
 alternative routes of administration and, 44
- First-pass elimination  
 bioavailability and, 43–44
- FK-binding protein (FKBP), 986
- Flagyl, 898, 935. *See also* Metronidazole
- Flavin monooxygenase, 65
- Flavoxate, 127
- Flecainide  
 for cardiac arrhythmias, 237*t*, **241**
- Fleets Phospho-soda, 1112. *See also* Sodium phosphate
- Flexeril, 481. *See also* Cyclobenzaprine
- Flexible regulation, 29
- Flolan, 328. *See also* Epoprostenol
- Flomax, 167. *See also* Tamsulosin
- Florinef Acetate, 712. *See also* Fludrocortisone acetate
- Flovent, 355. *See also* Fluticasone
- Flow-dependent elimination, 39*t*–40*t*, 42
- Floxin, 838. *See also* Ofloxacin
- Fluconazole  
 for skin infections, 1066  
 for systemic infections, **854–855**
- Flucytosine  
 for systemic infections, **852–853**
- Fludarabine  
 for cancer, **962**  
 clinical activity and toxicities of, 959*t*
- Fludrocortisone, **709**  
 clinical uses and dosage of, 703*t*, 712
- Fluke(s)  
 drugs used for, 938*t*
- Flumadine, 889. *See also* Rimantadine
- Flumazenil, 379, **381–382**  
 as poisoning antidote, 1033*t*
- Flunarizine  
 for migraine, 285
- Flunisolide, 355
- Fluoride  
 in bone mineral homeostasis, 777
- Fluoropyrimidines  
 for cancer, **960**
- Fluoroquinolones, **834–836**  
 for tuberculosis, 840*t*, 844–845
- Fluorouracil, **1076**
- 5-Fluorouracil  
 for cancer, **960**
- Fluothane, 446. *See also* Halothane
- Fluoxetine, 528–529, 539  
 dosage of, 535*t*  
 pharmacodynamics of, 39*t*, 530*t*
- Fluoxymesterone, dosage of, 736*t*
- Fluphenazine  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*  
 ionization constants of, 11*t*
- Fluphenazine decanoate, 519
- Fluprednisolone  
 clinical uses and dosage of, 703*t*
- Flurazepam  
 hepatic clearance of  
 aging effects on, 1052*t*  
 pharmacokinetic properties of, 377*t*
- Flurbiprofen, 637*f*, **641**, 655  
 properties of, 638*t*
- Flutamide, 738, 740
- Fluticasone, 355
- Fluvastatin, 633
- Fluvoxamine  
 dosage of, 535*t*  
 pharmacodynamics of, 530*t*  
 pharmacokinetics of, 529*t*
- Focalin, 148. *See also* Dexmethylphenidate
- Folate antagonists, 918*f*
- Folate synthesis  
 inhibitors of  
 for malaria, **925–926**

- Folic acid/folates, 589*f*; 598, 958*f*  
 for anemia, **588–590**, 589*f*  
 deficiency of  
 anemia due to, 584*t*  
 supplementation with, 589
- Follicle-stimulating hormone (FSH),  
**666–669**, 715
- Follistim, 678. *See also* Follitropin beta
- Follitropin, 667, 678
- Fomepizole, 398, 398*f*; 400  
 as poisoning antidote, 1033*t*
- Fondaparinux, 605*f*; 606, 617
- Food and Drug Administration (FDA)  
 in clinical trials, 73–74, 74*t*  
 review of OTC drug ingredients by,  
**1115–1124**
- Foradil, 355. *See also* Formoterol
- Forane, 446. *See also* Isoflurane
- Formaldehyde  
 as antiseptic/disinfectant, 893*t*, 896
- Formalin, 896
- Formoterol  
 for asthma, 344, 355
- Fortaz, 807. *See also* Cefotaxime
- Forteo, 786. *See also* Teriparatide
- Fosamax, 786. *See also* Alendronate sodium
- Fosamprenavir, 870*t*, **879**, 889  
 drug interactions with, 874*t*
- Fosaprepitant, 307  
 for nausea and vomiting, 1099
- Foscarnet  
 for CMV infections, **868**, 889  
 dosage of, 863*f*; 865*t*, 867*t*, 889
- Foscavir, 889. *See also* Foscarnet
- Fosfomycin, **805**, 808
- Fosinopril, 190, 225
- Fosphenytoin, 407, 427
- Fospropofol, **441**, 446
- Fragmin, 617. *See also* Dalteparin
- Frova, 292. *See also* Frovatriptan
- Frovatriptan  
 pharmacokinetics of, 286*t*
- Full agonists, 19, 20*f*
- Fulvestrant, 733, 740
- Fulvicin P/G, 858. *See also* Griseofulvin
- Fungizone  
 properties of, 850*t*
- Furacin, 898. *See also* Nitrofurazone
- Furosemide, 259*f*; 270  
 in chronic heart failure management, 220  
 dosage of, 259*t*  
 ionization constants of, 11*t*  
 pharmacokinetics, 39*t*
- Fuzeon, 888. *See also* Enfuvirtide
- G**
- G<sub>10</sub>-coupled receptors, drugs of abuse and,  
**572–573**
- G-CSF. *See* Granulocyte colony-stimulating  
 factor (G-CSF)
- G protein(s), 25–26, 25*f*; 26*f*; 26*t*
- G protein-coupled receptor(s) (GPCRs),  
 25, 26*f*
- G protein-coupled receptor kinase (GRK),  
 133
- GABA (gamma-aminobutyric acid)  
 in ANS, ENS, and NANC neurons, 84*t*  
 as CNS neurotransmitter, 366*t*, 369
- GABA (gamma-aminobutyric acid) receptor  
 heterogeneity and pharmacologic  
 selectivity of, 379
- GABA<sub>A</sub> receptor  
 molecular pharmacology of, 378–379,  
 378*f*
- GABA<sub>B</sub> agonist, 477
- Gabapentin, **413**, 478  
 for seizures, **413**  
 for tremors, 494
- Gabapentin/pregabalin  
 for chronic pain, 550
- Gabitril, 427. *See also* Tiagabine
- Gablofen, 481. *See also* Baclofen
- Galanin  
 in ANS, ENS, and NANC  
 neurons, 84*t*
- Galantamine, 112  
 for Alzheimer's disease, 1055
- Gallamine  
 tissue effects of, 474*t*
- Gallium nitrate  
 for hypercalcemia, 778–779, 786
- Gallstones, 1112  
 bile acid therapy for, **1107**
- Gametocides, 915
- Gamma-delta T cells, 978
- Gamma-hydroxybutyric acid  
 abuse of, 569*t*, 573, 574*f*
- Ganciclovir, 863*f*; 889  
 for CMV infections, **866–867**  
 dosage of, 867*t*
- Ganglion  
 prevertebral, 81
- Ganglion-blocking drugs, **124–125**  
 as antihypertensive drug, 177
- Ganirelix, 671, 678
- Ganite, 786. *See also* Gallium nitrate
- Gantacurium  
 pharmacokinetics of, 468
- Garamycin, 828. *See also* Gentamicin
- Garlic, **1128–1129**
- Gas(es)  
 irritant poisoning by, 1036*t*  
 toxic poisoning by, **1035**, 1036*t*
- Gastric acidity  
 decreased  
 proton pump inhibitors and, 1089
- Gastric emptying  
 impaired  
 domperidone for, 1092  
 metoclopramide for, 1092
- Gastric lavage  
 in decontamination of poisoned patient,  
 1032
- Gastrin, 743, 1082*f*
- Gastrinoma  
 proton pump inhibitors for, 1088
- Gastritis  
 stress-related  
 prevention of bleeding from  
 H<sub>2</sub>-receptor antagonists in, 1085
- Gastroesophageal reflux disease (GERD)  
 domperidone for, 1092  
 H<sub>2</sub>-receptor antagonists for, 1083*t*, 1084  
 metoclopramide for, 1092  
 proton pump inhibitors for, 1087
- Gastrointestinal cancers. *See also specific  
 types*  
 chemotherapeutic drugs for, **972–973**
- Gastrointestinal diseases  
 drugs used for, **1081–1114**. *See also  
 specific drugs and diseases*  
 acid-peptic disease, **1081–1091**  
 antidiarrheal agents, **1094–1095**  
 antiemetic drugs, **1097–1100**  
 antimuscarinic drugs, 121–122, 122*t*  
 cholinomimetic drugs, 108  
 gastrointestinal motility stimulation,  
**1091–1092**, 1091*f*  
 inflammatory bowel disease,  
**1100–1106**, 1101*f*; 1102*f*,  
 1105*t*  
 irritable bowel syndrome,  
**1095–1097**, 1097*f*  
 laxatives, **1092–1094**  
 oral contraceptives and, 730
- Gastrointestinal tract  
 alcohol effects on, 392–393  
 antimuscarinic drug effects on, 120, 120*f*  
 autonomic nerve activity effects on, 90*t*  
 cholinomimetic drug effects on  
 direct-acting, 102*t*, 104  
 indirect-acting, 107  
 decontamination of poisoned patient,  
 1031–1032  
 disorders of  
 cholinomimetic drugs for, 108  
 dopamine receptor agonists effects on,  
 489  
 drug absorption effects on  
 in infants and children, 1044, 1044*t*  
 eicosanoid effects on, 327  
 ganglion-blocking drug effects on, 125  
 lead poisoning effects on, 1015  
 levodopa effects on, 487  
 lipoxygenase effects on, 323  
 methylxanthines effects on, 346  
 opioid analgesics effects on, 551*t*, 552  
 prostaglandins and thromboxanes effects  
 on, 320  
 serotonin effects on, 284



- Gastrointestinal tract (*Cont.*):  
 smooth muscle of  
 histamine effects on, 276  
 stimulation of motility of  
 drugs used for, **1091–1092**, 1091*f*  
 tetracyclines effects on, 812
- Gatifloxacin, 835  
 pharmacokinetics of, 836*t*
- Gaviscon, 1111. *See also* Aluminum hydroxide/magnesium hydroxide
- Gefitinib  
 for cancer, **967–968**
- Gelusil, 1111. *See also* Aluminum hydroxide/magnesium hydroxide
- Gemcitabine  
 for cancer, **959–961**
- Gemfibrozil  
 for hyperlipidemias, **628–629**
- Gemifloxacin, 835  
 pharmacokinetics of, 836*t*
- Gender  
 in drug metabolism, 66
- Gene therapy, 3  
 for parkinsonism, 492
- General anesthetics, **429–447**. *See also specific drugs*  
 in current clinical practice, 446  
 inhaled, **430–438**  
 intravenous, **438–446**  
 mechanism of action of, **429–430**
- Generalized seizures  
 drugs used for, **417–418**, **422–423**
- Generalized tonic-clonic seizures, 421  
 drugs used for, **407–417**, **422**
- Generic prescriptions, 1147
- Generic products, 75–76
- Genetic(s)  
 pharmacology of, 3
- Genetic factors  
 in drug metabolism, 61–65, 62*t*–63*t*, 64*f*  
 phase I enzyme polymorphisms,  
 61–65, 62*t*–63*t*, 64*f*  
 phase II enzyme polymorphisms, 65
- Genitourinary smooth muscle  
 autonomic nerve activity effects on, 90*t*
- Genitourinary system  
 antimuscarinic drug effects on, 120, 120*f*  
 direct-acting cholinomimetic drug effects  
 on, 102*t*, 104  
 disorders of  
 sympathomimetic drugs for, 145–146  
 ganglion-blocking drug effects on, 125  
 sympathomimetic drug effects on, 139
- Gentamicin, **825–826**  
 pharmacokinetics, 39*t*  
 topical, 825, **1064**
- Gentamicin, netilmicin, 822*f*
- Geocillin, 807. *See also* Carbenicillin
- Geodon, 519. *See also* Ziprasidone
- GERD. *See* Gastroesophageal reflux disease (GERD)
- Geriatric patients. *See* Aging; Elderly
- Germander  
 risks associated with, 1127*t*
- GHRH. *See* Growth hormone–releasing hormone (GHRH)
- Giardia lamblia*  
 drugs used for, 931*t*
- Giardiasis  
 drugs used for, 928
- Gigantism, 665
- Gilles de la Tourette's syndrome, 495
- Ginkgo, **1129–1130**
- Ginseng, **1130–1131**
- Gland-derived extracts  
 risks associated with, 1127*t*
- Glaucoma  
 drugs used for, 160, 161*t*, 1057  
 beta-receptor antagonists,  
 163–164  
 carbonic anhydrase inhibitors, 257,  
 257*t*  
 eicosanoid effects on, 328  
 treatment of, 160, 161*t*, 1057
- Glicentin, 762
- Glimepiride, 755*t*, 766  
 for diabetes mellitus, 756
- Glipizide, 755*t*, 766  
 for diabetes mellitus, 755–756
- Glipizide plus metformin, 766
- Globulin  
 antithymocyte, 999
- GLP-1 receptor antagonists. *See* Glucagon-like polypeptide-1 (GLP-1) receptor agonists
- Glucagon, 743, **762–763**  
 “gut,” 762  
 as poisoning antidote, 1033*t*
- Glucagon-like polypeptide-1 (GLP-1)  
 receptor agonists  
 for diabetes mellitus, **760–761**,  
 766
- Glucocorticoid(s), **697**, 700*f*, 712  
 antagonists of, **709–711**  
 anti-inflammatory effects of, 636  
 in bone mineral homeostasis, **775**  
 clinical uses of, **703–706**  
 for diagnostic purposes, 705  
 for gout, **655**  
 for hypercalcemia, 779  
 as immunosuppressive drugs, **985–986**,  
 985*t*  
 for inflammatory bowel disease,  
**1103**  
 mechanism of action of, 21–22, 22*f*  
 pharmacodynamics of, **699–701**  
 pharmacokinetics of, **698**, **703**
- Glucocorticoid receptor elements (GREs),  
 699
- Glucophage, 766. *See also* Metformin
- Glucosamine, **1135**
- Glucose  
 in acute alcohol intoxication  
 management, 395
- Glucose transporters, 746, 746*t*
- Glucotrol, 766. *See also* Glipizide
- Glucovance, 766. *See also* Glyburide plus metformin
- Glucuronidation, 60*t*
- Glutamate, 365  
 as CNS neurotransmitter, 366*t*,  
 367–369, 368*f*
- Glutamate hypothesis  
 of schizophrenia, 502–503
- Glutaraldehyde, 893*t*, 896, 898
- Glutathione conjugation, 60*t*
- Glutethimide, structure of, 375*f*
- Glyburide  
 for diabetes mellitus, 754–755, 766
- Glyburide plus metformin, 766
- Glycemic control  
 benefits of, 751, 752
- Glycemic memory, 752
- Glycerin suppository, 1093
- Glycine, 365, 478  
 as CNS neurotransmitter,  
 366*t*, 369
- Glycine conjugation, 60*t*
- Glycol poisoning, 398, 1037
- Glycopeptide(s), **802–803**  
 pharmacokinetics and dosage of, 798*t*,  
 802–803
- Glycoprotein IIB/IIIA receptors  
 blockade of, 613
- Glycopyrrolate, 117*f*, 127, 1111
- Glycosides  
 digitalis, **215–218**  
 drug interactions with, 1156*t*
- Glynase PresTab, 766. *See also* Glyburide
- Glyphosphate, **1009–1010**
- Glyset, 766. *See also* Miglitol
- GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor (GM-CSF)
- GnRH. *See* Gonadotropin-releasing hormone (GnRH)
- Goiter(s)  
 nontoxic, **694**  
 toxic multinodular, **692**  
 toxic uninodular, **692**
- Gold sodium thiomalate, 656
- Goldman-Hodgkin-Katz equation, 230
- Golimumab, **648–649**, 992–993  
 adverse effects of, 649  
 indications for, 649  
 mechanism of action of, 648–649  
 pharmacokinetics of, 649
- GoLYTELY, 1112. *See also* Polyethylene glycol electrolyte solution

- Gonadal hormones, **715–741**  
 inhibitors of, **731–734, 737–739**
- Gonadarche, 715
- Gonadorelin, 669–671
- Gonadorelin hydrochloride, 678
- Gonadotropin(s), **666–669**. *See also specific types*
- Gonadotropin antagonists, 678
- Gonadotropin-releasing hormone (GnRH), 661, 661*t*, **669–671**, 715, 733  
 receptor agonists, **671–672**
- Gonal-f, 678. *See also* Follitropin alfa
- Goserelin acetate, 678
- Gossypol, **739**
- Gout  
 drugs used for, 656
- Graft-versus-host disease, 994–995
- Gramicidin  
 topical, **1063**
- Grand mal seizures, 421  
 drugs used for, **404–417, 422**
- Granisetron  
 for nausea and vomiting, 1098–1099, 1111
- Granulocyte colony-stimulating factor (G-CSF), 591*t*, 593–594, 593*f*
- Granulocyte-macrophage colony-stimulating factor (GM-CSF), 591*t*, 593–594, 593*f*
- Graves' disease, **691–692**
- Gray baby syndrome, 817
- Grifulvin, 858. *See also* Griseofulvin
- Grisactin, 858. *See also* Griseofulvin
- Griseofulvin  
 for mucocutaneous infections, **855–856**  
 oral, **1066–1067**
- Growth factor(s)  
 megakaryocyte, **594–595**
- Growth factor receptor inhibitors  
 for cancer, **967–968**
- Growth hormone, 660, 661*t*, **662–665**, 678
- Growth hormone antagonists, **665–666**, 665*f*, 678
- Growth hormone-releasing hormone (GHRH), 661, 661*t*
- Growth stimulators  
 androgens as, 736
- Guanabenz, 176, 189
- Guanadrel, 189
- Guanethidine  
 as antihypertensive drug, 175*t*, **177**
- Guanfacine, 176, 189
- Guanine, 962*f*
- Guanylate cyclase C agonists  
 in constipation management, **1094**
- Gynazole-1, 858. *See also* Butoconazole
- Gynecologic disorders  
 androgens in, 736
- Gynecomastia  
 potassium-sparing drugs and, 263
- H**
- H<sub>2</sub> antagonists  
 ingredients in, 1118*t*
- H<sub>2</sub>-histamine receptor blockers, 1111
- H<sub>1</sub>-receptor antagonists, **277–280**, 279*t*  
 for nausea and vomiting, **1100**
- H<sub>2</sub>-receptor antagonists, **280–281**, 292  
 for acid-peptic diseases, **1083–1085**, 1083*t*, 1084*f*  
 serotonin-blocking actions of, 278–279
- H<sub>3</sub>-receptor antagonists, **281**
- H<sub>4</sub>-receptor antagonists, **281**
- Haemophilus influenzae* type b conjugate vaccine, 1164*t*
- Hair growth stimulants  
 ingredients in, 1121*t*
- Halazepam  
 dosages of, 383*t*
- Halcion, 387. *See also* Triazolam
- Haldol, 519. *See also* Haloperidol
- Half-life, 39*t*–40*t*, 42, 42*f*  
 as pharmacokinetic variable, 48
- HalfLyte, 1112. *See also* Polyethylene glycol electrolyte solution
- Halofantrine  
 clinical uses of, 917*t*  
 for malaria, **927**  
 structure of, 918*f*
- Halogen(s)  
 as antiseptics/disinfectants, 893*t*, **895**
- Halogenated aliphatic hydrocarbons  
 TLVs of, 1005*t*  
 toxic exposure to, **1005**
- Haloperidol, 155  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*  
 for Huntington's disease, 495  
 for tics, 495
- Halothane  
 pharmacologic properties of, 433*t*, 446
- Halothane hepatitis, 437
- Hand hygiene, 894
- Haplotype(s), 134
- Hashish  
 abuse of, 572
- Hazard  
 defined, 1002
- HDLs. *See* High-density lipoproteins (HDLs)
- Headache(s)  
 migraine  
 5-HT<sub>1D/1B</sub> agonists for, 285–286, 285*f*
- Heart  
 alcohol effects on, 391  
 antipsychotic drugs effects on, 512
- Heart (*Cont.*):  
 autonomic nerve activity effects on, 90*t*  
 contractility of  
 control of, 212, 213*f*  
 digitalis effects on, 216–217, 217*f*, 217*t*  
 glucagon effects on, 763  
 lipoxigenase effects on, 323  
 lithium effects on, 517  
 performance of  
 pathophysiology of, 215, 215*f*
- Heart disease  
 alcohol and, 394  
 cholinomimetic drugs for, 109  
 ischemic  
 beta-receptor antagonists for, 162, 163*f*  
 coenzyme Q10 for, 1134
- Heart failure  
 acute  
 management of, **222**  
 sympathomimetic drug effects on, 144  
 alcohol and, 393–394  
 cardiac resynchronization therapy for, 221  
 chronic  
 classification of, 220*t*  
 management of, **220–221**, 220*t*  
 coenzyme Q10 for, 1134  
 diastolic, 211  
 management of, 221–222  
 drugs used in, **211–226**, 212*t*. *See also specific drugs*  
 ACE inhibitors, **219**  
 ARBs, **219**  
 basic pharmacology of, **215–219**  
 beta-adrenoceptor antagonists, **219**  
 beta-adrenoceptor stimulants, **218**  
 beta-receptor antagonists, 162–163  
 bipyridines, **218**  
 digitalis, **215–218**  
 diuretics, 219, **265–266**  
 positive inotropic drugs, 212*t*, **218**  
 vasodilators, **219**  
 without positive inotropic effects, 212*t*, **218–219**  
 “high-output” failure, 214  
 pathophysiology of, 212, 214–215, 214*f*  
 systolic, 211
- Heart muscle  
 calcium channel blockers effects on, 203–204
- Heart rate  
 in cardiac performance, 215
- Heart rhythm  
 normal  
 electrophysiology of, **227–233**
- Heavy metals  
 as antiseptics/disinfectants, **897**  
 toxicology of, **1013–1321**. *See also specific types*

- Heavy metals, toxicology of (*Cont.*):  
 lead, **1013–1017**  
 mercury, 1014*t*, **1019–1021**
- Hectorol, 786. *See also* Doxercalciferol
- Helicobacter pylori* ulcers  
 proton pump inhibitors for, 1087–1088
- Helixate, 617. *See also* Antihemophilic factor
- Helminthic infections  
 chemotherapy of, **937–947**. *See also specific drugs*
- Hemabate, 328. *See also* Carboprost
- Hematopoiesis  
 sulfonamides effects on, 833
- Hematopoietic growth factors, **590–595**.  
*See also specific types*  
 erythropoietin, **591–592**  
 megakaryocyte growth factors, **594–595**  
 myeloid growth factors, **592–594**
- Hemicholiniums, 82, 83*f*
- Hemochromatosis  
 causes of, 586
- Hemodialysis  
 in drug overdose and poisoning, 1031, 1031*t*, 1032
- Hemofil M, 617. *See also* Antihemophilic factor
- Hemorrhage  
 postpartum  
 ergot alkaloids for, 290  
 subarachnoid  
 cerebral vasospasm and infarct following  
 calcium channel blockers effects on, 204  
 variceal  
 drugs used for, **1107–1108**
- Henderson-Hasselbalch equation, **10**, 449
- Heparin, **604–607**, 605*f*
- Heparin-induced thrombocytopenia, 606
- Hepatic cirrhosis  
 diuretics for, **267**
- Hepatic injury  
 milk thistle effects on, 1131
- Hepatitis  
 halothane, 437  
 isoniazid-induced, 841  
 viral  
 drugs used for, **882–886**. *See also specific drugs*
- Hepatitis A  
 passive immunization for, 1168*t*
- Hepatitis A vaccine, 1164*t*
- Hepatitis B  
 passive immunization for, 1168*t*
- Hepatitis B vaccine, 1164*t*
- Hepatitis B virus (HBV) infection  
 drugs used for, **883–885**, 883*t*
- Hepatitis C virus (HCV) infection  
 drugs used for, 883*t*, **885–886**
- Hepoxillin(s), 317
- Hepsera, 888. *See also* Adefovir
- Heptachlor  
 toxicity rating for, 1006*t*
- Herbal medications, **1125–1138**. *See also specific types*
- Herbicides, **1008–1010**  
 bipyridyl, **1010**  
 chlorophenoxy, **1008–1009**, 1009*f*  
 glyphosphate, **1009–1010**
- Herceptin, 999. *See also* Trastuzumab
- Hereditary vitamin D-resistant rickets, **783–784**
- Heroin, 557  
 fetal effects of, 1042*t*  
 during lactation, 1048*t*
- Herpes simplex virus (HSV) infection  
 drugs used for, **862–866**
- Heterocyclic antidepressants  
 drug interactions with, 1152*t*
- Heterodimers, 25
- Heterologous desensitization, 133
- Heteroreceptor(s), 92, 92*t*
- Hetrazan, 946. *See also* Diethylcarbamazine
- Hexachlorocyclohexane, **1068**
- Hexachlorophene, 895, 898
- Hexamethonium, 124
- Hibiclens, 898. *See also* Chlorhexidine gluconate
- Hibistat, 898. *See also* Chlorhexidine gluconate
- High-density lipoproteins (HDLs), 619–621  
 deficiency of, 625
- “High-output” heart failure, 214
- Hirudin, 607
- Histamine, **274–277**  
 basic pharmacology of, **274–277**  
 as CNS neurotransmitter, 367*t*  
 inhibitory effects of, 92*t*  
 “triple response” of, 276
- Histamine antagonists, **277**. *See also specific types*
- Histamine receptors  
 subtypes of, 275, 275*t*
- Histamine receptor antagonists, **277–281**.  
*See also specific antagonists, e.g.,*  
 H<sub>1</sub>-receptor antagonists
- Histex, 292. *See also* Carbinoxamine
- Histrelin acetate, 678
- HIV  
 life cycle of, 873*f*
- HIV infection, 985  
 in children  
 IGIV passive immunization, 1168*t*
- Hivid, 889. *See also* Zalcitabine
- HMG-CoA reductase inhibitors,  
**625–627**, 626*f*  
 in drug combinations, 631  
 drug interactions with, 1157*t*
- Hodgkin’s lymphoma  
 chemotherapeutic drugs for, **970**
- Homatropine, 127
- Homeostasis  
 bone mineral, **769–785**
- Homodimers, 25
- Homologous desensitization, 133
- Hookworm infections  
 albendazole for, 938–939
- Hormonal contraception, 725*t*, **726–731**.  
*See also specific types and* Oral contraceptives
- Hormonal therapy  
 postmenopausal  
 estrogen in, 720–722
- Hormone(s). *See also specific types*  
 adrenal, 697–713  
 bone mineral-regulating disorders involving, **780–785**  
 defined, 4  
 gonadal, **750–741**  
 inhibitors of, **750–741**  
 hypothalamic-pituitary, 659–679  
 ovarian, **726**  
 thyroid, **684–688**. *See also* Thyroid hormones
- Hormone secretion  
 sympathomimetic drug effects on, 139–140
- HSV infection. *See* Herpes simplex virus (HSV) infection
- 5-HT agonists, 292
- 5-HT<sub>1D/1B</sub> agonists  
 for migraine, 285–286, 285*f*
- 5-HT<sub>2</sub> antagonists, 286, **526–531**, 539  
 adverse effects of, 536
- 5-HT<sub>3</sub>-receptor antagonists, 1092–1098, 1111
- 5-HT<sub>4</sub>-receptor agonists, 1092  
 in constipation management, **1094**  
 for irritable bowel syndrome, **1096–1097**
- Human chorionic gonadotropin (hCG), **666–669**
- Human development  
 critical periods of  
 schematic diagram of, 1041*f*
- Human liver P450 enzymes, **55–59**  
 described, 55–57  
 enzyme induction, 57–59, 58*t*  
 enzyme inhibition, 58*t*, 59
- Human menopausal gonadotropins (hMGs), 666
- Human papillomavirus (HPV) vaccine, 1164*t*
- Human placenta derivatives  
 risks associated with, 1127*t*
- Humatin, 828, 935. *See also* Paromomycin
- Humira, 656, 999, 1112. *See also* Adalimumab
- Humoral immunity, 978

- Humorsol, 112. *See also* Demecarium
- Huntington's disease, 494–495, 494*f*
- Hydatid disease  
 albendazole for, 939  
 praziquantel for, 944
- Hydeltrasol, 712. *See also* Prednisolone sodium phosphate
- Hydralazine, 181, 181*f*, 189  
 as antihypertensive drug, **181**  
 in chronic heart failure management, 220  
 dosage of, 175*t*, 181  
 ionization constants of, 11*t*  
 pharmacokinetics of, 39*t*, 175*t*, 181
- Hydrazines  
 chemistry of, 527–528
- Hydro-Diuril, 270. *See also* Hydrochlorothiazide
- Hydrocarbons  
 aromatic  
 TLVs of, 1005*t*  
 toxic exposure to, **1005**  
 halogenated aliphatic  
 TLVs of, 1005*t*  
 toxic exposure to, **1005–1006**, 1005*t*
- Hydrochlorothiazide, 260*f*, 270  
 dosage of, 261*t*  
 pharmacokinetics/dosage of, 175*t*
- Hydrocodone, 558  
 pharmacokinetics of, 545*t*  
 mixtures, 562
- Hydrocortisone, **698–702**. *See also* Cortisol  
 preparations available, 712, 1112
- Hydroflumethiazide, 270
- Hydrogen peroxide  
 as antiseptic/disinfectant, **896–897**
- Hydrogen sulfide  
 poisoning by, 1036*t*
- Hydrolyses, 57*t*
- Hydromorphone, 556, 562, 563  
 pharmacokinetics of, 545*t*
- Hydromox, 270. *See also* Quinethazone
- Hydrophobic bonds, 4
- Hydroquinone, **1068–1069**
- Hygroton, 270. *See also* Chlorthalidone
- Hydroxocobalamin, 586  
 as poisoning antidote, 1033*t*
- Hydroxyamphetamine, 148
- Hydroxychloroquine, **644**  
 as immunosuppressive drug, **989**
- Hydroxyprogesterone  
 structure of, 719*f*
- Hydroxyprogesterone caproate  
 properties of, 723*t*
- 5-Hydroxytryptamine, **281–287**. *See also* Serotonin
- Hydroxyurea, 582, 961*f*
- Hydroxyzine, 292, 387  
 dosage of, 279*t*
- Hygiene  
 hand, 894
- Hylorel, 189. *See also* Guanadrel
- Hymenolepis nana*  
 praziquantel for, 944
- Hyoscine  
 for nausea and vomiting, 1100
- Hyoscyamine, 127, 1111  
 for irritable bowel syndrome, 1096
- Hypercalcemia, **778–779**  
 diuretics for, **267–268**
- Hypercalciuria  
 idiopathic, **784**
- Hyperchloremic metabolic acidosis  
 carbonic anhydrase inhibitors and, 257*t*, 258  
 potassium-sparing drugs and, 263
- Hypercholesterolemia(s)  
 familial, 624, 624*f*  
 drugs used for, 622*t*  
 primary, **624–625**
- Hyperhidrosis  
 antimuscarinic drugs for, 123
- Hyperimmune immunoglobulins, **991**
- Hyperkalemia  
 heart rhythm and, 230  
 loop diuretics for, 259  
 neuromuscular blocking drugs and, 474  
 osmotic diuretics and, 264  
 potassium-sparing drugs and, 263
- Hyperlipidemia(s), 619  
 drugs used for, **625–631**  
 thiazide diuretics and, 261
- Hyperlipoproteinemia(s), 619  
 dietary management of, **625**  
 drugs used for, 622*t*  
 familial combined, 623, 624  
 drugs used for, 622*t*  
 lipoprotein(a), 624  
 drugs used for, 622*t*  
 pathophysiology of, **620–625**  
 secondary, 625  
 causes of, 622, 623*t*
- Hypernatremia  
 osmotic diuretics and, 264
- Hyperosmolar coma  
 nonketotic, 744
- Hyperosmolar hyperglycemic syndrome  
 insulin for, 752
- Hyperparathyroidism  
 primary, **780**
- Hyperphosphatemia, **780**
- Hyperplasia  
 congenital adrenal  
 synthetic corticosteroids for, 704  
 prostatic, 738–739
- Hyperprolactinemia  
 dopamine agonists for, 672–673, 672*f*  
 ergot alkaloids for, 290
- Hypersecretory conditions  
 proton pump inhibitors for, 1088
- Hypersensitivity, **981–983**, 983*f*, 984*f*  
 contact, 983  
 defined, 32  
 tuberculin, 983  
 type I, 981, 983*f*  
 type II, 981–982  
 type III, 982  
 type IV (delayed-type), 982–983, 984*f*
- Hyperstat IV, 189. *See also* Diazoxide
- Hypertension, **169–171**  
 alcohol and, 394  
 alpha-receptor antagonists for, 156  
 causes of, 170  
 classification of, 170*t*  
 coenzyme Q10 for, 1134  
 diagnosis of, 169–170, 170*t*  
 diuretics for, **172–174**, 174*f*, **267**  
 outpatient therapy in, 186  
 prevalence of, 169  
 pulmonary  
 eicosanoids and, 326  
 resistant  
 polypharmacy for, 173  
 treatment of, **171–187**
- Hypertensive emergencies, **187**  
 alpha-receptor antagonists for, 156
- Hyperthermia, **284**, **284*t***, **479**. *See* Malignant hyperthermia
- Hyperthyroidism, **691–694**  
 beta-receptor antagonists for, 164
- Hypertriglyceridemia(s)  
 familial, 623  
 drugs used for, 622*t*  
 primary, **622–624**
- Hyperuricemia  
 gout and, 651–655  
 loop diuretics and, 260  
 thiazide diuretics and, 261
- Hypnosis  
 sedative-hypnotic drugs causing, 380
- Hypocalcemia, 259, **779–780**  
 calcium for, 779–780  
 vitamin D for, 780
- Hypoglycemia  
 glucagon for, 763  
 insulin and, 753
- Hypogonadism  
 primary  
 estrogens for, 720
- Hypokalemia, 230
- Hypokalemic metabolic acidosis  
 loop diuretics and, 257*t*, 260
- Hypokalemic metabolic alkalosis  
 thiazide diuretics and, 261
- Hypomagnesemia  
 loop diuretics and, 260
- Hyponatremia  
 osmotic diuretics and, 264  
 thiazide diuretics and, 261
- Hypoparathyroidism, **780–781**

- Hypophosphatemia, **780**  
 autosomal dominant, **783**  
 X-linked, **783**
- Hypotension, sympathomimetic drugs for, 144
- Hypothalamic hormones, **659–679**  
 clinical uses of, 661*t*  
 receptors of, **660–673**
- Hypothalamic-pituitary endocrine system, 659, 660*f*
- Hypothalamic-pituitary-thyroid axis, 684*f*
- Hypothyroidism, 687*t*, **690–691**
- Hypoxanthine, 962*f*
- Hytrin, 167, 189. *See also* Terazosin
- I**
- Ibandronate  
 for osteoporosis, 775, 783, 786
- Ibritumomab tiuxetan, 992, 999
- Ibuprofen, **641**, 655  
 ionization constants of, 11*t*  
 from prescription to OTC status, 1116*t*  
 properties of, 638*t*
- Ibutilide  
 for cardiac arrhythmias, **244–245**  
 membrane actions of, 237*t*  
 pharmacologic properties of, 238*t*
- Icatibant, 302
- Idarubicin  
 for cancer, 963*t*, 965  
 clinical activity and toxicities of, 963*t*
- Idiopathic edema  
 diuretics for, **267**
- Idiopathic hypercalciuria, **784**
- Idiopathic short stature  
 growth hormone for, 663, 663*t*
- Idiopathic thrombocytopenic purpura (ITP)  
 passive immunization for, 1168*t*
- IDLs. *See* Intermediate-density lipoproteins (IDLs)
- Idrocilamide, 478
- IGIV. *See* Immune globulin intravenous (IGIV)
- Ilaris, 999. *See also* Canakinumab
- Iloprost, 325*f*, 326, 328
- Imatinib  
 for cancer, **966–967**, 967*t*
- Imidazoline receptor, 176
- IMiDs. *See* Immunomodulatory derivatives of thalidomide (IMiDs)
- Imipenem  
 pharmacokinetics and dosage of, 798*t*, 801–802
- Imipenem/cilastatin, 807
- Imipramine, **525–530**, 539  
 hepatic clearance of  
 aging effects on, 1052*t*  
 ionization constants of, 11*t*  
 pharmacokinetics of, 39*t*, 529*t*  
 for urinary disorders, 122, 122*t*
- Imiquimod, **888**, **1067**, 889
- Imitrex, 292. *See also* Sumatriptan
- Immobility  
 anesthesia and, 435
- Immune globulin intravenous (IGIV), **990**, 999, 1163, 1168*t*
- Immune insulin resistance, 753
- Immune modulation  
 echinacea in, 1126–1128
- Immune response(s), **635–636**  
 abnormal, **981–985**, 982*f*–984*f*  
 normal, **977–981**, 979*f*, 980*f*
- Immune system  
 adaptive, **978–981**, 979*f*, 980*f*  
 alcohol effects on, 394–395  
 eicosanoid effects on, 327–328  
 elements of, **977–985**  
 innate, **977–978**, 979*f*  
 isoniazid effects on, 841
- Immunity  
 cell-mediated, 978  
 humoral, 978  
 innate  
 complement in, 979*f*  
 prostaglandins and, 322
- Immunization(s), **1163–1170**. *See also specific vaccines*  
 active, **1163**, 1164*t*–1167*t*  
 materials used for, 1164*t*–1166*t*  
 passive, **1163**, **1167**, 1168*t*–1169*t*  
 materials used for, 1168*t*–1169*t*  
 routine childhood schedule, 1167*t*  
 for travel, 1170  
 untoward reactions to  
 legal liability for, **1167**, **1170**
- Immunodeficiency diseases, **984–985**  
 primary  
 passive immunization for, 1168*t*
- Immunoglobulin(s)  
 hyperimmune, **991**
- Immunologic contact urticaria  
 topical dermatologic medications and, 1063*t*
- Immunologic reactions to drugs and drug allergy, **997–998**
- Immunomodulation therapy  
 immunosuppressive drugs in, **995–997**, 995*t*–996*t*
- Immunomodulators, **1067**
- Immunomodulatory derivatives of thalidomide (IMiDs)  
 as immunosuppressive drugs, **987–988**
- Immunopharmacology, **977–1000**
- Immunosuppressive antibodies, **989–991**
- Immunosuppressive drugs, **985–994**.  
*See also specific drugs*  
 in autoimmune diseases, **995**
- Imodium, 1112. *See also* Loperamide
- Implantable cardioverter-defibrillator (ICD)  
 for cardiac arrhythmias, 228
- Impulse conduction  
 disturbances of, 234–235, 234*f*–236*f*
- Impulse formation  
 disturbances of, 233*f*, 234
- Imuran, 999
- Inamrinone, 225
- Inapsine, 446. *See also* Droperidol
- Incertohypothalamic pathway, 506
- Increlex, 678. *See also* Mecasermin
- IND (Investigational new drug), 74–76
- Indapamide, 260*f*, 270  
 dosage of, 261*t*
- Inderal, 167, 189, 249. *See also* Propranolol
- Indinavir, 871*t*, **879**  
 drug interactions with, 874*t*
- Indirect thrombin inhibitors, **604–607**, 605*f*. *See also specific drugs*  
 heparin, **604–607**, 605*f*
- Indocin, 655. *See also* Indomethacin
- Indomethacin, **641**, 638*t*  
 pharmacokinetic, 39*t*
- Indoramin, 155
- Infant(s)  
 drug therapy in, **1044–1046**
- Infantile spasms, 421  
 drugs used for, **423**
- Infarction(s)  
 following subarachnoid hemorrhage  
 calcium channel blockers effects on, 204
- Infection(s). *See also specific types*  
 eicosanoids and, 328
- Infergen, 889
- Infertility  
 female  
 GnRH agonists for, 669–670  
 male  
 GnRH agonists for, 670  
 gonadotropins for, 668
- Inflammation  
 echinacea for, 1127–1128  
 eicosanoids and, 328  
 kinins role in, 302  
 lipoxygenase and, 323  
 nitric oxide and, 335–336  
 prostaglandins and, 322  
 systemic  
 treatment of, 636
- Inflammatory bowel disease  
 described, 1100–1101  
 drugs used for, **1100–1106**, 1101*f*, 1102*f*, 1105*t*  
 pancreatic enzyme supplementation, **1106–1107**  
 for variceal hemorrhage, **1107–1108**
- Infliximab, 649, 993  
 for inflammatory bowel disease, 1104–1106, 1105*t*  
 for rheumatoid arthritis, **649**  
 for psoriasis, **1072**

- Influenza  
 drugs used for, **886–887**  
 Influenza vaccine, 1164*t*–1165*t*
- Inhalant(s)  
 abuse of, 576
- Inhaled anesthetics, **430–438**. *See also*  
*specific drugs*
- Inhibin, 726
- Inhibitory postsynaptic potential (IPSP),  
 92, 93*f*, 363, 363*f*
- Innohep, 617. *See also* Tinzaparin
- INOmax, 337. *See also* Nitric oxide
- Inositol 1,4,5-trisphosphate (IP<sub>3</sub>), 28,  
 131, 131*t*, 132*f*,  
 137*t*  
 as second messenger, 28–29, 28*f*
- Inotropic drugs  
 positive  
 in the elderly, 1056  
 in heart failure management, 212*t*,  
**218**
- Inotropic effect  
 positive, 138
- Insomnia  
 melatonin for, 1136
- Inspired concentration of inhaled  
 anesthetics, 430–432, 432*f*
- Inspra, 225, 262*t*, 270.  
*See also* Eplerenone
- Insulin, 743, **744–753**  
 targets for  
 effects of, 747, 747*f*  
 treatment with, 751
- Insulin aspart, 747, 748*t*, 749
- Insulin delivery systems, 748*t*, 750–751  
 insulin pumps, 750–751  
 portable pen injectors, 748*t*, 750
- Insulin detemir, 748*t*, 750
- Insulin glargine, 748*t*, 749–750
- Insulin glulisine, 747, 748*t*, 749
- Insulin-like growth factor-I (IGF-I), 661,  
 661*f*
- Insulin lispro, 747, 748*t*, 749
- Insulin pumps, 750–751
- Insulin receptor, 746–747, 746*f*, 746*t*
- Insulin resistance  
 immune, 753
- Insulin secretagogues, **754–756**. *See also*  
*specific types, eg, Sulfonylureas*
- Integrase strand transfer inhibitors, 871*t*,  
**882**
- Integrilin, 617. *See also* Eptifibatide
- Intention tremor, 494
- Interferon alfa-2a  
 for HBV infection, 883*t*
- Interferon alfa-2b  
 for HBV infection, 883*t*
- Interferon(s), **882–887, 995**  
 dermatologic uses of, 1078*t*  
 properties of, 995*t*
- Interleukin(s)  
 properties of, 995*t*–996*t*
- Interleukin-1 inhibitors  
 for gout, **655**
- Interleukin-2, 999
- Interleukin-11  
 agents mimicking actions of, 591*t*,  
 594–595  
 clinical uses of, 591*t*, 594–595
- Intermediate-density lipoproteins (IDLs),  
 619
- Intermittent claudication  
 treatment of, 207
- Intestinal osteodystrophy, **782**
- Intestine  
 actions of PTH, FGF23, and vitamin D  
 on, 774*t*  
 disorders of, 1091–1114
- Intracellular signaling pathways  
 in renin release, 296, 297*f*
- Intracellular sodium  
 concentration of, 212
- Intracranial pressure  
 reduction of  
 osmotic diuretics for, 264
- Intragastric acidity  
 reducing of  
 drugs used for, **1081–1089**
- Intragastric pressure  
 increased  
 neuromuscular blocking drugs and, 474
- Intraocular pressure  
 increased  
 neuromuscular blocking drugs  
 and, 474  
 reduction of  
 osmotic diuretics for, 264
- Intravenous anesthetics, **438–446**. *See also*  
*specific drugs*  
 pharmacologic properties of, 439*t*
- Intrinsic efficacy, 7
- Intrinsic factor, 586
- Intron-A, 889, 999. *See also* Interferon  
 alfa-2b
- Intropin, 148, 225. *See also* Dopamine
- Invanz, 807. *See also* Ertapenem
- Invega, 519. *See also* Paliperidone
- Inverse agonists, 8, 8*f*
- Inversine, 127, 189. *See also* Mecamylamine
- Iodide(s)  
 antithyroid activity of, **689**  
 fetal effects of, 1042*t*  
 metabolism of, 681
- Iodide organification, 682
- Iodine  
 as antiseptic/disinfectant, 895  
 during lactation, 1048*t*  
 radioactive  
 antithyroid activity of, **689**  
 for Graves' disease, 692
- Iodophor(s)  
 as antiseptic/disinfectant, 895
- Iodoquinol, 929*f*, 935  
 for amebiasis, **929–930**
- Iodotope, 695. *See also* Radioactive iodine  
 sodium
- Ion channel(s)  
 characterization of  
 tools for, 360–360*t*  
 CNS drugs and, 360–361  
 novel analgesic targets and, 550
- Ion channel blockers  
 in chronic heart failure  
 management, **221**
- Ion transport  
 lithium effects on, 514
- Ionization  
 of weak acids and bases, 10–12, 11*t*, 12*f*,  
 12*t*
- Ionization constant  
 of common drugs, 11*t*
- Ionotropic receptors, **360–361**  
 drugs mediating their effects via  
 abuse of, **573–576**
- Iopidine, 148. *See also* Apraclonidine
- Ipratropium, 127, 347, 355  
 for COPD, 121, 353
- Iprivask, 617. *See also* Desirudin
- IPSP. *See* Inhibitory postsynaptic potential  
 (IPSP)
- Irbesartan, 190, 225
- Irinotecan  
 clinical activity and toxicities of, 963*t*
- Iron, **582–586**, 598  
 drug interactions with, 1157*t*  
 poisoning by, **1037**
- Iron deficiency anemia  
 treatment of, 585–586, 586*t*
- Iron dextran, 585
- Iron-sucrose complex, 585–586
- Irritable bowel syndrome  
 drugs used for, **1095–1097**, 1097*f*
- Irritant(s)  
 gases  
 poisoning by, 1036*t*  
 topical dermatologic medications as,  
 1063*t*
- Ischemic heart disease  
 beta-receptor antagonists for, 162, 163*f*  
 coenzyme Q10 for, 1134
- Isentress, 889. *See also* Raltegravir
- Islet amyloid polypeptide (IAPP), 743, **763**
- Ismelin, 189. *See also* Guanethidine
- Ismo, 209. *See also* Isosorbide mononitrate
- Isocarboxazid  
 dosage of, 535*t*
- Isoicosanoids, 317
- Isoetharine, 355
- Isoflurane, 432*f*, 446  
 pharmacologic properties of, 432*f*, 433*t*

- Isimmune disease  
 immunosuppressive drugs for, 985*t*
- Isolan  
 toxicity rating for, 1008*t*
- Isoniazid, 840–841, 848  
 during lactation, 1048*t*  
 for tuberculosis, **840–841**, 840*t*
- Isothane insulin, 748*t*, 749
- Isopropyl alcohol  
 as antiseptic/disinfectant,  
 893*t*, **894**
- Isoproterenol, 136*f*, 138*t*, 139*f*, **141**, 148,  
 343*f*, 355  
 for asthma, 343  
 cardiovascular responses to, 138*t*  
 ionization constants of, 11*t*
- Isoptin, 190, 209, 249. *See also* Verapamil
- Isopto Carpine, 112. *See also* Pilocarpine
- Isopto Homatropine, 127. *See also*  
 Homatropine
- Isordil, 209. *See also* Isosorbide dinitrate
- Isosorbide dinitrate, 196, 209
- Isosorbide mononitrate, 197, 209
- Ispora belli*  
 drugs used for, 931*t*
- Isotretinoin  
 for acne, **1070**  
 fetal effects of, 1042*t*
- Isradipine  
 clinical pharmacology of, 202*t*
- Istaroxime  
 in heart failure management, 218
- Isuprel, 148, 355. *See also* Isoproterenol
- Itraconazole, 853*f*, 858  
 pharmacologic properties of, 854*t*  
 for systemic infections, **854**
- Ivermectin, **940–941**  
 for helminthic infections, 938*t*,  
**940–941**
- J**
- Janumet, 766. *See also* Sitagliptin plus  
 metformin
- Janus-kinase (JAK) family, 23, 24*f*
- Januvia, 766. *See also* Sitagliptin
- Jerking  
 myotonic, 421
- Jet lag  
 melatonin for, 1135–1136
- Jin Bu Huan  
 risks associated with, 1127*t*
- K**
- Kaletra, 889. *See also* Lopinavir/ritonavir
- Kallikrein(s), 300
- Kallikrein-kinin system  
 drugs affecting, **302–303**
- Kanamycin, 822*f*, **826–827**, 828  
 for tuberculosis, 840*t*, 844
- Kantrex, 828. *See also* Kanamycin
- Kava-kava  
 risks associated with, 1127*t*
- Kawasaki disease  
 passive immunization for, 1168*t*
- Kefauver-Harris Amendments of 1962, 74,  
 74*t*
- Keflex, 807. *See also* Cephalexin
- Kefurox, 807. *See also* Cefuroxime
- Kefzol, 807. *See also* Cefazolin
- Kemadrin, 499. *See also* Procyclidine
- Kenalog, 712. *See also* Triamcinolone
- Keppra, 427. *See also* Levetiracetam
- Keratolytic agents, **1074–1076**
- Kerlone, 189. *See also* Betaxolol
- Ketalar, 446. *See also* Ketamine
- Ketamine, 438*f*, **444–445**, 446  
 abuse of, 569*t*, 575–576, 577*f*  
 for chronic pain, 550  
 as intravenous anesthetic, **444–445**  
 pharmacologic properties of, 439*t*
- Ketanserin, 286
- Ketek, 819. *See also* Telithromycin
- Ketoacidosis  
 diabetic, 744  
 insulin for, 751–752
- Ketoconazole, 709*f*, **710**, 712, 737,  
 853*f*, 858  
 oral, 1066  
 pharmacologic properties of, 854*t*  
 from prescription to OTC status, 1116*t*  
 for systemic infections, **854**
- Ketolides, **814–815**, 819
- Ketoprofen, **641–642**, 655  
 properties of, 638*t*
- Ketorolac, **642**, 655  
 properties of, 638*t*
- Ketotifen, 292
- Ketotifen fumarate  
 from prescription to OTC status,  
 1116*t*
- Kidney(s). *See also under* Renal  
 actions of PTH, FGF23, and vitamin D  
 on, 774*t*  
 angiotensin II effects on, 298  
 inhaled anesthetics effects on, 436–437  
 lead poisoning effects on, 1015  
 lipoxygenase effects on, 323  
 lithium effects on, 516–517  
 methylxanthines effects on, 346  
 opioid analgesics effects on, 552  
 prostaglandins and thromboxanes effects  
 on, 320–321
- Kidney disease  
 chronic, **781–782**  
 vitamin D for, 781–782  
 diuretics for, **266–267**
- Kidney stones  
 carbonic anhydrase inhibitors and, 258  
 potassium-sparing drugs and, 263
- Kineret, 999. *See also* Anakinra
- Kinin(s), **300–303**
- Kinin receptors  
 mechanisms of action of, **302**
- Kininogen(s), 301
- Klonopin, 387, 427. *See also* Clonazepam
- Knockin mice, 3
- Knockout mice, 3  
 adrenoceptor subtypes and, 133
- Koate-HP, 617. *See also* Antihemophilic  
 factor
- Kogenate, 617. *See also* Antihemophilic  
 factor
- Kombiglyze, 766. *See also* Saxagliptin plus  
 metformin
- Konyne 80, 617. *See also* Factor IX  
 complex, human
- Krystexxa, 656. *See also* Pegloticase
- Kytril, 1111. *See also* Granisetron
- L**
- Labetalol, 155, 158*f*, 159*t*, **161–162**, 167,  
 189  
 as antihypertensive drug, 179  
 for hypertensive emergencies, 156  
 pharmacokinetic and pharmacodynamic  
 parameters for, 39*t*
- Labor, obstetrical  
 facilitation of  
 eicosanoids in, 325–326  
 premature  
 suppression of  
 sympathomimetic drugs for, 145
- Lacosamide  
 for seizures, **413–414**
- Lactation  
 drug use during, **1046–1047**, 1048*t*  
 milk thistle effects on, 1132  
 physiologic  
 dopamine agonists for, 673
- Lactation stimulation  
 postpartum  
 domperidone for, 1092
- Lactulose  
 in constipation management, 1093
- Lamictal, 427, 519. *See also* Lamotrigine
- Lamisil, 858. *See also* Terbinafine
- Lamivudine, 863*f*, 871*t*, **874**, 889  
 for HBV infection, 883*t*, **884–885**  
 during pregnancy, 876, 876*t*
- Lamotrigine, 414*f*, 427, 519  
 for bipolar disorder, 517  
 for seizures, **414**
- Lamprene, 848. *See also* Clofazimine
- Lanoxicaps, 225. *See also* Digoxin
- Lanoxin, 225. *See also* Digoxin
- Lanreotide, 666, 678
- Lansoprazole, 1086*f*, 1111  
 pharmacokinetics of, 1086*t*  
 from prescription to OTC status, 1116*t*
- Lariam, 935. *See also* Mefloquine

- Lasix, 270. *See also* Furosemide
- Latanoprost, 315, 328
- Laxative(s), **1092–1094**. *See also specific types*  
 ingredients in, 1122*t*
- LDLs. *See* Low-density lipoprotein(s) (LDLs)
- Lead  
 toxicology of, **1013–1017**
- Lead compounds, 71  
 toxicology of, 1014*t*
- Lead poisoning, **1013–1017**
- Learning  
 maladaptive  
 addiction as, **568–571**
- Leflunomide, **645**, 656, 999  
 as immunosuppressive drug, **989**, 999
- Legal issues  
 immunization-related, **1167**, **1170**  
 in prescribing drugs, **1144–1147**, 1144*t*, 1145*t*
- Leiomyomata  
 uterine  
 gonadotropins in, 670
- Leishmaniasis  
 drugs used for, 931*t*, **933–934**  
 pentamidine for, 932
- Lenalidomide, 988, 999  
 for multiple myeloma, 971
- Lepirudin, 607, 617
- Leprosy  
 drugs used for, **845–846**, 848
- Lescol, 633. *See also* Fluvastatin
- Lethal dose  
 median, 31–32, 31*f*; 71–72  
 minimum, 71
- Letrozole, 733, 740
- Leu-enkephalin, 543–544, 544*t*
- Leukemias  
 chemotherapeutic drugs for, **969–970**  
 chronic lymphocytic  
 passive immunization for, 1168*t*
- Leukine, 598. *See also* Sargramostim
- Leukotriene antagonists  
 for asthma, **352**
- Leukotriene inhibitors, **349–350**
- Leuprolide acetate, 678
- Levalbuterol, 355
- Levaquin, 838. *See also* Levofloxacin
- Levatol, 167, 189. *See also* Penbutolol
- Levetiracetam, 414*f*; 427  
 for seizures, **414–415**
- Levitra, 209. *See also* Vardenafil
- Levo-Dromoran, 562. *See also* Levorphanol
- Levo-T, 695. *See also* Levothyroxine
- Levobunolol, 161, 167
- Levobupivacaine, **460**, 463
- Levocabastine, 292
- Levocetirizine, 292
- Levodopa  
 drug interactions with, 488, 1157*t*  
 ionization constants of, 11*t*  
 for parkinsonism, **484–488**, 485*f*; 486*f*  
 sympathomimetic drug effects of, 143
- Levofloxacin, 835*f*; 838  
 clinical uses of, 836  
 dosage of, 840*t*, 838  
 pharmacokinetics of, 836*t*
- Levolet, 695. *See also* Levothyroxine
- Levomethadyl acetate, 562
- Levonorgestrel, 740  
 from prescription to OTC status, 1116*t*
- Levophed, 148. *See also* Norepinephrine
- Levopropoxyphene, 559
- Levorphanol, 557, 562  
 pharmacokinetics of, 545*t*
- Levosimendan, 212  
 in heart failure management, 218
- Levothroid, 695. *See also* Levothyroxine
- Levothyroxine, 687–688, 695
- Levoxyl, 695. *See also* Levothyroxine
- Levsin, 127, 1111. *See also* Hyoscyamine
- Lexapro, 539. *See also* Escitalopram
- Lexiva, 889. *See also* Fosamprenavir
- Lialda, 1102, 1102*f*
- Librium, 387, 400. *See also* Chlordiazepoxide
- Lidocaine, 240*f*; 249, 451*t*, **460**, 463  
 for cardiac arrhythmias, **237–241**  
 cardiac effects of, 237*t*, 240, 240*f*  
 for chronic pain, 550  
 ionization constants of, 11*t*  
 pharmacokinetics of, 39*t*, 452*t*
- Lidocaine mixtures, 463
- Lifestyle changes  
 aging and, 1053
- Ligand-gated channels, 23–24, 24*f*, 360–361
- Linacotide  
 in constipation management, 1094
- Linagliptin  
 for diabetes mellitus, 761, 766
- Lincomycin, 819
- Lindane, **1068**  
 toxicity rating for, 1006*t*
- Linezolid, 817, 819  
 for tuberculosis, 840*t*, 845
- Lioresal, 481. *See also* Baclofen
- Liothyronine, 687–688, 695
- Liotrix, 695
- Lipid diffusion, 9, 9*f*
- Lipid metabolism  
 oral contraceptives effects on, 728
- Lipid resuscitation  
 local anesthetics and, 459
- Lipid-soluble drugs  
 intracellular receptors for, 21–22, 21*f*  
 during pregnancy, 1039
- Lipid:aqueous partition coefficient, 9, 9*f*
- Lipodystrophy  
 insulin and, 753
- Lipopeptides  
 pharmacokinetics and dosage of, 798*t*, 802–803
- Lipoprotein(s), 619. *See also specific types, e.g.,* High-density lipoproteins (HDLs)  
 disorders of, **621–622**, 622*t*, 623*t*  
 metabolism of, **620–621**, 621*f*  
 structure of, 630  
 synthesis and catabolism of, 620, 621*f*
- Lipoprotein lipase, 620
- Lipoprotein(a), 619, 620
- Lipoprotein(a) hyperlipoproteinemia, 624  
 drugs used for, 622*t*
- Lipoxin(s), 317
- Lipoxygenase(s)  
 products of, 316–317, 316*f*  
 prostaglandins and thromboxanes effects on, 322–323
- Liquaemin, 617. *See also* Heparin sodium
- Liraglutide  
 for diabetes mellitus, 760–761, 766
- Lisinopril  
 pharmacokinetics/dosage of, 175*t*, 190, 225
- Lithium  
 for bipolar disorder, **513–517**  
 drug interactions with, 516, 1158*t*  
 fetal effects of, 1042*t*  
 during lactation, 1048*t*  
 pharmacokinetics of, 39*t*, 514, 514*t*
- Lithium carbonate, 519
- Liver  
 alcohol effects on, 392–393  
 inhaled anesthetics effects on, 437  
 insulin effects on, 746, 747*t*  
 oral contraceptives effects on, 727–728
- Liver abscess, amebic, chloroquine for, 917
- Liver impairment  
 antimicrobial drugs in patients with, 908*t*, 909
- Livostin, 292. *See also* Levocabastine
- Loa loa*  
 diethylcarbamazine citrate for, 940
- Loading dose, 46–47, 47*f*
- Lobeline, 100*f*
- Local anesthesia/anesthetics, **449–464**.  
*See also specific drugs*  
 H<sub>1</sub>-receptor antagonists in, 279  
 neuromuscular blocking drugs with, 475  
 neuronal factors affecting, 455  
 in OTC products, 1123*t*  
 transient neurologic symptoms of, 459
- Local circuit neurons, 365, 365*f*
- Lodine, 655. *See also* Etodolac
- Lodosyn, 499. *See also* Carbidopa
- Lofibra, 633. *See also* Fenofibrate
- Log-kill hypothesis, 951, 951*f*



- Lomefloxacin  
 pharmacokinetics of, 836*t*, 838
- Lomotil, 1112. *See also* Diphenoxylate
- Lomustine  
 clinical activity and toxicities of, 956*t*
- Long-term potentiation (LTP), 369, 571
- Loniten, 189. *See also* Minoxidil
- Loop diuretics, **258–260**  
 sites of action of, 252*f*  
 thiazide diuretics and, **265**  
 toxicity of, 260
- Loop of Henle  
 in renal tubule transport, 252*t*,  
 253–254, 254*f*  
 sites of action of, 252*t*
- Loperamide, 558  
 for diarrhea, 1094, 1112
- Lopid, 633. *See also* Gemfibrozil
- Lopinavir, 871*t*, **879–880**
- Lopinavir/ritonavir, 889  
 drug interactions with, 874*t*  
 during pregnancy, 876, 876*t*
- Lopressor, 167, 189, 225. *See also*  
 Metoprolol
- Lorabid, 807. *See also* Loracarbef
- Loracarbef, 807
- Loratadine  
 dosage of, 279*t*, 292  
 from prescription to OTC status,  
 1116*t*
- Lorazepam  
 dosages of, 383*t*  
 for epilepsy, 420  
 pharmacology of, 377*t*, 439*t*  
 preparations available, 387, 400, 427,  
 446
- Lorcaserin  
 in obesity management, 664, 665*t*
- Lortab, 562. *See also* Hydrocodone/acetaminophen
- Losartan  
 pharmacokinetics/dosage of, 175*t*, 185,  
 190, 225
- Lotensin, 190, 225. *See also* Benazepril
- Lotrimin, 858. *See also* Clotrimazole
- Lotrimin Ultra, 858. *See also* Butenafine
- Lotronex, 1111. *See also* Alosetron
- Lovastatin, 626*f*, 633
- Lovaza, 633. *See also* Omega-3 fatty acids
- Lovenox, 617. *See also* Enoxaparin
- Low-density lipoproteins (LDLs), 619, 620
- 5-LOX-activating protein (FLAP), 316,  
 316*f*
- Loxapine  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*, 519
- Loxitane, 519. *See also* Loxapine
- Lozol, 270. *See also* Indapamide
- LSD  
 abuse of, 569*t*, 573
- LTP. *See* Long-term potentiation (LTP)
- Lubiprostone  
 in constipation management,  
 1094  
 for irritable bowel syndrome, 1097,  
 1112
- Lucentis, 999. *See also* Ranibizumab
- Lufyllin, 355. *See also* Dyphylline
- Lugol's Solution, 898. *See also* Iodine
- Lumefantrine, 918*f*  
 clinical uses of, 917*t*  
 for malaria, **927**
- Lumigan, 328. *See also* Bimatoprost
- Luminal Sodium, 387, 427. *See also*  
 Phenobarbital
- Lunesta, 387. *See also* Eszopiclone
- Lung(s)  
 maturation of, fetal, corticosteroids and,  
 705–706, 706*t*
- Lung cancer  
 chemotherapeutic drugs for, **973**
- Lupron, 678. *See also* Leuprolide acetate
- Lusedra, 446. *See also* Fospropofol
- Luteinizing hormone (LH),  
**666–669**, 715
- Lutropin alfa, 667, 678
- Luveris, 678. *See also* Lutropin alfa
- Lymphocyte(s)  
 T, 978–981, 979*f*, 980*f*
- Lymphocyte immune globulin, 999
- Lymphoma(s)  
 Hodgkin's  
 chemotherapeutic drugs for, **970**  
 non-Hodgkin's  
 chemotherapeutic drugs for,  
**970–971**
- Lynestrenol, 723*t*
- Lyrica, 427. *See also* Pregabalin
- Lysodren, 712. *See also* Mitotane
- M**
- Ma-huang  
 risks associated with, 1127*t*
- Maalox, 1111
- MABs. *See* Monoclonal antibodies (MABs)
- Macrodantin, 898. *See also*  
 Nitrofurantoin
- Macrolides, **813–815**. *See also specific drugs*  
 drug interactions with, 1158*t*  
 in gastrointestinal motility stimulation,  
**1092**
- Macrophage colony-stimulating factor  
 properties of, 996*t*
- Macugen, 999. *See also* Pegaptanib
- Macula densa  
 in renin release, 296, 297*f*
- Macular degeneration  
 drugs used in, 1057
- Mafenide, 837
- Magan, 655. *See also* Magnesium salicylate
- Magnesium  
 for cardiac arrhythmias, **246**  
 digitalis with, 218
- Magnesium citrate  
 in constipation management, 1093
- Magnesium hydroxide  
 as antacid, 1083  
 in constipation, 1093, 1112
- Magnesium salicylate, 655
- Magnesium sulfate, 250
- Maintenance dose, 46
- Major depressive disorder. *See also*  
 Depression  
 antidepressants for, **521–541**. *See also*  
 Antidepressants(s)
- BDNF in, 522–523, 522*f*  
 characteristics of, 521  
 monoamine(s) and, 523, 524*f*  
 monoamine hypothesis of, 522, 523,  
 523*f*  
 neurotransmitters and, 523, 524*f*  
 neurotrophic hypothesis of, 522–523,  
 522*f*  
 pathophysiology of, 522  
 neuroendocrine factors in, 524–525  
 prevalence of, 521
- Maladaptive learning  
 addiction as, **568–571**
- Malaoxon, 106*f*
- Malaria, **915–927**  
 chemoprophylaxis of, 922, 924  
 drugs used for, **915–927**. *See also specific*  
*drugs and* Antimalarial drugs
- falciparum  
 chloroquine-resistant  
 treatment of, 926  
 treatment of, 920, 920*t*, 922
- ovale  
 treatment of, 924
- parasites carrying  
 life cycle of, 915, 916*f*  
 prevention of  
 drugs used for, 919*t*
- vivax  
 treatment of, 924
- Malarone, 935. *See also*  
 Atovaquone-proguanil  
 for malaria, 924  
 in malaria prevention in travelers, 919*t*
- Malathion, **1068**  
 structure of, 106*f*  
 toxicity rating for, 1007*t*
- Male chemical contraception, **739**
- Male infertility  
 GnRH agonists for, 670  
 gonadotropins for, 668
- Male reproductive system  
 eicosanoid effects on, 326  
 prostaglandins and thromboxanes effects  
 on, 321

- Malignancy(ies)  
 secondary  
 chemotherapeutic drugs for, **974**
- Malignant hyperthermia, 284, 284*t*, 475  
 inhaled anesthetics and, 437  
 treatment of  
 dantrolene in, 479
- Malignant melanoma  
 chemotherapeutic drugs for, **974**
- Mammalian target of rapamycin (mTOR)  
 inhibitors, 985*t*, **986–987**
- Mannitol, 270
- MAOIs. *See* Monoamine oxidase inhibitors (MAOIs)
- Maprotiline, **527–530**
- Maraviroc, 871*t*, **881–882**, 889  
 drug interactions with, 874*t*
- Marcaine, 463. *See also* Bupivacaine
- Marezine. *See also* Cyclizine
- Marijuana  
 abuse of, 572
- Marinol, 1111. *See also* Dronabinol
- Marplan, 539. *See also* Isocarboxazid
- Materia medica  
 defined, 2
- Maternal drug actions  
 during pregnancy, 1040
- Maturation  
 female  
 estrogen effects on, 719–720  
 male, 735
- Mavik, 190, 225. *See also* Trandolapril
- Maxair, 355. *See also* Pirbuterol
- Maxaquin, 838. *See also* Lomefloxacin
- Maximum effect  
 as pharmacodynamic variable, 48
- Maxipime, 807. *See also* Cefepime
- Maxzide, 262*t*
- Mean arterial pressure, 89
- Measles  
 passive immunization for, 1168*t*
- Measles-mumps-rubella (MMR) vaccine,  
 1165*t*
- Mebaral, 387, 427. *See also* Mephobarbital
- Mebendazole, **941–942**, 946  
 for helminth infections, 938*t*, **941–942**
- Met-enkephalin, 543–544, 544*t*
- Mecamylamine, 124, 127, 189
- Mecasermin, **665**, 678
- Mechlorethamine, 954*f*  
 clinical activity and toxicities of, 956*t*
- Meclizine  
 dosage of, 279*t*, 292  
 for nausea and vomiting, 1100
- Meclofenamate sodium, 656
- Meclofenamic acid, 637*f*
- Mectizan, 946. *See also* Ivermectin
- Med Watch program, 1146
- Median effective dose (ED<sub>50</sub>), 31–32, 31*f*
- Median lethal dose (LD<sub>50</sub>), 31–32, 31*f*; 71–72
- Median toxic dose (TD<sub>50</sub>), 31–32
- Medicare Modernization Act of 2003, 1146
- Medication Therapy Management (MTM)  
 program, 1146
- Medrol, 712. *See also* Methylprednisolone
- Medrol Enpack, 1112. *See also*  
 Methylprednisolone
- Medrohalol, 162
- Medroxyprogesterone, 719*f*  
 properties of, 723*t*
- Medroxyprogesterone acetate, 725, 740
- Medullary-periventricular pathway, 506
- Mefenamic acid, 656
- Mefloquine  
 clinical uses of, 917*t*  
 for malaria, 919*t*, **923**  
 in malaria prevention in travelers, 919*t*
- Mefoxin, 807. *See also* Cefoxitin
- Megace, 740. *See also* Megestrol acetate
- Megakaryocyte growth factors, 591*t*,  
**594–595**
- Megestrol acetate, 723*t*, 740
- Meglitinide  
 for diabetes mellitus, 756, 756*t*, 766
- Melagatran, 607
- Melanoma(s)  
 malignant  
 chemotherapeutic drugs for, **974**
- Melarsoprol  
 clinical uses of, 933
- Melatonin, **283**, **1135–1136**
- Melatonin receptor agonists, 292
- Mellaril, 519. *See also* Thioridazine
- Meloxicam, **640**, 656  
 properties of, 638*t*
- Melphalan, 954*f*  
 clinical activity and toxicities of, 956*t*
- Memantine  
 for Alzheimer's disease, 1055
- Membrane-delimited pathways, 361, 362*f*
- Membrane electrical activity  
 ionic basis of, 229–230, 229*f*
- Menest, 740. *See also* Esterified estrogens;  
 Estrone
- Meningococcal conjugate vaccine, 1165*t*
- Menopause, 715, 716*f*
- Menopur, 678. *See also* Menotropins
- Menotropins, 666, 678
- Menstrual cycle, 715, 716*f*
- Mental disturbances  
 dopamine receptor agonists and,  
 489–490
- Mentax, 858. *See also* Butenafine
- Mepenzolate, 127
- Meperidine, 40*t*, 557, 562  
 abuse of, 572  
 cardiovascular system effects of, 551–552  
 hepatic clearance of  
 aging effects on, 1052*t*  
 pharmacokinetics of, 40*t*, 545*t*
- Mephenytoin  
 for seizures, **409**, 427
- Mephobarbital, 387, 427
- Mepivacaine, 451*t*, **460–461**, 463  
 pharmacokinetic properties of, 452*t*
- Meprednisone  
 clinical uses and dosage of, 703*t*
- Meproamate, 375*f*
- Mepron, 935. *See also* Atovaquone
- Mequinol, **1068–1069**
- 6-Mercaptopurine (6-MP)  
 for inflammatory bowel disease,  
**1103–1104**  
 mechanism of action of, 961, 961*f*
- Mercury poisoning, 1014*t*, **1019–1021**
- Meropenem  
 pharmacokinetics and dosage of, 798*t*,  
 801–802
- Merrem, 807. *See also* Meropenem
- Mersol, 898. *See also* Thimerosal
- Mesalamine, 1112
- Mesalamine compounds, 1102, 1102*f*
- Mesantoin, 427. *See also* Mephenytoin
- Mescaline  
 abuse of, 569*t*, 573
- Mesolimbic-mesocortical pathway, 506
- Mestinon, 112. *See also* Pyridostigmine
- Mestranol, 718*f*
- Metabolic acidosis  
 hyperchloremic  
 carbonic anhydrase inhibitors and,  
 257*t*, 258  
 potassium-sparing drugs and, 263  
 hypokalemic  
 loop diuretics and, 257*t*, 260
- Metabolic alkalosis  
 carbonic anhydrase inhibitors for, 257,  
 257*t*  
 hypokalemic  
 thiazide diuretics and, 261
- Metabolic functions  
 autonomic nerve activity effects on, 90*t*
- Metabolic syndrome, 664
- Metabolism  
 antipsychotic drugs effects on, 512  
 beta-receptor antagonists effects on,  
 160  
 bone  
 prostaglandins effects on, 322  
 estrogen effects on, 720  
 ginkgo effects on, 1130  
 glucagon effects on, 762–763  
 histamine effects on, 276  
 oral contraceptive effects on, 728  
 sympathomimetic drug effects on, 139  
 synthetic corticosteroids effects on, 706
- Metabolizers, drug  
 extensive, 64  
 poor, 63  
 ultrarapid, 63–64

- Metabotropic receptors, 361
- Metaglip, 766. *See also* Glipizide plus metformin
- Metal(s)  
as environmental pollutant,  
**1011–1012**
- Metalloprotein(s)  
nitric oxide interactions with, 331–332
- Metamucil, 1112. *See also* Psyllium
- Metaproterenol  
for asthma, 344, 355
- Metaraminol, 148  
ionization constants of, 11*t*
- Metaxalone, 481
- Metformin, 757, 766
- Methacholine  
properties of, 99, 100*t*
- Methadone, 557, 562  
fetal effects of, 1042*t*  
ionization constants of, 11*t*  
during lactation, 1048*t*  
pharmacokinetics of, 545*t*
- Methallenestril  
dosage of, 719*t*
- Methamphetamine, 148  
ionization constants of, 11*t*  
sympathomimetic drug effects of, 142
- Methanol  
pharmacology of, **397–398**,  
398*f*, 400
- Methanol poisoning, **1037**
- Methantheline, 127
- Methazolamide, 270  
dosage of, 257*t*
- Methenamine, 898  
as urinary antiseptic, **893**
- Methergine, 292. *See also* Methylergonovine
- Methimazole  
for Graves' disease, 691–692, 695
- Methocarbamol, 481
- Methohexital, 446  
pharmacologic properties of, 439*t*
- Methomyl  
toxicity rating for, 1008*t*
- Methotrexate, **645, 958**  
adverse effects of, 645, 1104  
for cancer, **958**  
clinical activity and toxicities of, 959*t*  
clinical uses of, 1104  
fetal effects of, 1043*t*  
as immunosuppressive drug, 989  
indications for, 645  
for inflammatory bowel disease, **1104**  
ionization constants of, 11*t*  
mechanism of action of, 645  
pharmacodynamics of, 40*t*, 1104  
pharmacokinetics of, 40*t*, 645, 1104
- Methoxamine, 136*f*, **141**  
for acute hypotension, 144
- Methoxsalen, **1069**
- Methoxychlor  
toxicity rating for, 1006*t*
- Methscopolamine, 127
- Methsuximide, 427  
for seizures, **418**
- N*-Methyl-D-aspartate glutamate  
antagonists  
for Alzheimer's disease, 1055*t*
- Methylation, 60*t*
- Methylcellulose, 1093, 1112
- Methyclothiazide, 270  
dosage of, 261*t*
- Methyldopa  
as antihypertensive drug,  
**175–176**, 175*t*  
ionization constants of, 11*t*  
pharmacokinetics/dosage of, 175*t*, 176
- Methylene-dioxymethamphetamine  
(MDMA)  
abuse of, 569*f*; 577–578
- Methylergonovine, 292
- Methylnaltrexone, 560, 562
- Methylnaltrexone bromide  
in constipation management, 1094,  
1112
- Methylphenidate, 142  
for ADHD, 146
- Methylprednisolone  
clinical uses and dosage of, 703*t*  
preparations available, 712, 1112
- Methyltestosterone, 735*t*, 740  
in replacement therapy  
dosage of, 736*t*
- Methylthiouracil  
fetal effects of, 1043*t*
- Methylxanthine(s)  
for asthma, **344–346**
- Meticorten, 712. *See also* Prednisone
- Metipranolol, 167
- Metoclopramide  
in gastrointestinal motility stimulation,  
**1092**  
for nausea and vomiting, 1100
- Metolazone  
dosage of, 261*t*
- Metoprolol, 159*t*, **161**  
as antihypertensive drug, 175*t*, 179  
ionization constants of, 11*t*  
pharmacokinetics, 40*t*  
preparations available, 167, 189, 225
- Metrifonate, **942**  
for helminthic infections, 938*t*, **942**
- Metronidazole, **891–892**  
for acne, 1064  
adverse effects of, 929  
for amebiasis, **927–929**, 928*t*  
drug interactions with, 610*t*  
fetal effects of, 1043*t*  
pharmacokinetics of, 40*t*, 928  
preparations available, 898, 935
- Metyrapone, **710**
- Metyrosine, 85  
for pheochromocytoma, 156, 167
- Mevacor, 633. *See also* Lovastatin
- Mevalonate, 626*f*
- Mexiletine  
for cardiac arrhythmias, **241**  
for chronic pain, 550  
membrane actions of, 237*t*
- Mexitil, 249. *See also* Mexiletine
- Mibefradil, 203
- Micafungin, 855, 858
- Micardis, 190, 225. *See also* Telmisartan
- Micatin, 858. *See also* Miconazole
- Michaelis-Menten elimination, 42
- Miconazole, 858  
from prescription to OTC status, 1116*t*
- Microcytic hypochromic anemia, 582
- Micronase, 766. *See also* Glyburide
- Micronized estradiol  
dosage of, 719*t*
- Microorganisms  
chemical and physical killing of  
terms related to, 894*t*
- MicroRNAs (miRNAs), 2
- Microsomal ethanol oxidizing system  
(MEOS), 390
- Microsomal mixed function  
oxidase system  
phase I reactions and, 54–55, 55*f*,  
56*t*–57*t*
- Microsporidia  
drugs used for, 931*t*
- Midamor, 270. *See also* Amiloride  
dosage of, 262*t*
- Midazolam, 438*f*  
pharmacokinetics, 40*t*  
preparations available, 387, 446
- Midodrine, **141**, 148
- Mifeprex, 712, 740. *See also*  
Mifepristone
- Mifepristone (RU-486), **710–711**,  
**731–732**
- Miglitol  
for diabetes mellitus, 759, 766
- Migraine(s)  
beta-receptor antagonists for, 164  
ergot alkaloids for, 290  
5-HT<sub>1D/1B</sub> agonists for, 285–286, 285*f*
- Milk of magnesia, 1112  
in constipation management, 1093
- Milk thistle, **1131–1132**
- Milnacipran, 525–529  
dosage of, 535*t*, 539  
sympathomimetic drug effects of, 143
- Milophene, 740. *See also* Clomiphene
- Milrinone, 225
- Miltefosine  
clinical uses of, 934
- Miltown, 387. *See also* Meprobamate

- Mineral oil  
as stool softener, 1093
- Mineralocorticoids, **708–709**. *See also specific drugs*  
aldosterone, **708**  
antagonists of, **711**  
fludrocortisone, **709**
- Minimal bactericidal concentration (MBC), 903
- Minimum inhibitory concentration (MIC), 792, 903
- Minimum lethal dose, 71
- Minipress, 167, 189. *See also* Prazosin
- Minirin, 678. *See also* Desmopressin acetate
- Minocin, 819. *See also* Minocycline
- Minocycline, 812, 819
- Minoxidil  
as antihypertensive drug, **181**, 181*f*, 189  
pharmacokinetics/dosage of, 175*t*, 181  
from prescription to OTC status, 1116*t*
- Mintezol, 946. *See also* Thiabendazole
- Miochol-E, 112. *See also* Acetylcholine (ACh)
- Miosis  
opioid analgesics and, 551, 551*t*
- Miradon, 617. *See also* Anisindione
- Mirapex, 499. *See also* Pramipexole
- Mircera, 598. *See also* Epoetin beta  
miRNAs, 2
- Mirtazapine, 527, 530  
dosage of, 535*t*
- Misoprostol, 315, 327, 1090  
fetal effects of, 1043*t*  
preparations available, 328, 1111
- Mithracin, 786. *See also* Plicamycin
- Mitomycin  
for cancer, **966**  
clinical activity and toxicities of, 963*t*
- Mitotane, **711**
- Mitoxantrone  
for cancer, 965
- Mitrolan, 1112. *See also* Polycarbophil
- Mivacron, 481. *See also* Mivacurium
- Mivacurium  
pharmacodynamics of, 470*t*  
pharmacokinetics of, 468, 470*t*  
tissue effects of, 474*t*
- Mixed function oxidases, 55
- Moban, 519. *See also* Molindone
- Mobic, 656. *See also* Meloxicam
- Mobidin, 655. *See also* Magnesium salicylate
- Modafinil  
for narcolepsy, 146, 148  
sympathomimetic drug effects of, 142–143
- Moduretic, dosage of, 262*t*
- Moexipril  
preparations available, 190, 225
- Molecular weight  
of drugs, 4
- Molecule(s)  
special carrier, 9, 9*f*  
transport, 9, 10*t*
- Molindone  
dosage of, 510*t*, 519
- Mometasone, 355
- Monistat 1, 858. *See also* Tioconazole
- Monoamine(s)  
as CNS neurotransmitters, 370  
major depression and, 523, 524*f*
- Monoamine hypothesis  
of major depression, 522, 523, 523*f*
- Monoamine oxidase (MAO)  
metabolism of catecholamines by, 87, 88*f*
- Monoamine oxidase inhibitors (MAOIs)  
for depression, 527–528, 528*f*  
overdose of, 1034  
for parkinsonism, **490**
- Monoamine transporters  
pharmacologic targeting of, 134, 135*f*
- Monobactam(s), **801**, 807–808
- Monobenzene, **1068–1069**
- Monoclate, 617. *See also* Antihemophilic factor
- Monoclonal antibodies (MABs), **991–994**, 993*f*  
actions of, 993, 993*f*  
anti-IgE  
for asthma, 350, **352**  
antitumor, **991–992**  
to deliver isotopes to tumors, **992**  
described, 989–990  
as immunosuppressants and anti-inflammatory agents, **992–994**, 993*f*
- Monoiodotyrosine (MIT), 682
- Mononine, 617. *See also* Factor IX complex, human
- Monoxygenase(s), 55
- Monopril, 190, 225. *See also* Fosinopril
- Montelukast, 328, 349, 349*f*, 355
- Monurol, 808. *See also* Fosfomycin
- Mood stabilizers, 519
- Moricizine  
for cardiac arrhythmias, **242**
- “Morning after” contraception, 731
- Morphinans  
with mixed receptor actions, 559  
strong, 557
- Morphine, 556. *See also* Opioid analgesics  
ionization constants of, 11*t*  
mechanism of action of, 546–549, 547*f*–549*f*  
metabolism of, 545–546  
organ system effects of, **549–552**
- Morphine (*Cont.*):  
pharmacodynamics of, 40*t*, **546–552**  
pharmacokinetic and pharmacodynamic parameters for, 40*t*  
pharmacokinetics of, 40*t*, 545*t*  
source of, 543
- Motility disorders  
drugs used for, 1111
- Motion sickness  
antimuscarinic drugs for, 121  
H<sub>1</sub>-receptor antagonists for, 280
- Motofen, 1112. *See also* Difenoxin
- Motrin, 655. *See also* Ibuprofen
- Mountain sickness  
carbonic anhydrase inhibitors for, 257–258
- Mouth  
poisoning effects on, 1029
- Movement disorders, **493–497**, 498, 499  
drugs used for, **483–500**. *See also specific drugs and* Parkinsonism, drugs used for
- MoviPrep, 1112. *See also* Polyethylene glycol electrolyte solution
- Moxifloxacin, 835, 835*f*, 838  
pharmacokinetics of, 836*t*
- Mozobil, 598. *See also* Plerixafor
- 6-MP, 961. *See also* 6-Mercaptopurine
- mTOR inhibitors. *See* Mammalian target of rapamycin (mTOR) inhibitors
- Mucocutaneous infections  
oral systemic antifungal drugs for, **855–856**
- Mucosal bleeding  
stress-related, 1088
- Mucosal protective agents, 1111
- Multidrug resistance type 1 (MDR1) transporter, 9, 10*t*
- Multidrug resistance–associated protein (MRP) transporter, 9, 10*t*
- Multiple myeloma  
chemotherapeutic drugs for, **971**
- Mupirocin, **892**, 898  
topical, **1063**
- Muromonab-CD3, **990**, 999
- Muscarine, 100*f*
- Muscarinic agonists, **99–110**
- Muscarinic antagonists, **115–124**  
for asthma, **351**
- Muscarinic receptors, 87, 89*t*
- Muscarinic signaling, 101*f*
- Muscle  
insulin effects on, 746, 747*t*
- Muscle pain  
neuromuscular blocking drugs and, 474–475
- Muscle relaxants, **465–482**. *See also specific drugs*  
neuromuscular blocking drugs, **465–476**  
nondepolarizing *vs.* depolarizing, 471*t*

- Muscle relaxants (*Cont.*):  
 sedative-hypnotic drugs, 381  
 spasmolytic drugs, **476–479**  
 tizanidine, 146
- Muscle spasm  
 acute local  
 drugs for, 479
- Mushroom poisoning  
 antimuscarinic drugs for, 123
- Myambutol, 848. *See also* Ethambutol
- Mycamine, 858. *See also* Micafungin
- Mycelex-3, 858. *See also* Butoconazole
- Mycifradin, 828. *See also* Neomycin
- Mycobacteria  
 atypical  
 drugs active against,  
**845, 846t**
- Mycobacterial infections  
 drugs used for, **845, 846t**  
 isoniazid, 840–841  
 rifampin, 841–842  
 streptomycin, 824, 843
- Mycobutin, 848. *See also* Rifabutin
- Mycophenolate mofetil, **645–646**  
 dermatologic uses of, 1078t  
 fetal effects of, 1043t  
 as immunosuppressive drug, 985t, **987, 999**
- Mycostatin, 858. *See also* Nystatin
- Mydracil Ophthalmic, 127. *See also* Tropicamide
- Mydriasis, 118, 119f
- Myeloid growth factors, **592–594**
- Myeloma multiple,  
 chemotherapeutic drugs for, **971**
- Myenteric plexus, 81f, 82
- Myfortic, 999. *See also* Mycophenolate mofetil
- Mykrox, 270. *See also* Metolazone
- Mylanta, 1111
- Myobloc, 481. *See also* Botulinum toxin type B
- Myocardial infarction  
 acute  
 thrombolytic drugs for,  
 611, 612  
 oral contraceptives and, 729
- Myocardial oxygen demand  
 determinants of, 194, 194t
- Myocardial oxygen supply  
 determinants of, 194
- Myoclonic jerking, 421
- Myopathy  
 coenzyme Q10 in, 1134
- Mysoline, 427. *See also* Primidone
- Mytelase, 112. *See also* Ambenonium
- Myxedema  
 coronary artery disease and,  
 690–691
- Myxedema coma, 691
- N**
- Na<sup>+</sup>/K<sup>+</sup>-ATPase  
 activity of, 212
- Nabilone  
 abuse of, 572–573  
 for nausea and vomiting, 1100, 1112
- Nabumetone, **642**
- Nadolol, 161  
 as antihypertensive drug, 179  
 properties of, 159t
- NADPH-cytochrome P450  
 oxidoreductase, 55
- Nafarelin acetate, 678
- Nafcillin  
 adverse effects of, 796–797  
 dosage of, 795t  
 pharmacokinetics of, 794–795
- Naftifine, 858  
 topical, **1065**
- Naftin, 858. *See also* Naftifine
- Nalbuphine, 558, 562  
 pharmacokinetics of, 545t
- Nalfon, 655. *See also* Fenoprofen
- Nalidixic acid, 835f
- Nalmefene, 559–560
- Naloxone, 559–560  
 clinical uses of, 560  
 for opioid abuse, 572  
 pharmacokinetics of, 560  
 as poisoning antidote, 1033t
- Naltrexone, 559–560  
 in addiction management, 578  
 in alcoholism management, 396–397
- NANC neurons  
 transmitter substances found in, 83f, 84t,  
**87–88**
- Nandrolone decanoate, 735t, 740
- Naphazoline, 148
- Naphazoline/pheniramine  
 from prescription to OTC status, 1116t
- Naprosyn, 656. *See also* Naproxen
- Naproxen, 638t, **642**  
 preparations available, 656  
 from prescription to OTC status, 1116t
- Naqua, 270. *See also* Trichlormethiazide
- Naratriptan  
 pharmacokinetics of, 286t
- Narcan, 562. *See also* Naloxone
- Narcolepsy  
 modafinil for, 146
- Nardil, 539. *See also* Phenelzine
- Naropin, 463. *See also* Ropivacaine
- Natacyn, 858. *See also* Natamycin
- Natalizumab, **993, 999**
- Natamycin, 858
- Nateglinide  
 for diabetes mellitus, 756, 766
- National Cholesterol Education Program:  
 Adult Treatment Guidelines  
 (2011), 622t
- National Institute for Occupational Safety  
 and Health (NIOSH),  
 1005–1006
- National Research Council (NRC) Wound  
 Classification Criteria, 911
- Natrecor, 225, 270. *See also* Nesiritide
- Natriuretic peptides, **303–304**
- Natural estrogens, 716f, 717–718, 717f
- Natural killer (NK) cells, 978
- Natural killer–T (NKT) cells, 978
- Natural products  
 for cancer, **962–965, 963t**  
 clinical activity and toxicities of, 963t
- Natural progestins, 723
- Natural toxins, 360, 360t
- Nature-Throid, 695. *See also* Thyroid  
 desiccated
- Naturetin, 270. *See also*  
 Bendroflumethiazide
- Nausea  
 H<sub>1</sub>-receptor antagonists for, 278, 279t
- Nausea and vomiting  
 chemotherapy-induced  
 5-HT<sub>3</sub>-receptor antagonists for, 1099  
 drugs used for, **1097–1100**. *See also*  
*specific drugs and* Antiemetic  
 drugs  
 opioid analgesics and, 551, 551t  
 pathogenesis of  
 neurologic pathways involved in,  
 1097, 1098f  
 postoperative and postradiation  
 5-HT<sub>3</sub>-receptor antagonists for, 1099  
 of pregnancy  
 H<sub>1</sub>-receptor antagonists for, 280
- Navane, 519. *See also* Thiothixene
- NDA, 75–76
- Nebcin, 828. *See also* Tobramycin
- Nebivolol, **161**  
 as antihypertensive drug, 179–180  
 pharmacokinetics/dosage of, 175t  
 preparations available, 167,  
 189, 225  
 properties of, 159t
- Nedocromil  
 for asthma, **348–349, 352**
- Nefazodone  
 chemistry of, 526, 527f  
 dosage of, 535t  
 pharmacodynamics of, 530t, 531  
 pharmacokinetics of, 529, 529t
- Nelfinavir, 871t, **880, 889**  
 drug interactions with, 874t
- Nematodes  
 drugs used for, 938t
- Nembutal, 427. *See also* Pentobarbital
- Nembutal Sodium, 387.  
*See also* Pentobarbital
- Neo-Synephrine, 148.  
*See also* Oxymetazoline

- Neoadjuvant chemotherapy, 950
- Neoendorphin(s)  
alpha and beta, 544
- Neomycin, **826–827**, 828  
topical, 827, **1064**
- Neonate(s)  
Graves' disease in, 693  
half-lives of drugs in, 1045*t*  
oral drug absorption in, 1044, 1044*t*  
special pharmacodynamic features in, 1046
- Neoplasm(s), **949**  
thyroid, **694**
- Neoral, 999. *See also* Cyclosporine
- Neostigmine, **105–106**, 112
- Nephrogenic diabetes insipidus  
ADH antagonists and, 265  
lithium effects on, 516–517
- Nephrolithiasis  
diuretics for, **267**
- Nephron  
segments of, 252*t*
- Nephrotic syndrome, **784**
- Neptazane, 270. *See also* Methazolamide
- Nernst equation, 230
- Nerve growth factor  
for Alzheimer's disease, 1055*t*
- Nervous system. *See also* Autonomic nervous system (ANS); Central nervous system (CNS); Enteric nervous system; Peripheral nervous system  
alcohol effects on, 393  
antipsychotic drugs effects on, 511  
histamine effects on, 275  
inhaled anesthetics effects on, 434–436  
lead poisoning effects on, 1014–1015  
lithium effects on, 516  
local anesthetics effects on, 458–459  
poisoning effects on, 1029–1030  
properties in common, endocrine system, 80  
serotonin effects on, 282–283
- Nesacaine, 463. *See also* Chloroprocaine
- Nesiritide  
in heart failure management, 219  
preparations available, 225, 270
- Netilmicin, **826**
- Neulasta, 598. *See also* Pegfilgrastim
- Neumega, 598. *See also* Oprelvekin
- Neupogen, 598. *See also* Filgrastim
- Neural injury  
local anesthetics and, 458–459
- Neurocysticercosis  
albendazole for, 939  
praziquantel for, 944
- Neuroendocrine system  
in depression, 524–525  
opioid analgesics effects on, 551*t*, 552
- Neuroendocrine tumors  
diarrhea due to  
octreotide for, 1095
- Neurokinin A, 307
- Neurokinin B, 307
- Neurokinin receptor antagonists  
for nausea and vomiting, **1099–1100**
- Neuroleptanesthesia, 509
- Neuroleptic(s), 501
- Neuroleptic malignant syndrome, 284, 284*t*, 496  
antipsychotic drugs and, 512–513
- Neurologic diseases  
beta-receptor antagonists for, 164
- Neuromuscular blocking drugs, **465–476**.  
*See also specific drugs*  
depolarizing, 468–469, 470*f*, 470*t*, 473  
neuromuscular transmission of  
assessment of, 471*f*, 472–473  
nondepolarizing, 467–468, 468*f*, 470*t*
- Neuromuscular junction  
cholinomimetic drug effects on  
direct-acting, 102*t*, 104–105  
indirect-acting, 107  
disorders of  
cholinomimetic drugs for, 108–109
- Neuromuscular response  
aging effects on, 475  
disease effects on, 475
- Neuron(s)  
local circuit, 365, 365*f*
- NANC  
transmitter substances found in, 83*f*, 84*t*, **87–88**  
in parkinsonism, 483, 485*f*  
projection, 365, 365*f*  
relay, 365, 365*f*
- Neurontin, 427, 481. *See also* Gabapentin
- Neuropathy target esterase, 1007
- Neuropeptide Y, **308–309**  
in ANS, ENS, and NANC neurons, 84*t*  
inhibitory effects of, 92*t*
- Neuroprotective therapy  
for parkinsonism, 492
- Neurotensin, **307–308**
- Neurotransmission  
prostaglandins effects on, 321
- Neurotransmitter(s)  
central  
identification of  
CNS drugs and, **364**  
major depression and, 523, 524*f*
- Neurotransmitter receptors  
CNS drugs and, **360–361**, 362*f*
- Neurotransmitter uptake carriers, 87
- Neurotrophic hypothesis  
of major depression, 522–523, 522*f*
- Neutral antagonism, 7
- Neutropenia, 582  
chemotherapy-induced  
G-CSF for, 593, 593*f*
- Nevirapine, 871*t*, **877–878**, 889  
drug interactions with, 874*t*  
during pregnancy, 876, 876*t*
- New Drug Application (NDA), 75–76
- Nexium, 1111. *See also* Esomeprazole
- Niacin  
for hyperlipidemias, **627–628**
- Nicardipine  
clinical pharmacology of, 202*t*  
organ system effects of, 204
- Niclosamide, for helminthic infections, 938*t*, **942–943**
- Nicotine  
abuse of, 569*t*, 573–575  
treatment of, 574–575  
ionization constants of, 11*t*  
as pesticide, 1008  
structure of, 100*f*  
toxicity of  
acute, 109–110  
chronic, 110
- Nicotine polacrilex gum  
from prescription to OTC status, 1116*t*
- Nicotine transdermal system  
from prescription to OTC status, 1116*t*
- Nicotinic acetylcholine receptor (nAChR), 24, 24*f*
- Nicotinic acid, 627–628. *See also* Niacin
- Nicotinic receptors, 87, 89*t*
- Nicotinic signaling, 101*f*
- Nicotinic stimulants  
direct-acting  
toxicity of, 109–110
- Nifedipine, 190, 203*f*, 209  
clinical pharmacology of, 202*t*  
dosage of, 175*t*  
pharmacokinetics of, 40*t*, 175*t*
- Nifurtimox  
clinical uses of, 934
- Nigrostriatal pathway, 506
- Nilandron, 740. *See also* Nilutamide
- Nilotinib  
for cancer, **966–967**, 967*t*
- Nilutamide, 739, 740
- Nimbex, 481. *See also* Cisatracurium
- Nirvanol, 409
- Nisoldipine, 209  
clinical pharmacology of, 202*t*
- Nitazoxanide, **933**
- Nitrates/nitrites  
for angina pectoris, **195–201**  
carcinogenicity of, 200, 200*t*  
in chronic heart failure management, 220
- Nitrazepam  
for epilepsy, 420

- Nitrendipine  
clinical pharmacology of, 202*t*
- Nitric oxide, **331–337**  
in ANS, ENS, and NANC neurons, 84*t*  
as CNS neurotransmitter, 370–371
- Nitric oxide donors, 334
- Nitric oxide gas inhalation, 334
- Nitric oxide synthase (NOS)  
isoforms of  
properties of, 331, 332*t*
- Nitro-vasodilators  
for angina pectoris, **201**
- Nitrofurantoin, 898  
as urinary antiseptic, **892–893**
- Nitrofurazone, 898
- Nitrogen dioxide  
TLVs of, 1005*t*
- Nitrogen oxides, 332, 333*t*  
toxic exposure to, **1004–1005**
- Nitroglycerin, **195–201**
- Nitropress, 189. *See also* Nitroprusside
- Nitroprusside, 189. *See also* Sodium nitroprusside
- Nitrosourea(s)  
for cancer, **955, 957**
- Nitrous oxide  
pharmacologic properties of, 433*t*
- Nizatidine, 1111  
from prescription to OTC status, 1116*t*  
*vs.* other H<sub>2</sub>-receptor antagonists, 1083*t*
- Nizoral, 712, 858. *See also* Ketoconazole
- NNRTIs. *See* Nonnucleoside reverse transcriptase inhibitors (NNRTIs)
- No-effect dose, 71
- Nolahist, 292. *See also* Phenindamine
- Nolvadex, 740. *See also* Tamoxifen
- Non-Hodgkin's lymphoma  
chemotherapeutic drugs for, **970–971**
- Non-immunologic contact urticaria  
topical dermatologic medications and, 1063*t*
- Nonadrenal corticosteroids for, 705–706, 706*t*
- Nonadrenergic, noncholinergic (NANC) neurons  
transmitter substances found in, 83*f*, 84*t*, **87–88**
- Nonketotic hyperosmolar coma, 744
- Nonnucleoside reverse transcriptase inhibitors (NNRTIs), 870*t*–871*t*, **876–878**
- Nonsteroidal anti-inflammatory drugs (NSAIDs), **636–643, 1076**.  
*See also specific drugs*  
for Alzheimer's disease, 1055*t*  
drug interactions with, 1159*t*  
in the elderly, 1057  
ulcers due to  
proton pump inhibitors for, 1088
- Nontoxic goiter, **694**
- Nontuberculous infections  
streptomycin for, 824
- Nonulcer dyspepsia  
domperidone for, 1092  
H<sub>2</sub>-receptor antagonists for, 1085  
metoclopramide for, 1092  
proton pump inhibitors for, 1088
- NOP (nociceptin receptor), 544
- Noradrenergic fibers, 80*f*, 82
- Norco, 562. *See also* Hydrocodone/  
acetaminophen
- Norcuron, 481. *See also* Vecuronium
- Norepinephrine, 136*f*, 138*t*, **141**, 148  
for acute hypotension, 144  
in ANS, ENS, and NANC neurons, 84*t*  
as CNS neurotransmitter, 367*t*, 370  
dose-response curves to, 152, 153*f*  
inhibitory effects of, 92*t*  
ionization constants of, 11*t*
- Norepinephrine transporter (NET), 85–87, 134
- Norethindrone, properties of, 719*f*, 723*t*
- Norethindrone acetate, 740  
properties of, 723*t*
- Norethynodrel  
properties of, 723*t*
- Norfex, 481. *See also* Orphenadrine
- Norfloxacin, 835, 836*t*, 838
- Norgestrel  
dosage of, 731*t*
- L-Norgestrel  
dosage of, 731*t*  
properties of, 723*t*
- Normodyne, 167, 189. *See also* Labetalol
- Noroxin, 838. *See also* Norfloxacin
- Norpace, 249. *See also* Disopyramide
- Norplant, 740. *See also* Levonorgestrel
- Norpramin, 539. *See also* Desipramine
- 19-Nortestosterone derivatives  
properties of, 723*t*
- Nortriptyline, 527*f*, 539  
dosage of, 535*t*  
hepatic clearance of  
aging effects on, 1052*t*  
pharmacodynamics of, 40*t*, 530*t*  
pharmacokinetics of, 40*t*
- Norvasc, 189, 209. *See also* Amlodipine
- Norvir, 889. *See also* Ritonavir
- Notice of Claimed Investigational Exemption for a New Drug (IND), 74–76
- Novo-Seven, 617. *See also* Coagulation factor VIIa recombinant
- Novocain, 463. *See also* Procaine
- Novothyrox, 695. *See also* Levothyroxine
- Noxafil, 858. *See also* Posaconazole
- NPH (neutral protamine Hagedorn), 748*t*, 749
- Nplate, 598. *See also* Romiplostim
- NRC. *See* National Research Council (NRC)
- NRTIs. *See* Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
- NSAIDs. *See* Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Nubain, 562. *See also* Nalbuphine
- Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), **869–876**, 870*t*–872*t*. *See also specific drugs*  
during pregnancy, 876, 876*t*
- Nucleus accumbens, 565–566
- Nucynta, 562. *See also* Tapentadol
- Numorphan, 562. *See also* Oxymorphone
- Nupercainal, 463. *See also* Dibucaine
- Nuprin, 655. *See also* Ibuprofen
- Nurse practitioners  
prescribing authority of, 1144–1145, 1144*t*
- Nutrition  
proton pump inhibitors effects on, 1088
- Nutritional supplements  
purified, **1134–1136**  
coenzyme Q10, **1134–1135**  
glucosamine, **1135**  
melatonin, **1135–1136**
- Nuvigil, 148. *See also* Armodafinil
- Nystatin, 858  
topical, **856, 1066**
- O**
- Obesity  
management of, 664, 665*t*
- Obsessive compulsive disorder (OCD)  
antidepressants for, 532
- Occlusion  
as factor in pharmacologic response to dermatologic drugs, 1061
- Octreotide, 665–666, 665*f*, 678  
adverse effects of, 1095  
clinical uses of, 1095  
for diarrhea, **1095**  
for variceal hemorrhage, **1107–1108**
- Ofatimumab, 991, 999
- Ofloxacin, 838  
pharmacokinetics of, 836*t*
- Ogen, 740. *See also* Estropipate
- Olanzapine, 504*f*, 519  
advantages and disadvantages of, 509*t*  
dosage of, 510*t*  
for Huntington's disease, 495
- Oligonucleotide(s)  
antisense, 2
- Olmesartan, 190, 225
- Olopatadine, 292
- Olsalazine, 1101*f*, 1112

- Omalizumab, **993**  
 for asthma, 350  
 preparations available, 355, 999
- Omecantiv mecarbil, 212
- Omega-3 fatty acids, marine, 633
- Omeprazole  
 pharmacokinetics of, 1086*t*  
 from prescription to OTC status, 1116*t*
- Omnicef, 807. *See also* Cefdinir
- On-off phenomenon, 487
- Onchocerciasis  
 ivermectin for, 941
- Oncogenes  
 cancer related to, 950
- Ondansetron, 287, 1097*f*, 1111  
 for nausea and vomiting, 1098–1099
- Onglyza, 766. *See also* Saxagliptin
- Ontak, 999. *See also* Denileukin diftitox
- Ophthalmologic disorders. *See also* Eye(s)  
 antimuscarinic drugs for, 121, 121*t*  
 in the elderly  
 drugs for, **1057**  
 sympathomimetic drugs for, 145
- Ophthalmopathy  
 thyroid disease-related, 693
- Opioid(s), **572**  
 abuse of, 569*t*, 572  
 treatment of, 572  
 overdose of, **1037**
- Opioid agonists  
 for diarrhea, **1094–1095**
- Opioid analgesics, 446, **543–564**, 545*t*,  
 549–550, 553. *See also specific drugs*  
 with agonist and antagonist actions  
 effects of, 552  
 antitussives, **559**  
 basic pharmacology of, **543–552**  
 classification of, 543, 544*t*  
 clinical pharmacology of, **552–560**  
 CNS effects of, 549–551, 551*t*  
 contraindications to, 556  
 dependence on, 549, 551*t*, 555  
 mechanism of action of, 546–549,  
 547*f*–549*f*  
 sites of action of, 548, 548*f*  
 source of, 543  
 specific agents, **556–560**  
 supraspinal actions of, 548  
 tolerance to, 549, 551*t*, 554–555  
 toxicity of, 554–556, 554*t*
- Opioid antagonists, **559–560**, 562
- Opioid peptides  
 in ANS, ENS, and NANC neurons, 84*t*  
 as CNS neurotransmitter, 367*t*  
 endogenous, 543–544, 544*t*
- Opioid receptor antagonists  
 in constipation management, **1094**
- Opiosthorchiasis  
 praziquantel for, 944
- Opium, 543
- Oprelvekin, 594, 598
- Optipranolol, 167. *See also* Metipranolol
- Optometrists  
 prescribing authority of, 1144–1145,  
 1144*t*
- Oral contraceptives, 725*t*, **726–731**  
 during lactation, 1048*t*
- Oral direct factor XA inhibitors, **607**
- Orap, 519. *See also* Pimozide
- Orencia, 656, 999. *See also* Abatacept
- Organ transplant rejection  
 cell-mediated  
 eicosanoids and, 327
- Organ transplantation  
 immunosuppressive drugs in, 985*t*,  
**994–995**
- Organic nitrates, 334
- Organic nitrites, 334
- Organic solvents  
 fetal effects of, 1043*t*
- Organochlorine pesticides, **1006–1007**  
 toxicity rating for, 1006*t*
- Organolead poisoning, 1014*t*, 1016
- Organon, 678. *See also* Ganirelix acetate
- Organophosphate(s)  
 for cholinergic poisoning, 123  
 durations of action of, 106*t*  
 therapeutic uses for, 106*t*
- Organophosphorus pesticides, **1007–1008**  
 toxicity rating for, 1007*t*
- Orgaran, 617. *See also* Danaparoid
- Orinase, 766. *See also* Tolbutamide
- Orlaam, 562. *See also* Levomethadyl acetate
- Orlistat  
 in obesity management, 664, 665*t*  
 from prescription to OTC status, 1116*t*
- Ornidyl, 935. *See also* Eflornithine
- Orphan drugs  
 development of, 77
- Orphan receptors, 16
- Orphanin FQ, 544
- Orphanin opioid-receptor-like subtype I,  
 544
- Orphenadrine  
 for parkinsonism, 492*t*, 499
- Ortho-phthalaldehyde, 896, 898
- Orthoclone OKT3, 999. *See also*  
 Muromonab-CD3
- Orudis, 655. *See also* Ketoprofen
- Os-Cal, 786. *See also* Calcium carbonate
- Oseltamivir  
 for influenza, **886–887**, 889
- Osmitol, 270. *See also* Mannitol
- Osmol gap  
 causes of, 1030, 1030*t*
- OsmoPrep, 1112. *See also* Sodium  
 phosphate
- Osmotic agents  
 sites of action of, 252*f*
- Osmotic diuretics, **263–264**
- Osmotic laxatives, **1093**
- Osteoarthritis  
 in the elderly, 1056–1057
- Osteodystrophy  
 intestinal, **782**
- Osteoporosis, **782–783**, 782*f*  
 androgens in, 736
- OTC drugs. *See* Over-the-counter (OTC)  
 drugs
- Ototoxicity  
 aminoglycosides and, 824  
 loop diuretics and, 260
- Otrivin, 148. *See also* Xylometazoline
- Ovarian cancer  
 chemotherapeutic drugs for, **973**
- Ovarian hormones, **726**
- Ovarian hyperstimulation syndrome, 667,  
 668*f*  
 gonadotropins and, 668–669
- Ovary, **715–731**  
 functions of, 715–716  
 disturbances in, 716  
 mechanism of action of, 718–719  
 oral contraceptives effects on, 727
- Over-the-counter (OTC) drugs,  
**1115–1124**  
 ingredients in  
 to be avoided in selected patients,  
 1117, 1123*t*  
 FDA review of, **1115–1124**  
 hidden, 1117, 1123*t*  
 of known efficacy, 1117,  
 1118*t*–1122*t*  
 overuse/misuse of, 1117, 1123*t*, 1124  
 switched from prescription to,  
 1115–1117, 1116*t*
- Ovidrel, 678. *See also* Choriogonadotropin  
 alfa
- Ovulation induction  
 drugs for, **733–734**  
 gonadotropins for, 667–668, 668*f*
- Oxacillin  
 dosage of, 795*t*
- Oxaliplatin  
 clinical activity and toxicities of, 956*t*
- Oxaluria enteric, **785**
- Oxamniquine, **943**  
 for helminthic infections,  
 938*t*, **943**
- Oxandrin, 740. *See also* Oxandrolone
- Oxandrolone, 735*t*, 740
- Oxantel pamoate, 946
- Oxaprozin, **642**, 656  
 properties of, 638*t*
- Oxazepam  
 dosages of, 383*t*  
 pharmacokinetic properties of, 377*t*
- Oxazolidinediones  
 for seizures, 419



- Oxazolidinones,  
for infection, **817**
- Oxcarbazepine  
for seizures, **410–411**, 427
- Oxiconazole, 858
- Oxidase(s)  
mixed function, 55
- N*-Oxidation, 56*t*
- S*-Oxidation, 56*t*
- Oxidative dealkylation, 56*t*
- Oxidizing agents  
poisoning by, 1036*t*
- Oxistat, 858. *See also* Oxiconazole
- Oxybutynin  
for urinary disorders, 122, 122*t*, 127
- Oxycodone, 558  
pharmacokinetics of, 545*t*
- Oxycodone mixtures, 562
- Oxygen  
as poisoning antidote, 1033*t*
- Oxymetazoline, **141**, 148
- Oxymetholone, 735*t*, 740
- Oxymorphone, 556  
pharmacokinetics of, 545*t*
- Oxytocin, **673–674**
- Oxytocin antagonists, **674**
- Ozone  
TLVs of, 1005*t*  
toxic exposure to, **1004–1005**
- P**
- P-glycoprotein transporter, 9, 10*t*
- Paclitaxel  
for cancer, 963*t*, 964  
clinical activity and toxicities of, 963*t*
- Paget's disease of bone, **784**
- Pain. *See also* Analgesia/Analgesics  
acetaminophen and, 650  
chronic  
opioid analgesics for, 550  
kinins role in, 302  
muscle  
neuromuscular blocking drugs and,  
474–475
- Pain disorders  
antidepressants for, 533
- Paliperidone, 519
- Palivizumab, **888**, 889, 994
- Palonosetron  
for nausea and vomiting, 1098–1099
- Palosuran, 309
- Pamelor, 539. *See also* Nortriptyline
- Pamidronate, 776*f*, 786
- Pamine, 127. *See also* Methscopolamine
- Panadol, 656. *See also* Acetaminophen
- Pancreas  
endocrine, **743–744**
- Pancrease, 1111. *See also* Pancrelipase
- Pancreatic cancer  
chemotherapeutic drugs for, 973
- Pancreatic enzyme supplementation,  
**1106–1107**
- Pancreatic islet cells, 744*t*
- Pancreatic peptide, 743
- Pancreatin, 1106–1107
- Pancrelipase, 1106–1107, 1111
- Pancuronium  
pharmacokinetic and pharmacodynamic  
properties of, 470*t*  
tissue effects of, 474*t*
- Panitumumab, 991–992, 999  
for cancer, **967–968**
- Pantoprazole, 1086*f*, 1111  
pharmacokinetics of, 1086*t*
- Papaverine  
for erectile dysfunction, 156–157
- Parabens, 897
- Paragonimiasis  
praziquantel for, 944
- Paraldehyde, 387
- Paramethasone  
clinical uses and dosage of, 703*t*
- Paraoxon  
structure of, 106*f*
- Paraquat, 1009*f*, 1010
- Parathion, 106*f*  
toxicity rating for, 1007*t*
- Parathion-methyl  
toxicity rating for, 1007*t*
- Parathyroid hormone (PTH)  
in bone mineral homeostasis, **769–771**,  
770*f*, 771*f*  
vitamin D and FGF23 interactions with,  
**773–774**
- Paravertebral chains, 81
- Paremyd, 148. *See also*  
Hydroxyamphetamine
- Paricalcitol, 786
- Parkinsonism  
drug-induced, 493  
drugs used for, **483–500**. *See also*  
*specific drugs*  
gene therapy for, 492  
neurons involved in, 483, 485*f*  
neuroprotective therapy for, 492  
nonmotor manifestations of  
therapy for, 492  
pathogenesis of, 484  
surgical procedures for, 492
- Parlodel, 499, 678. *See also*  
Bromocriptine
- Parnate, 539. *See also* Tranylcypromine
- Paromomycin  
clinical uses of, 934  
preparations available, 828, 935  
structure of, 929*f*
- Paromomycin sulfate  
for amebiasis, **930**
- Paroxetine, 526–530, 535*t*, 539
- Partial agonists, 19–20, 20*f*
- Partial seizures  
clinical pharmacology of, 420–421
- Paser, 848. *See also* 5-Aminosalicylic acid
- Pasteurization  
defined, 894*t*
- Patanol, 292. *See also* Olopatadine
- Patent ductus arteriosus  
eicosanoids and, 326
- Pathilon, 127. *See also* Tridihexethyl
- Patient-controlled analgesia (PCA), 554
- Paxil, 539. *See also* Paroxetine
- Pazopanib  
for cancer, **968**
- Pediatric patients  
clinical pharmacology of, **1039–1049**  
immunization for, 1167*t*  
passive immunization for, 1168*t*
- Pediculicides  
ingredients in, 1122*t*
- PEG-Intron, 889, 999. *See also*  
Peginterferon alfa-2b
- Pegademase, 985, 999
- Peganone, 427. *See also* Ethotoin
- Pegaptanib, 994, 999
- Pegasys, 889, 999. *See also* Peginterferon  
alfa-2a
- Pegfilgrastim, 598
- Peginterferon alfa-2a  
for HBV infection, 883*t*  
preparations available, 889, 999
- Peginterferon alfa-2b  
for HBV infection, 883*t*  
preparations available,  
889, 999
- Pegloticase  
for gout, **654–655**
- Pegvisomant, 665, 666
- Pen-Vee K, 807. *See also* Penicillin V
- Penbutolol, 159*t*  
as antihypertensive drug, 179
- Penciclovir  
dosage of, 865*t*  
for HSV and VZV infections, **866**  
topical, **1067**
- Penicillamine, **1024**  
fetal effects of, 1043*t*  
indications and toxicity of, 1024  
ionization constants of, 11*t*  
for Wilson's disease, 496–497
- Penicillin(s), **790–797**. *See also specific types*  
adverse effects of, 796–797  
clinical uses of, 795–796  
during lactation, 1048*t*  
mechanism of action of, 792,  
792*f*–794*f*  
units and formulations of, 791–792
- Penicillin G, 790
- Penicillin G benzathine, 807
- Penicillin G procaine, 807  
clinical uses of, 795

- Penicillin V, 807  
dosage of, 795*t*
- Pennyroyal  
risks associated with, 1127*t*
- Pentacarinat, 935. *See also* Pentamidine
- Pentam 300, 935. *See also* Pentamidine
- Pentamidine, 929*f*; **930–932**, 935  
for trypanosomiasis, **930–932**
- Pentasa, 1102, 1102*f*
- Pentazocine, 545*t*, 559  
ionization constants of, 11*t*
- Pentetate calcium trisodium  
preparations available, 1025
- Pentetate Zinc Trisodium, 1025. *See also*  
Pentetate calcium trisodium
- Pentids, 807. *See also* Penicillin G
- Pentobarbital, 375*f*, 387, 427  
ionization constants of, 11*t*
- Pentostatin  
as immunosuppressive drug, 989
- Pentothal, 446. *See also* Thiopental
- Pentoxifylline, 209, 346, 355  
for intermittent claudication, 207
- Pepcid, 1111. *See also* Famotidine
- Peptic ulcer disease  
H<sub>2</sub>-receptor antagonists for, 1084–1085  
proton pump inhibitors for, 1087–1088
- Peptide(s)  
as CNS neurotransmitters, 370  
natriuretic, **303–304**. *See also* Natriuretic  
peptides
- opioid  
in ANS, ENS, and NANC neurons,  
84*t*  
as CNS neurotransmitter, 367*t*  
endogenous, 543–544, 544*t*  
pancreatic, 743  
in renal tubule transport, 256  
vasoactive, **295–312**. *See also specific  
drugs and* Vasoactive peptides
- vasoactive intestinal  
in ANS, ENS, and NANC neurons,  
84*t*
- Pepto-Bismol, 1112. *See also* Bismuth  
subsalicylate
- Peracetic acid, **896–897**
- Peramivir  
for influenza, 887
- Percocet, 562. *See also* Oxycodone mixtures
- Percodan, 562. *See also* Oxycodone  
mixtures
- Performance anxiety  
beta-receptor antagonists for, 164
- Pergolide  
for parkinsonism, 489, 499
- Perinatal pharmacology, **1039–1045**
- Perindopril, 190, 225
- Peripheral artery disease  
drugs used for, 209  
treatment of, 207
- Peripheral blood stem cells, 592
- Peripheral nervous system  
direct-acting cholinomimetic drug effects  
on, 102*t*, 104  
nitric oxide effects on, 336  
opioid analgesics effects on, 551–552  
prostaglandins and thromboxanes effects  
on, 321
- Peripheral tissues  
muscarinic receptor subgroups important  
in, 118*t*
- Peripheral vascular disease  
alpha-receptor antagonists for, 156  
eicosanoids and, 326
- Peritoneal dialysis  
in decontamination of poisoned patient,  
1032
- Permapen, 807. *See also* Penicillin G  
benzathine
- Permax, 499. *See also* Pergolide
- Permeation  
drug, 9–10, 9*f*
- Permethrin, **1068**
- Pernicious anemia, 588
- Peroxisome proliferator-activated  
receptor-gamma (PPAR- $\gamma$ )  
in diabetes mellitus, 757–758
- Peroxygen compounds  
as antiseptics/disinfectants, **896–897**
- Perphenazine, 503*f*  
dosage of, 510*t*, 519  
for Huntington's disease, 495
- Persantine, 617. *See also* Dipyridamole
- Pesticide(s)  
botanical, **1008**, 1009*f*  
carbamate, **1008**, 1008*t*  
organochlorine, **1006–1007**  
organophosphorus, **1007–1008**  
toxic exposure to, **1006–1008**,  
1006*t*–1008*t*
- Petit mal seizures, 421
- Pfizerpen, 807. *See also* Penicillin G
- pFOX inhibitors  
for angina pectoris, 205
- pH  
of drugs  
during pregnancy, 1040
- pH-partitioning phenomenon  
body fluids with potential for drug  
“trapping” through, 11, 12*t*
- Pharmaceutical industry  
described, 69–70  
pharmacology and, 3
- Pharmacists  
prescribing authority of, 1144–1145,  
1144*t*
- Pharmacodynamics  
components in, 38*f*  
defined, 6  
in dose individualization, **47–49**
- Pharmacodynamics (*Cont.*):  
drug receptors and, **15–35**  
principles of, 6–8, 7*f*, 8*f*  
processes involved in, 2*f*, 6  
variables related to, 48–49
- Pharmacogenetic testing  
in drug therapy, 65
- Pharmacogenomics  
defined, 2, 3
- Pharmacokinetics, **37–48**  
bioavailability and, 39*t*–40*t*, 43–44, 43*f*,  
43*t*  
clearance and, 38–42, 39*t*–41*t*  
components in, 38, 38*f*  
defined, 6  
in dose individualization, **47–49**  
drug accumulation and, 42–43, 42*f*  
drug effects, **44–45**, 45*f*. *See also* Drug  
effects, time course of  
extraction ratio and, 44  
first-pass effect and, 44  
half-life and, 39*t*–40*t*, 42, 42*f*  
primary processes of, 38, 38*f*  
principles of, **8–12**, 9*f*, 10*t*–12*t*, 12*f*  
variables related to, 47–48  
volume of distribution and, 38,  
39*t*–41*t*
- Pharmacology  
areas of study in, 2*f*  
autonomic  
introduction to, **79–96**. *See also*  
Autonomic nervous system  
(ANS)  
basic principles of, 1–77  
defined, 1  
dermatologic, **1061–1079**  
experimental, 2  
general principles of, **3–12**  
genetics and, 3  
history of, **1–3**  
medical  
defined, 1, 2*f*  
pediatric, **1039–1045**  
perinatal, **1039–1045**  
pharmaceutical industry and, 3  
sources of information, 13  
transport molecules in, 9, 10*t*
- Phase I reactions, 56*t*–57*t*. *See also*  
Biotransformation of drugs,  
phase I reactions
- Phase II reactions, 59–60, 59*f*, 60*t*
- Phenacemide  
for seizures, **409**
- Phenanthrene analgesics  
mild to moderate agonists, 558  
with mixed receptor actions, 558–559  
strong, **556–557**
- Phencyclidine (PCP)  
abuse of, 569*t*, 575–576, 577*f*  
fetal effects of, 1043*t*

- Phenelzine  
dosage of, 535*t*  
pharmacokinetics of, 529*t*
- Phenergan, 292, 1112. *See also*  
Promethazine
- Phenindamine, 292
- Phenindione, 609*f*
- Phenmetrazine, 142
- Phenobarbital  
clinical uses of, 411  
dosages of, 383*t*, 411  
half-life of  
in neonates and adults, 1045*t*  
ionization constants of, 11*t*  
during lactation, 1048*t*  
mechanism of action of, 411  
oral absorption of  
in neonates *vs.* older children and  
adults, 1044*t*  
pharmacokinetics of, 40*t*, 411  
for seizures, **411**  
therapeutic levels/dosage of, 411
- Phenolics  
as antiseptics/disinfectants, 893*t*, **895**
- Phenothiazine(s)  
advantages and disadvantages of, 509*t*  
for nausea and vomiting, **1100**  
potency and toxicity of  
chemical structure effects on, 505*t*
- Phenothiazine derivatives  
of antipsychotic drugs, 503–504, 503*f*,  
505*t*
- Phenoxybenzamine, **154**, 286  
mechanism of action of, 151–152  
for pheochromocytoma, 155–156, 156*f*
- Phensuximide  
for seizures, **418**
- Phentolamine, **154**  
cardiovascular effects of, 152, 153*f*  
for erectile dysfunction, 156–157, 199
- D-Phenylalanine derivative  
for diabetes mellitus, 756, 756*t*
- Phenylbutazone  
drug interactions with, 610*t*  
hepatic clearance of  
aging effects on, 1052*t*
- Phenylephrine, 133*t*, 136*f*, **141**, 148  
for acute hypotension, 144  
cardiovascular responses to, 138*t*  
ionization constants of, 11*t*
- Phenylethylamine, 134, 136*f*
- Phenylethylmalonamide (PEMA)  
structure of, 412*f*
- Phenylheptylamine analgesics  
mild to moderate agonists, 558  
strong, 557
- O-Phenylphenol, 895
- Phenylpiperidine analgesics  
mild to moderate, 558  
strong, 557
- Phenylpropanolamine  
sympathomimetic drug effects of, 142
- Phenytoin, **407–409**, 427  
drug interactions with, 409, 1159*t*  
fetal effects of, 1043*t*  
half-life of  
in neonates and adults, 1045*t*  
ionization constants of, 11*t*  
during lactation, 1048*t*  
oral absorption of  
in neonates *vs.* older children and  
adults, 1044*t*  
pharmacokinetics of, 40*t*, 408, 408*f*
- Pheochromocytoma, **155–156**, 156*f*
- pHisoHex, 898. *See also* Hexachlorophene
- PhosLo, 786. *See also* Calcium acetate
- Phosphate, 786  
for hypercalcemia, 779
- 3'-Phosphoadenosine 5'-phosphosulfate  
(PAPS), 60
- Phosphodiesterase(s)  
in heart failure management, 218
- Phosphoinositide(s), 25  
as second messengers, 28–29, 28*f*
- Phospholine, 112. *See also* Echothiophate
- Phosphorus  
for hypocalcemia, **780**
- Phosphorylation  
second messenger signaling in, 29
- Photoallergic contact dermatitis  
topical dermatologic medications and,  
1063*t*
- Photoirritation  
topical dermatologic medications and,  
1063*t*
- Physician's assistants  
prescribing authority of, 1144–1145, 1144*t*
- Physiologic antagonism, 20
- Physostigmine, **105–106**, 112  
ionization constants of, 11*t*  
as poisoning antidote, 1033*t*
- Phytonadione, 609*f*
- Pigmentation  
drugs affecting, **1068–1069**
- Pilocarpine, 100*f*, 112  
ionization constants of, 11*t*
- Pimecrolimus, **1067**
- Pimozide, 504, 519  
drug interactions with, 1159*t*  
for tics, 495
- Pin-rid, 946. *See also* Pyrantel pamoate
- Pin-X, 946. *See also* Pyrantel pamoate
- Pindolol, 159*t*, 167, 189  
as antihypertensive drug, 179  
ionization constants of, 11*t*
- Pinworm infections  
albendazole for, 938–939
- Pioglitazone, 758*t*, 786  
for diabetes mellitus, 758
- Pioglitazone mixtures, 766
- Pipecuronium, 469*f*
- Piperacillin, 791*f*, 807  
dosage of, 795*t*
- Piperacillin and tazobactam sodium, 807
- Piperazine, 918*f*  
clinical uses of, 917*t*  
for malaria, 920
- Piperazine, **943**  
for helminthic infections,  
938*t*, **943**
- Piperazine antihistamines, 279*t*
- Piperidine antipsychotics,  
advantages and disadvantages of, 509*t*
- Piperidine antihistamines, 278*f*
- Pipracil, 807. *See also* Piperacillin
- Pirbuterol, 355  
for asthma, 344
- Pirenzepine, 117*f*
- Piroxicam, 637*f*, **642**, 656  
preparations available  
properties of, 638*t*
- Pitavastatin, 633
- Pitocin, 678. *See also* Oxytocin
- Pitressin, 678. *See also* Vasopressin
- Pituitary hormones, **659–679**  
anterior, **660–673**  
posterior, **673–675**
- Placental drug metabolism  
during pregnancy, 1040
- Placental transporters  
of drugs, 1040
- Plant(s)  
medical use of  
history of, 1125
- Plant systemic pesticides, 1007
- Plasma fractions  
for bleeding disorders, 615–616, 615*t*
- Plasma protein binding  
importance of, 49
- Platelet(s)  
nitroglycerin effects on, 198  
prostaglandins and thromboxanes effects  
on, 320
- Platelet-rich thrombi, 601–602
- Platinum analogs  
for cancer, **957–958**
- Plavix, 617. *See also* Clopidogrel
- Plendil, 190, 209. *See also* Felodipine
- Plerixafor  
G-CSF with  
clinical uses for, 594  
preparations available, 598
- Pletal, 209, 617. *See also* Cilostazol
- Plexus  
myenteric, 81*f*  
submucous, 81*f*, 82
- Plicamycin  
in bone mineral homeostasis, 777  
for hypercalcemia, 779  
preparations available, 786

- PLX4032, **974**
- Pneumococcal conjugate vaccine, 1165*t*
- Pneumococcal polysaccharide vaccine, 1165*t*
- Pneumocystis* spp.  
*P. carinii*  
 drugs used for, 931*t*  
*P. jiroveci*  
 drugs used for, 924, 931*t*
- Pneumocystosis  
 drugs used for, 924, 926  
 pentamidine, 932
- Podofilox, **1075–1076**
- Podophyllum resin, **1075–1076**
- Poison ivy  
 contact hypersensitivity due to, 983
- Poisoning(s). *See also specific types*  
 arsenic, 1014*t*, **1017–1019**  
 arsine gas, 1019  
 cholinergic  
 antimuscarinic drugs for, 122–123  
 death due to, 1028  
 ergot, 287  
 heavy metals, **1013–1021**. *See also specific types and Heavy metals*  
 hemodialysis in, 1031, 1031*t*, 1032  
 lead, **1013–1017**  
 management of, **1027–1038**  
 mercury, 1014*t*, **1019–1021**  
 mushroom  
 antimuscarinic drugs for, 123  
 organolead, 1014*t*, 1016  
 sulfur dioxide, **1004**
- Poisons, 4
- Poke root  
 risks associated with, 1127*t*
- Poliovirus vaccine, 1165*t*
- Pollutant(s)  
 air, **1002–1005**, 1005*t*  
 TLVs of, 1005*t*  
 environmental, **1010–1011**. *See also specific types and Environmental pollutants*
- Polycarbophil, 1093, 1112
- Polychlorinated biphenyls  
 as environmental pollutants, **1010**
- Polychlorinated dibenzo-*p*-dioxins (PCDDs), 1010
- Polychlorinated dibenzofurans (PCDFs), 1010
- Polyethylene glycol  
 balanced  
 in constipation management, 1093  
 from prescription to OTC status, 1116*t*
- Polyethylene glycol electrolyte solution, 1112
- Polymyxin(s), **892**
- Polymyxin B, 892, 898  
 topical, **1063–1064**
- Polymyxin E, 892
- Polythiazide, 270  
 dosage of, 261*t*
- Polyvinyl pyrrolidone (PVP)  
 as antiseptic/disinfectant, 895
- Ponstel, 656. *See also* Mefenamic acid
- Pontocaine, 463. *See also* Tetracaine
- Portable pen injectors  
 in insulin delivery, 748*t*, 750
- Posaconazole, 858  
 pharmacologic properties of, 854*t*  
 for systemic infections, **855**
- Positive chronotropic effect, 138
- Positive dromotropic effect, 138
- Positive inotropic drugs  
 in the elderly, 1056  
 in heart failure management, 212*t*, **218**
- Positive inotropic effect, 138
- Postantibiotic effects, 823
- Postantibiotic leukocyte enhancement, 907
- Postcoital contraceptives, 731, 731*t*
- Postganglionic sympathetic nerve terminal blockers, 189
- Postmenopausal hormonal therapy  
 estrogen in, 720–722
- Postpartum hemorrhage  
 ergot alkaloids for, 290
- Postsynaptic density, 369
- Postsynaptic regulation  
 functional organization of, 92–93, 93*f*
- Post-traumatic stress disorder (PTSD)  
 antidepressants for, 533
- Postural baroreflex, 87, 171, 171*f*
- Posture, 786. *See also* Tricalcium phosphate
- Potassium  
 for cardiac arrhythmias, **246**  
 digitalis with, 218  
 effects of, 230
- Potassium iodide  
 preparations available, 695
- Potassium-sparing diuretics, **261–265**  
 drug interactions with, 1159*t*
- Povidone-iodine  
 as antiseptic/disinfectant, 895  
 preparations available, 898
- Prader-Willi syndrome  
 growth hormone for, 663, 663*t*
- Pralatrexate  
 for cancer, **959–960**
- Pralidoxime, 123*f*, 127  
 for cholinergic poisoning, 123  
 as poisoning antidote, 1033*t*
- Pramipexole, 489*f*, 499  
 for parkinsonism, 489  
 for restless legs syndrome, 496
- Pramlintide, 760, 763, 766  
 for diabetes mellitus  
 combination therapy with, 762
- Pramoxine, **1077**  
 local anesthetic, 463
- Prandin, 766. *See also* Repaglinide
- Prasugrel, 617  
 as antiplatelet agent, 613
- Pravachol, 633. *See also* Pitavastatin
- Praiquantel, **943–945**, 946  
 for helminthic infections, 938*t*, **943–945**
- Prazosin, 152*f*, **154**, 167, 189  
 as antihypertensive drug, **180**  
 pharmacokinetics of, 40*t*, 175*t*, 180
- Precedex, 148, 446. *See also* Dexmedetomidine
- Precocious puberty  
 gonadotropins in, 670–671
- Precose, 766. *See also* Acarbose
- Prednisolone  
 clinical uses and dosage of, 703*t*, 712
- Prednisone  
 clinical uses and dosage of, 703*t*, 712  
 during lactation, 1048*t*
- Pregabalin, 413*f*, 427  
 mechanism of action of, 413  
 for seizures, **413**
- Pregnancy  
 drug therapy during, **1039–1043**  
 antipsychotic drugs, 512  
 antiretroviral drugs, 876, 876*t*  
 lithium, 517  
 opioid analgesics, 556  
 pharmacodynamics of, **1040–1043**  
 pharmacokinetics of, **1039–1040**  
 hypothyroidism during, 691  
 multiple  
 gonadotropins and, 668–669  
 nausea and vomiting of  
 H<sub>1</sub>-receptor antagonists for, 280  
 thyrotoxicosis during, 693
- Pregnyl, 678. *See also* Chorionic gonadotropin
- Preload  
 in cardiac performance, 215, 215*f*
- Prelone, 712. *See also* Prednisolone
- Premarin, 740. *See also* Conjugated estrogens
- Premature depolarizations, 216, 218*f*
- Premature labor  
 suppression of  
 sympathomimetic drugs for, 145
- Premenstrual dysphoric disorder  
 antidepressants for, 533
- Pemetrexed  
 for cancer, **959**
- Prenalterol, 141, 142*f*
- Prepidil, 328. *See also* Dinoprostone
- Prescribing, **1139–1148**. *See also* Prescription(s)  
 compliance issues in, **1143–1144**  
 cost factors in, 1147–1148

- Prescribing (*Cont.*):  
 E-prescribing, **1143**  
 errors in, **1141–1143**  
 generic, 1147  
 legal issues in, **1144–1147**, 1144*t*, 1145*t*  
 rational, **1139–1141**, 1140*f*  
 socioeconomic factors in, **1147–1148**
- Prescription(s), **1139–1148**. *See also*  
 Prescribing  
 abbreviations for, 1142*t*  
 costs of, 1147–1148  
 elements of, 1140–1141, 1140*f*  
 generic, 1147  
 inappropriate, 1143  
 writing of, **1139–1141**, 1140*f*  
 poor, 1142–1143
- Prescription drug(s)  
 dietary supplements *vs.*, 1125
- Prescription Drug User Fee Act (PDUFA)  
 of 1992, 76
- Preservatives  
 as antiseptics/disinfectants, **897**
- Presynaptic inhibition, 363
- Presynaptic regulation  
 in functional organization of autonomic  
 activity, 91–92, 92*t*
- Prevacid, 1111. *See also* Lansoprazole
- Prevertebral ganglia, 81
- Prezista, 888. *See also* Darunavir
- Prialt, 562. *See also* Ziconotide
- Priftin, 848. *See also* Rifapentine
- Prilocaine, **461**  
 pharmacokinetic properties of, 452*t*  
 preparations available, 463
- Prilosec, 1111. *See also* Omeprazole
- Primacor, 225. *See also* Milrinone
- Primaquine, 919*t*, **923–924**  
 for malaria, 919*t*, **923–924**  
 in malaria prevention in travelers, 919*t*
- Primary amine, 11
- Primary chylomicronemia, 623  
 drugs used for, 622*t*
- Primary generalized glucocorticoid  
 resistance  
 synthetic corticosteroids for, 704
- Primary hyperparathyroidism, **780**
- Primary immunodeficiency disorders  
 passive immunization for, 1168*t*
- Primary induction chemotherapy, 950
- Primaxin, 807. *See also* Imipenem/cilastatin
- Primidone  
 for seizures, **411–412**  
 for tremors, 494
- Prinivil, 190, 225. *See also* Lisinopril
- Prinzmetal angina, 193
- Priscoline, 167. *See also* Tolazoline
- Pristiq, 539. *See also* Desvenlafaxine
- Privine, 148. *See also* Naphazoline
- Pro-Banthine, 127. *See also* Propantheline
- ProAmatine, 148. *See also* Midodrine
- Probenecid, 656  
 drug interactions with, 1160*t*
- Procainamide  
 for cardiac arrhythmias, **238–239**  
 ionization constants of, 11*t*  
 pharmacokinetics of, 40*t*, 239  
 pharmacologic properties of, 238*t*
- Procaine, 451*t*, 463  
 ionization constants of, 11*t*
- Procaine penicillin, 794, 807
- Procarbazine  
 for cancer, 957  
 clinical activity and toxicities of, 956*t*
- Procardia, 190, 209. *See also* Nifedipine
- Prochlorperazine  
 preparations available, 1112
- Procrit, 598. *See also* Epoetin alfa
- ProctoFoam-HC, 1112. *See also*  
 Hydrocortisone
- Procyclidine  
 for parkinsonism, 492*t*
- Prodrug, 8
- Profasi, 678. *See also* Chorionic  
 gonadotropin
- Profenal, 656. *See also* Suprofen
- Profilnine, 617
- Profilnine SD, 617. *See also* Factor IX  
 complex, human
- Progabide, 478
- Progesterone, 719*f*, **723**, 740  
 effects of, 724
- Progesterone inhibitors, **731–734**
- Progestin(s), **723–726**  
 contraception with, 725*t*, 730–731  
 preparations available, 740
- Prograf, 999. *See also* Tacrolimus
- Proguanil, 925, 918*f*
- Proinsulin, 744*f*
- Projection neurons, 365, 365*f*
- Prokinetic agents, 1091
- Prolactin, 660, **672**
- Prolactin antagonists  
 preparations available, 678
- Proleukin, 999. *See also* Interleukin-2
- Prolia, 786, 999. *See also* Denosumab
- Prolixin, 519. *See also* Fluphenazine
- Proloprim, 837. *See also* Trimethoprim
- Promacta, 598. *See also* Eltrombopag
- Promethazine, 279, 1100  
 ionization constants of, 11*t*
- Pronestyl, 249. *See also* Procainamide
- Propafenone  
 for cardiac arrhythmias, **242**  
 membrane actions of, 237*t*  
 pharmacologic properties of,  
 238*t*
- Propanteline, 117*f*, 127
- Proparacaine, 463
- Prophylactic drugs, in malaria, causal,  
 915
- Propiverine  
 for urinary disorders, 122, 122*t*
- Proprex SX-T, 617. *See also* Factor IX  
 complex, human
- Proprex T, 617. *See also* Factor IX complex,  
 human
- Propofol, **438–441**  
 as intravenous anesthetic, 438–441
- Propoxur  
 toxicity rating for, 1008*t*
- Propoxyphene  
 mild to moderate agonists, 558
- Propranolol, **161**, **178–179**, 238*t*  
 as antihypertensive drug, 178  
 cardiac effects of, 242  
 dosage of, 175*t*, 179  
 hepatic clearance of  
 aging effects on, 1052*t*  
 ionization constants of, 11*t*  
 during lactation, 1048*t*  
 membrane actions of, 237*t*  
 properties of, 159*t*  
 structure of, 158*f*  
 for tremors, 493
- Propylene glycol, **1075**
- Propylthiouracil, 688*f*, 695  
 fetal effects of, 1043*t*  
 for Graves' disease, 691–692  
 ionization constants of, 11*t*  
 during lactation, 1048*t*
- Prorenin receptors, 300
- ProSom, 387. *See also* Estazolam
- Prostacyclin, 315
- Prostaglandin(s). *See also* Eicosanoid(s)  
 for open-angle glaucoma, 161*t*  
 organ system effects of, 320–322  
 PGE<sub>2</sub>, 315  
 PGF<sub>2 $\alpha$</sub> , 315  
 PGF<sub>2 $\omega$</sub> , 325*f*  
 in renal tubule transport, 256
- Prostaglandin analogs  
 for acid-peptic diseases, **1090**
- Prostaglandin E<sub>1</sub>, E<sub>2</sub>  
 inhibitory effects of, 92*t*
- Prostaglandin endoperoxide synthases  
 products of, 314–316, 315*f*
- Prostanoid(s)  
 biosynthesis of, 315*f*
- Prostanoid receptors  
 signaling pathways of, 318*f*
- Prostate cancer  
 advanced  
 GnRH receptor agonists in,  
 671  
 chemotherapeutic drugs for,  
**972**  
 gonadotropins in, 670
- Prostigmin, 112. *See also* Neostigmine
- Prostin E2, 328. *See also* Dinoprostone
- Protamine sulfate, 607, 617

- Protease inhibitors, 870*t*–871*t*, **878–881**.  
*See also specific drugs*  
 during pregnancy, 876, 876*t*
- Protein(s)  
 contractile  
 sensitivity to calcium, 212  
 FK-binding, 986  
 G. *See* G proteins  
 regulatory, 16  
 structural, 16  
 synaptosomal nerve-associated, 82–83  
 transport, 16
- Protein anabolic agents  
 androgens and anabolic steroids as, 736
- Protein binding  
 capacity-limited  
 in drug concentration measurements, 49  
 of drugs  
 during pregnancy, 1040  
 plasma  
 importance of, 49
- Protein C, 604
- Protein S, 604
- Proton pump inhibitors  
 for acid-peptic diseases, **1085–1089**,  
 1086*f*, 1086*t*  
 ingredients in, 1118*t*
- Protonix, 1111. *See also* Pantoprazole
- Protopam, 127. *See also* Pralidoxime
- Protozoal infections  
 drugs used for, **915–936**. *See also specific  
 drugs and indications*
- Protriptyline, 527*f*, 539  
 dosage of, 535*t*  
 pharmacodynamics of, 530*t*
- Proventil, 355. *See also* Albuterol
- Provera, 740. *See also* Medroxyprogesterone  
 acetate
- Provigil, 148. *See also* Modafinil
- Proximal tubule  
 in renal tubule transport, 251–253, 252*f*,  
 252*t*, 253*f*
- Proximal tubule diuretics  
 combination therapy, **265**
- Prozac, 539. *See also* Fluoxetine
- Prucalopride  
 in constipation management, 1094
- Pruritus  
 opioid analgesics and, 552  
 treatment of, 1076
- Prussian blue, **1024**  
 indications and toxicity of, 1024–1025  
 preparations available, 1025
- Pseudoephedrine, 142, 148  
 ionization constants of, 11*t*
- Pseudovitamin D deficiency rickets, **783–784**
- Psilocybin  
 abuse of, 569*t*, 573
- Psoriasis  
 drugs used for, **1071–1072**
- Psychosis(es)  
 nature of, 502
- Psychotic depression  
 antipsychotic drugs for, 509
- Psyllium, 1093  
 preparations available, 1112
- PTH. *See* Parathyroid hormone (PTH)
- PTSD  
 antidepressants for, 533
- Puberty  
 precocious  
 central  
 gonadotropins in, 670–671
- Pulmicort, 355. *See also* Budesonide
- Pulmonary edema  
 acute  
 diuretics for, 265–266  
 opioid analgesics for, 553
- Pulmonary hypertension  
 eicosanoids and, 326
- Pure Food and Drug Act of 1906,  
 73, 74*t*
- Purified nutritional supplements,  
**1134–1136**. *See also*  
 Nutritional supplements,  
 purified
- Purine analogs  
 for inflammatory bowel disease,  
**1103–1104**
- Purine antagonists  
 for cancer, **961–962**
- Pyramat  
 toxicity rating for, 1008*t*
- Pyrantel pamoate, **945**, 946  
 for helminthic infections,  
 938*t*, **945**
- Pyrazinamide  
 for tuberculosis, 840*t*, **842–843**
- Pyrethrin I, 1009*f*
- Pyrethrum, 1008
- Pyridostigmine  
 durations of action of, 106*t*  
 pharmacokinetic and pharmacodynamic  
 parameters for, 40*t*  
 therapeutic uses for, 106*t*
- Pyridoxine, 840*f*
- Pyrimethamine, 833, 925–926  
 ionization constants of, 11*t*  
 mechanism of action of, 833
- Pyrimethamine/sulfadoxine  
 clinical uses of, 917*t*  
 preparations available, 837, 925–926,  
 935
- Pyrimidines  
 pharmacokinetics of, 832*t*
- Pyriithione zinc  
 in OTC products, 1120*t*
- Pyrolan  
 toxicity rating for, 1008*t*
- Pyrophosphate, 776*f*
- Q**
- Qinghaosu, 919*t*, **920–921**. *See also*  
 Artemisinin(s)
- Quantrel, 946. *See also* Oxantel pamoate
- Quarzan, 127. *See also* Clidinium
- Quaternary amines, 11
- Quaternary ammonium compounds  
 as antiseptics/disinfectants, 893*t*,  
**895–896**
- Quazepam, 387
- Quelicin, 481. *See also* Succinylcholine
- Questran, 633. *See also* Cholestyramine
- Quetiapine, 504*f*, 519  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*
- Quinagolide, 672
- Quinapril, 190, 225
- Quinestrol, 718*f*  
 dosage of, 719*t*
- Quinethazone, 270  
 dosage of, 261*t*
- Quinidine, **238**, **921–922**  
 for cardiac arrhythmias, 238  
 chemistry of, 918*f*; 921–922  
 drug interactions with, 1160*t*  
 hepatic clearance of  
 aging effects on, 1052*t*  
 ionization constants of, 11*t*  
 for malaria, **921–922**  
 pharmacokinetics of, 40*t*, 239, 921–922
- Quinine, 918*f*; **921–922**, 935  
 for babesiosis, 922  
 hepatic clearance of  
 aging effects on, 1052*t*  
 for malaria, **921–922**
- Quinoline methanols, 918*f*
- Quinolones  
 antibacterial activity of, 835  
 described, 834, 834*f*  
 drug interactions with, 1160*t*
- Quinupristin-dalfopristin, 815–816, 819
- QVAR, 355. *See also* Beclomethasone
- R**
- Rabbit syndrome, 496
- Rabeprazole, 1086*f*, 111  
 pharmacokinetics of, 1086*t*
- Rabies vaccine, 1165*t*  
 passive immunization for, 1169*t*
- Radical cure, malaria, 915
- Radioactive iodine  
 antithyroid activity of, **689**  
 for Graves' disease, 692
- Radiofrequency catheter ablation  
 for cardiac arrhythmias, 228
- Radiogardase, 1025. *See also* Prussian blue
- Raloxifene, 731, 740  
 for osteoporosis, 783
- Raltegravir, 871*t*, **882**, 889
- Ramelteon, 283, 374, 376, 387

- Ramipril, 190, 225
- Ranexa, 209. *See also* Ranolazine
- Ranibizumab, 994, 999
- Ranitidine, 1083*t*, 1111  
pharmacokinetics, 40*t*  
from prescription to OTC status, 1116*t*
- RANK ligand (RANKL), 771
- Ranolazine, 209  
for angina pectoris, 205
- Rapaflo, 167. *See also* Silodosin
- Rapamune, 999. *See also* Sirolimus
- Rare diseases  
drugs for  
development of, 77
- Rasagiline, 499  
for parkinsonism, 488*f*, 490
- Rattlesnake envenomation, **1037**
- Razadyne, 112. *See also* Galantamine
- Rebetron, 889. *See also* Interferon alfa-2b
- Rebif, 999
- Reboxetine  
sympathomimetic drug effects on, 143
- Receptor(s). *See also specific types*  
beneficial and toxic drug effects related to, 34  
classes of  
drug development and, 22*f*, **29–30**  
consequences of, 15  
cytokine, 23, 24*f*  
defined, 4, 15  
EGF  
mechanism of action of, 22, 23*f*  
of G proteins, 25, 26*t*  
inert binding sites *vs.*, 8  
intracellular  
for lipid-soluble agents, 21–22, 21*f*  
macromolecular nature of, **16**  
nomenclature of, 6  
“orphan,” 16  
pharmacodynamics and, **15–35**  
“spare,” 17–18, 17*f*
- Receptor down-regulation, 23
- Receptor-effector coupling  
spare receptors and, 16–18, 17*f*
- Receptor-effector mechanism  
beneficial and toxic drug effects related to, 33–34
- Receptor recycling, 549
- Receptor regulation, **25**, 133–134
- Receptor selectivity, 133, 133*t*  
stereo (chiral), 4–5
- Receptor tyrosine kinase(s)  
inhibitors of, 22–23, 23*f*
- Receptor tyrosine kinase signaling pathway,  
22–23, 23*f*
- Receptor uncoupling, opioid, 549
- Recombinant activated factor VII  
for bleeding disorders, 616
- Recombinant factor VIIA  
for bleeding disorders, 603*f*, 616
- Recombinant, 617. *See also* Antihemophilic factor
- Rectal suppositories  
opioid analgesic, 554
- Recurrent endogenous depression  
lithium for, 516
- Red thrombi, 602
- Reductions, metabolic, 57*t*
- Reentry  
defined, 234, 234*f*
- Reflex(es). *See specific types*
- Refludan, 617. *See also* Lepirudin
- Refractory period, 231
- Reglan, 1112. *See also* Metoclopramide
- Regonol, 112. *See also* Pyridostigmine
- Regulation of receptors  
flexible, 29
- Regulatory proteins, 16
- Relaxin, 726
- Relay neurons, 365, 365*f*
- Relcovaptan, 303
- Relenza, 889. *See also* Zanamivir
- Relistor, 562, 1112. *See also*  
Methylnaltrexone
- Relpax, 292. *See also* Eletriptan
- Remeron, 539. *See also* Mirtazapine
- Remicade, 656, 999, 1112. *See also*  
Infliximab
- Remifentanyl, 557, 562  
pharmacokinetics of, 545*t*
- Reminyl, 112. *See also* Galantamine
- Remodulin, 328. *See also* Treprostinil
- Renagel, 786. *See also* Sevelamer carbonate
- Renal autacoids  
in renal tubule transport, 255–256
- Renal baroreceptor  
in renin release, 296, 297*f*
- Renal failure  
acute  
loop diuretics for, 259  
potassium-sparing drugs and, 263  
ADH antagonists and, 265  
diuretics for, **266–267**
- Renal function tests  
in poisoning assessment, 1030
- Renal impairment  
antimicrobial drugs in patients with,  
908*t*, 909
- Renal potassium wasting  
carbonic anhydrase inhibitors and, 258
- Renal stones. *See* Kidney stones
- Renal system  
eicosanoid effects on, 326  
lipoygenase effects on, 323
- Renal tubule  
transport mechanisms in, **251–256**  
adenosine, 256  
collecting tubule system, 252*t*,  
254–255, 254*f*  
distal convoluted tubule, 252*t*, 254, 254*f*
- Renal tubule, transport mechanisms in (*Cont.*):  
loop of Henle, 252*t*  
peptides, 256  
prostaglandins, 256  
proximal tubule, 251–253, 252*f*, 252*t*,  
253*f*  
renal autacoids, 255–256
- Renese, 270. *See also* Polythiazide
- Renin, 295–297, 296*f*, 297*f*  
release of  
control of, 296–297, 297*f*  
drugs blocking, 299  
pharmacologic alteration of, 297
- Renin-angiotensin system  
chemistry of, 296*f*  
inhibition of, **299–300**
- Renin inhibitors, 190, 300
- Renvela, 786. *See also* Sevelamer carbonate
- ReoPro, 617, 999. *See also* Abciximab
- Repaglinide  
for diabetes mellitus, 756, 756*t*
- Repaglinide plus metformin, 766
- Repinotan, 282
- Reproduction  
inhaled anesthetics effects on, 437–438
- Reproductive smooth muscle  
prostaglandins and thromboxanes effects  
on, 320
- Reproductive system  
female  
eicosanoid effects on, 324–326  
hormones and, 715–734  
melatonin effects on, 1136  
lead poisoning effects on, 1015  
male  
eicosanoid effects on, 326  
hormones and, 734–739  
melatonin effects on, 1136  
prostaglandins and thromboxanes effects  
on, 321
- Repronex, 678. *See also* Menotropins
- Requip, 499. *See also* Ropinirole
- Rescriptor, 888. *See also* Delavirdine
- Research  
translational, 70  
in drug development, 76
- Reserpine  
as antihypertensive drug, **178**  
for Huntington's disease, 494  
mechanism and sites of action of 83*f*, 178
- Resin(s)  
bile acid-binding. *See* Bile acid-binding resins  
bile salt-binding  
for diarrhea, **1095**  
podophyllum, **1075–1076**
- Respiration  
sedative-hypnotic drugs effects on, 381
- Respiratory depression  
opioid analgesics in, 551

- Respiratory disorders  
  antimuscarinic drugs for, 121  
  nitric oxide effects on, 336
- Respiratory infections  
  proton pump inhibitors and, 1088–1089
- Respiratory syncytial virus  
  passive immunization for, 1169*t*
- Respiratory system  
  antimuscarinic drug effects on, 119–120  
  barbiturates effects on, 442  
  benzodiazepines effects on, 443  
  beta-receptor antagonists effects on, 158, 160  
  cholinomimetic drug effects on  
    direct-acting, 102*t*, 103  
    indirect-acting, 107  
  dexmedetomidine effects on, 445  
  eicosanoid effects on, 327  
  etomidate effects on, 444  
  inhaled anesthetics effects on, 436  
  ketamine effects on, 445  
  propofol effects on, 440  
  serotonin effects on, 283
- Response elements, 21
- Rest tremor, 494
- Resting potential  
  effect on action potentials, 231–233, 232*f*, 233*f*, 233*t*
- Restless legs syndrome, 496
- Restoril, 387. *See also* Temazepam
- Resuscitation  
  lipid  
    local anesthetics and, 459
- Retapamulin  
  topical, **1063**
- Retavase, 617. *See also* Reteplase
- Reteplase  
  pharmacology of, 612  
  preparations available, 617
- Retigabine (ezogabine), **415**
- Retinoic acid, derivatives of,  
  for acne, **1069–1070**
- Retrograde signaling, 363
- Retrovir, 889. *See also* Zidovudine
- Revatio, 209. *See also* Sildenafil
- Reverse potential, 230
- Revex, 562. *See also* Nalmefene
- ReVia, 400, 562. *See also* Naltrexone
- Revlimid, 999. *See also* Lenalidomide
- Revonto, 481. *See also* Dantrolene
- Rexolate, 656. *See also* Sodium thiosalicylate
- Reyataz, 888. *See also* Atazanavir
- Rheumatoid arthritis  
  eicosanoids and, 328
- Rheumatrex, 656. *See also* Methotrexate
- Rhinoconjunctivitis  
  allergic, 349
- RH<sub>0</sub>(D) immune globulin micro-dose,  
  **990–991**  
  preparations available, 999
- RhoGam, 999. *See also* RH<sub>0</sub>(D) immune globulin micro-dose
- Ribavirin, **888**  
  for HCV infection, **886**
- Ricketts  
  pseudovitamin D deficiency, **783–784**  
  vitamin D–dependent  
    types I and II, **783–784**  
  vitamin D–resistant  
    hereditary, **783–784**
- Ridaura, 656. *See also* Auranofin
- Rifabutin  
  dosage of, 840*t*  
  for tuberculosis, 840*t*, 845
- Rifadin, 848. *See also* Rifampin
- Rifampin, 840*t*, **841–842**, 848  
  drug interactions with, 1160*t*  
  for leprosy, **846**
- Rifapentine, 848  
  dosage of, 840*t*  
  for tuberculosis, 840*t*, 845
- Rifaximin, **845**
- Rigidity  
  truncal  
    opioid analgesics and, 551, 551*t*
- Rilonacept, 996, 999
- Rilutek, 481. *See also* Riluzole
- Riluzole, 478, 481
- Rimactane, 848. *See also* Rifampin
- Rimantadine, 889  
  for influenza, **887**
- Rimonabant  
  in addiction management, 578
- Risedronate  
  for osteoporosis, 775, 783
- Risk  
  defined, 1002
- Risperidone, 504*f*, 519  
  advantages and disadvantages of, 509*t*  
  dosage of, 510*t*
- Ritalin, 148. *See also* Methylphenidate
- Ritanserlin, 286–287
- Ritodrine, 142*f*  
  in premature labor suppression, 145
- Ritonavir, 871*t*, **880**, 889  
  drug interactions with, 874*t*
- Rituxan, 656, 999. *See also* Rituximab
- Rituximab, **646**, 656, 992, 999
- Rivaroxaban, 607
- Rivastigmine  
  for Alzheimer's disease, 1055, 112
- Rizatriptan, 292  
  pharmacokinetics of, 286*t*
- Robaxin, 481. *See also* Methocarbamol
- Robinul, 127, 1111. *See also*  
  Glycopyrrolate
- Rocephin, 807. *See also* Ceftriaxone
- Rocuronium, 469*f*, 481  
  pharmacokinetic and pharmacodynamic properties of, 470*t*
- Rocuronium (*Cont.*):  
  tissue effects of, 474*t*
- Roferon, 999. *See also* Interferon alfa-2a
- Roferon-A, 889. *See also* Interferon alfa-2a
- Romidepsin, 1077  
  dermatologic uses of, 1078*t*
- Romiplostim  
  clinical uses of, 591*t*, 594–595
- Ropinirole, 489*f*, 499  
  for parkinsonism, 487  
  for restless legs syndrome, 496
- Ropivacaine, 451*t*, **461**, 463  
  pharmacokinetic properties of, 452*t*
- Rosiglitazone, 758*t*, 766  
  for diabetes mellitus, 758
- Rosiglitazone mixtures, 766
- Rosuvastatin, 633
- Rotavirus vaccine, 1165*t*
- Rotenone, 1009*f*  
  as pesticide, 1008
- Rotigotine  
  for parkinsonism, 489
- Roundworms  
  drugs used for, 938*t*
- Routes of administration. *See also specific types*  
  alternative  
    first-pass effect and, 44
- Rowasa, 1102, 1102*f*
- Royal jelly  
  risks associated with, 1127*t*
- Rozerem, 387. *See also* Ramelteon
- RU-486. *See* Mifepristone (RU-486)
- Rubella  
  passive immunization for, 1169*t*
- Rufen, 655. *See also* Ibuprofen
- Rufinamide, 415*f*, 427  
  clinical uses of, 415  
  mechanism of action of, 415  
  for seizures, **415**
- Ryanodine receptor (RyR) channel, 479
- Rythmol, 249. *See also* Propafenone
- S**
- Safety tests  
  in drug development, 71–72, 71*t*
- Salicylate(s)  
  drug interactions with, 1160*t*  
  half-life of  
    in neonates and adults, 1045*t*  
  metabolism of, 638, 639*f*  
  nonacetylated, **640**  
  in OTC products, 1123*t*  
  overdose of, **1034–1035**  
  properties of, 638*t*  
  structure of, 639*f*
- Salicylic acid, **1074–1075**  
  ionization constants of, 11*t*  
  pharmacokinetic and pharmacodynamic parameters for, 40*t*  
  structure of, 1074*f*



- Salicylsalicylic acid, 656
- Saline diuresis  
for hypercalcemia, 778
- Salivary glands  
sympathomimetic drug effects on, 139
- Salmeterol, 343*f*, 355  
for asthma, 344
- Salmeterol/fluticasone, 355
- Salsalate  
preparations available, 656
- Salt(s)  
nonabsorbable  
in constipation management, 1093
- Saluron, 270. *See also* Hydroflumethiazide
- Samsca, 270, 678. *See also* Tolvaptan
- Sanctura, 127. *See also* Trosipium
- Sandimmune, 999. *See also* Cyclosporine
- Sandostatin, 678. *See also* Octreotide acetate
- SangCya, 999. *See also* Cyclosporine
- Sanitization  
defined, 894*t*
- Saphris, 519. *See also* Asenapine
- Saquinavir, 871*t*, **880**, 889  
drug interactions with, 874*t*
- Saralasin, 299
- Sarcomere(s)  
cardiac muscle, 213*f*
- Sarcoplasmic reticulum  
calcium stored in and released from, 212
- Sargramostim  
preparations available, 598
- Sassafras  
risks associated with, 1127*t*
- Savella, 539. *See also* Milnacipran
- Saw palmetto, **1133–1134**
- Saxagliptin  
for diabetes mellitus, 761
- Saxagliptin plus metformin, 766
- Scavenger receptors, 619
- Schistosomiasis  
praziquantel for, 944
- Schizoaffective disorder  
antipsychotic drugs for, 508  
lithium for, 516
- Schizonticides  
blood, 915  
tissue, 915
- Schizophrenia  
antipsychotic drugs for, 508  
basic pharmacology of, 503–508, 509*t*, 510*t*  
clinical pharmacology of, **508–513**  
dopamine hypothesis of, 502  
glutamate hypothesis of, 503  
lithium for, 516  
nature of, 502  
serotonin hypothesis of, 502
- Scopolamine, 116, 127, 1111  
ionization constants of, 11*t*  
organ system effects of, 116, 118
- Screening  
drug, 70–71
- Secobarbital, 375*f*, 387
- Seconal, 387. *See also* Secobarbital
- Second messengers, 25–26, 25*f*, 26*f*, 26*t*  
calcium, 28–29, 28*f*  
cAMP, 26, 28, 28*f*  
cGMP, 29  
DAG, 28–29, 28*f*  
described, 25  
lithium effects on, 514–515, 515*f*, 514*t*  
phosphoinositides, 28–29, 28*f*  
well-established, 26, 28–29, 28*f*
- Secondarily generalized seizure attack, 421
- Secondary amine, 11
- Secretory glands  
direct-acting cholinomimetic drug effects  
on, 102*t*, 104
- Secretory tissue  
smooth muscle of, 276
- Sectral, 167, 189, 249. *See also* Acebutolol
- Sedation  
conscious, 430  
deep, 430  
dexmedetomidine for, 146  
H<sub>1</sub>-receptor antagonists for, 278, 279*t*  
monitored anesthesia care and, 430  
opioid analgesics in, 550–551
- Sedative-hypnotic drugs, **373–388**. *See also*  
*specific drugs*  
in the elderly, 1053–1054  
overdose of, **1037**
- Seizure(s)  
absence, 421  
antipsychotic drugs and, 511  
atonic, 421  
classification of, 404*t*, **420–421**  
complex partial, 421  
described, 403  
drugs used for, **403–427**. *See also*  
Antiseizure drugs  
generalized  
clinical pharmacology of, 421  
drugs used for, **417–418**, **422–423**  
generalized tonic-clonic, 421  
drugs used for, **407–417**, **422**  
grand mal, 421  
drugs used for, **407–417**, **422**  
partial  
clinical pharmacology of, 420–421  
petit mal, 421  
types of, 404*t*
- Selective estrogen receptor modulators  
(SERMs), 731  
in bone mineral homeostasis, 775
- Selective serotonin reuptake inhibitors  
(SSRIs)  
adverse effects of, 535  
chemistry of, 525, 526*f*  
dosage of, 535*t*
- Selective serotonin reuptake inhibitors  
(*Cont.*):  
drug interactions with, 536, 537*t*, 1161*t*  
fetal effects of, 1043*t*  
pharmacodynamics of, 530*t*, 531  
pharmacokinetics of, 528, 529*t*
- Selegiline  
dosage of, 535*t*  
for parkinsonism, 488*f*, 490, 499  
pharmacokinetics of, 529*t*, 530
- Selenium sulfate  
in OTC products, 1120*t*
- Selzentry, 889. *See also* Maraviroc
- Semustine, 954*f*
- Senile cerebral insufficiency  
ergot alkaloids for, 290
- Senna  
in constipation management, 1093,  
1112
- Senokot, 1112. *See also* Senna
- Sensipar, 786. *See also* Cinacalcet
- Sensitivity  
as pharmacodynamic variable, 48–49
- Sensorcaine, 463. *See also* Bupivacaine
- Septic shock  
nitric oxide in, 335, 335*t*
- Septocaine, 463. *See also* Articaine
- Sepra, 837. *See also* Trimethoprim-sulfamethoxazole (TMP-SMZ)
- Serevent, 355. *See also* Salmeterol
- Serine protease inhibitors  
for bleeding disorders, 617
- Seromycin Pulvules, 808, 848. *See also*  
Cycloserine
- Serophene, 740. *See also* Clomiphene
- Seroquel, 519. *See also* Quetiapine
- Serotonin, **281–287**  
in ANS, ENS, and NANC neurons, 84*t*  
basic pharmacology of, **281–284**  
chemistry of, 281, 281*f*  
clinical pharmacology of, **284–286**  
as CNS neurotransmitter, 366*t*–377*t*,  
370  
in coagulation, 601, 602*f*  
inhibitory effects of, 92*t*  
mechanisms of action of, 282, 282*t*  
pharmacodynamics of, 282–284, 282*t*,  
284*t*  
pharmacokinetics of, 281–282  
tissue and organ system effects of,  
282–284, 284*t*
- Serotonin agonists, 284–285
- Serotonin antagonists, **286**
- Serotonin-blocking actions  
of H<sub>1</sub>-receptor antagonists, 278–279
- Serotonin hypothesis  
of schizophrenia, 502
- Serotonin-norepinephrine reuptake  
inhibitors (SNRIs)  
adverse effects of, 535

- Serotonin-norepinephrine reuptake inhibitors (*Cont.*):  
 chemistry of, 525–526, 527*f*  
 dosage of, 535*t*  
 drug interactions with, 536–537  
 pharmacodynamics of, 530*t*, 531  
 pharmacokinetics of, 528–529, 529*t*
- Serotonin receptor(s)  
 subtypes of, 282*t*
- Serotonin syndrome, 284, 284*t*, 537, 1034
- Serotonin transporter, 577
- Serotonin-receptor antagonists, **286–287**
- Sertoli cells, 734
- Sertraline, 526*f*, 539  
 dosage of, 535*t*  
 pharmacodynamics of, 530*t*  
 pharmacokinetics of, 529*t*
- Serum gastrin  
 increased  
 proton pump inhibitors and, 1089
- Serum osmolality  
 in poisoning assessment, 1030, 1031*t*
- Serum sickness  
 immunologic reactions to drugs and, **998**
- Serutan, 1112. *See also* Psyllium
- Sevelamer, 780, 786
- Seven-transmembrane (7-TM) receptors, 25, 26*f*
- Sevoflurane, 432*f*, 446  
 pharmacologic properties of, 433*t*
- Shivering  
 reducing  
 opioid analgesics for, 553
- Shock  
 anaphylactic  
 sympathomimetic drugs for, 145  
 cardiogenic  
 sympathomimetic drugs for, 144  
 septic  
 nitric oxide in, 335, 335*t*  
 sympathomimetic drugs for, 144
- Short stature  
 growth hormone for children with, 662–663, 663*t*  
 idiopathic  
 growth hormone for, 663, 663*t*
- SIADH secretion  
 ADH antagonists for, 264
- Sibutramine  
 in obesity management, 664, 665*t*  
 sympathomimetic drug  
 effects on, 143
- Sickle cell disease, 582
- Signal transducers and activators of transcription (STATs), 23, 24*f*
- Signaling mechanisms  
 cytokine receptors, 23, 24*f*  
 drug action and, **21–29**, 21*f*–28*f*; 26*t*  
 G proteins, 25–26, 25*f*; 26*f*; 26*t*  
 interplay among, 29  
 intracellular receptors for lipid-soluble agents, 21–22, 21*f*  
 ligand-gated channels, 23–24, 24*f*  
 ligand-regulated transmembrane enzymes, 22–23, 23*f*  
 phosphorylation and, 29  
 receptor regulation, 25–26, 27*f*  
 second messengers, 25–26, 25*f*; 26*f*; 26*t*, 28–29, 28*f*  
 transmembrane, 21, 21*f*  
 voltage-gated channels, 23–24, 24*f*
- Sildenafil  
 for erectile dysfunction, 199  
 preparations available, 209
- Silodosin, 155, 167
- Silvadene, 837. *See also* Silver sulfadiazine
- Silver nitrate, 897, 898
- Silver sulfadiazine, 897, 837
- Simcor, 633
- Simponi, 656, 999. *See also* Golimumab
- Simulect, 999. *See also* Basiliximab
- Simvastatin, 633
- Sinecatechins, **1076**
- Sinemet, 499. *See also* Carbidopa/levodopa
- Sinequan, 539. *See also* Doxepin
- Single-blind design, 72
- Singulair, 328, 355. *See also* Montelukast
- siRNAs, 2
- Sirolimus  
 as immunosuppressive drug, 985*t*, **986–987**
- Sisomicin, 825
- Sitagliptin  
 for diabetes mellitus, 761
- Sitagliptin plus metformin, 766
- Skelaxin, 481. *See also* Metaxalone
- Skeletal muscle  
 calcium channel blockers effects on, 204  
 dantrolene effects on, 479  
 methylxanthines effects on, 346  
 serotonin effects on, 284
- Skeletal muscle paralysis, 472
- Skeletal muscle relaxants, **465–482**. *See also* Muscle relaxants
- Skelid, 786. *See also* Tiludronate disodium
- Skin  
 autonomic nerve activity effects on, 90*t*  
 decontamination of poisoned patient, 1031–1032  
 isoniazid effects on, 841  
 oral contraceptives effects on, 728  
 poisoning effects on, 1029
- Skin diseases  
 drugs used for, **1061–1079**. *See also* Dermatologic drugs
- Sleep  
 prostaglandins and, 321  
 sedative-hypnotics and, 382
- Sleep aids  
 ingredients in, 1122*t*
- Sleep disorders  
 sedative-hypnotic drugs for, **382–383**
- Slo-Phyllin, 355. *See also* Theophylline
- Slow acetylator phenotype, 65
- Slow-reacting substance of anaphylaxis (SRS-A), 317
- Small interfering RNAs (siRNAs), 2
- Smoking  
 cigarette  
 coronary disease related to, 619  
 fetal effects of, 1043*t*
- Smoking cessation  
 aids for  
 ingredients in, 1122*t*  
 antidepressants in, 533  
 varenicline in, 110
- Smooth muscle  
 alcohol effects on, 391  
 bronchiolar  
 autonomic nerve activity effects on, 90*t*  
 histamine effects on, 276  
 calcium channel blockers effects on, 203  
 contraction of  
 calcium channel blockers in control of, 194, 195*f*  
 digitalis effects on, 217  
 drugs with important actions on, **273–357**  
 genitourinary  
 autonomic nerve activity effects on, 90*t*  
 glucagon effects on, 763  
 lipoxigenase effects on, 323  
 methylxanthines effects on, 346  
 nitrates/nitrites in  
 mechanism of action of, 196*f*, 197  
 reproductive  
 prostaglandins and thromboxanes effects on, 320  
 uterine  
 ergot alkaloids effects on, 289  
 inhaled anesthetics effects on, 437  
 vascular  
 ergot alkaloids effects on, 288*t*, 289, 289*f*  
 nitroglycerin effects on, 196*f*, 197  
 vascular  
 nitrates/nitrites effects on, 196*f*, 197  
 nitroglycerin effects on, 196*f*, 197  
 prostaglandins and thromboxanes effects on, 320
- Snake bite  
 passive immunization for, 1169*t*
- SNAPs, 82–83

- SNRIs. *See* Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Social anxiety disorder  
antidepressants for, 532
- Socioeconomic factors  
in prescribing drugs, 1147
- Sodium  
intracellular  
concentration of, 212  
in OTC products, 1123*t*
- Sodium balance  
drugs altering, 172–174, 174*f*
- Sodium bicarbonate  
as antacid, 1083
- Sodium-calcium exchanger  
activity of, 212
- Sodium channel blockers, 238–242. *See also specific drugs*  
preparations available, 209, 249
- Sodium ferric gluconate complex, 585–586
- Sodium fluoride, 786
- Sodium Iodide I 131, 695. *See also*  
Radioactive iodine sodium
- Sodium nitroprusside, 182, 334. *See also*  
Nitroprusside  
as antihypertensive drug, 182  
pharmacokinetics/dosage of, 182
- Sodium phosphate  
in constipation management, 1093
- Sodium removal  
in chronic heart failure management, 220
- Sodium salicylate, 656
- Sodium stibogluconate, 929*f*, 933
- Sodium sulfacetamide  
for acne, 1064
- Sodium thiosalicylate, 656
- Sodium valproate  
for seizures, 418  
therapeutic levels/dosage of, 419
- Solganal, 656. *See also* Aurothioglucose
- Solid organ transplantation  
immunosuppressive drugs in, 994–995
- Solifenacin  
for urinary disorders, 122, 122*t*
- Solu-Cortef, 712. *See also* Hydrocortisone sodium succinate
- Solu-Medrol, 712. *See also*  
Methylprednisolone sodium succinate
- Solvents  
organic  
fetal effects of, 1043*t*  
TLVs of, 1005*t*  
toxic exposure to, 1005–1006, 1005*t*
- Soma, 481. *See also* Carisoprodol
- Soman, 106*f*
- Somatomedin C, 662
- Somatostatin, 661, 661*f*; 743  
for diarrhea, 1095  
for variceal hemorrhage, 1107–1108
- Somatostatin analogs, 665–666, 665*f*
- Somatotropin  
structure of, 662
- Somatropin, 678
- Somatuline Depot, 678. *See also* Lanreotide acetate
- Somavert, 678. *See also* Pegvisomant
- Sonata, 387. *See also* Zaleplon
- Sorafenib  
for cancer, 968  
clinical activity and toxicities of, 967*t*
- Sorbitol  
in constipation management, 1093
- Sotalol  
for cardiac arrhythmias, 244  
cardiac effects of, 242  
membrane actions of, 237*t*  
pharmacologic properties of, 238*t*  
properties of, 159*t*
- Spare receptors, 17–18, 17*f*  
receptor-effector coupling and, 16–18, 17*f*
- Spasm(s)  
acute local  
drugs for, 479  
infantile, 421  
drugs used for, 423
- Spasmex, 127. *See also* Trospium
- Spasmolytic drugs, 476–479, 481. *See also specific drugs*
- Special carrier molecules, 9, 9*f*
- Spectazole, 858. *See also* Econazole
- Spectinomycin, 827  
structure of, 827*f*
- Spectracef, 807. *See also* Cefditoren
- Spiriva, 127, 355. *See also* Tiotropium
- Spirolactone, 261–263, 711, 739  
during lactation, 1048*t*
- Spontaneously resolving hyperthyroidism, 692
- Sporanox, 858. *See also* Itraconazole
- SRS-A, 317
- SRX251, 303
- St. Anthony's fire, 287
- St. John's wort, 1132–1133
- Stadol, 562. *See also* Butorphanol
- Stage fright  
beta-receptor antagonists for, 164
- Stalevo, 499. *See also* Carbidopa/levodopa/entacapone  
for parkinsonism, 491
- Staphylococcus(i)  
methicillin-resistant  
cephalosporins active against, 800
- Starlix, 766. *See also* Nateglinide
- State-dependent drug action, 235, 236*f*
- Statin-induced myopathy  
prevention of  
coenzyme Q10 in, 1134
- STATs (signal transducers and activators of transcription), 23, 24*f*
- Status epilepticus  
drugs used for, 423
- Stavudine, 863*f*; 871*t*, 874–875, 889
- Stedesa, 427. *See also* Eslicarbazepine
- Stelara, 999. *See also* Ustekinumab
- Sterilants  
as antiseptics/disinfectants, 897  
preparations available, 898
- Sterilization, 894*t*
- Stereoisomerism, 4–5
- Steroid(s)  
anabolic, 734–737. *See also* Anabolic steroids
- Steroid synthesis inhibitors, 709–711, 737
- Sterol(s)  
intestinal absorption of  
inhibitors of  
for hyperlipidemias, 630–631
- Stilphostrol, 740. *See also* Diethylstilbestrol
- Stimate, 678. *See also* Desmopressin acetate
- Stimulant(s)  
overdose of, 1032–1034
- Stimulant laxatives, 1093
- Stiripentol, 427  
for seizures, 415
- Stool softeners, 1093
- STOP-NIDDM trial, 752, 759
- Streptase, 617. *See also* Streptokinase
- Streptogramins, 815–816
- Streptokinase, 604, 604*f*; 617  
pharmacology of, 611
- Streptomycin, 822*f*; 824–825, 828, 848  
for tuberculosis, 840*t*, 843
- Stress  
bleeding due to  
proton pump inhibitors in prevention of, 1088  
gastritis due to  
prevention of bleeding from  
H<sub>2</sub>-receptor antagonists in, 1085
- Stress test  
cardiac  
dobutamine in, 144
- Stretch reflex arc  
structures involved in, 476, 477*f*
- Stromectol, 946. *See also* Ivermectin
- Strongyloidiasis  
ivermectin for, 941
- Strontium ranelate  
in bone mineral homeostasis, 777–778  
for osteoporosis, 783
- Structural proteins, 16
- Structure-activity relationship  
of drug congeners, 22*f*; 29–30

- Strychnine, 366*t*  
 ionization constants of, 11*t*
- Subacute thyroiditis, **692**
- Subarachnoid hemorrhage  
 cerebral vasospasm and infarct following  
 calcium channel blockers effects on,  
 204
- Submucous plexus, 81*f*; 82
- Substance P, **307**  
 in ANS, ENS, and NANC neurons, 84*t*
- Substituted benzamides  
 for nausea and vomiting, **1100**
- Succimer, **1022–1023**, 1025  
 indications and toxicity of, 1022–1023
- Succinylcholine, 466, 467*f*; 481  
 pharmacokinetic and pharmacodynamic  
 properties of, 470*t*  
 tissue effects of, 474*t*
- Sucralfate  
 for acid-peptic diseases, **1089–1090**
- Sudafed, 148. *See also* Pseudoephedrine
- Sufenta, 562. *See also* Sufentanil
- Sufentanil, 557, 562  
 pharmacokinetics of, 545*t*
- Sugar(s)  
 nonabsorbable  
 in constipation management, 1093
- Suicidality, 536  
 antiseizure drugs and, 424
- Suicide inhibitors, of enzymes, 59
- Sular, 190, 209. *See also* Nisoldipine
- Sulbactam, 801*f*
- Sulconazole, 858
- Sulfacetamide sodium, 837
- Sulfacytine  
 pharmacokinetics of, 832*t*
- Sulfadiazine  
 ionization constants of, 11*t*  
 pharmacokinetics of, 832*t*
- Sulfadoxine, 918*f*; 925  
 pharmacokinetics of, 832*t*
- Sulfadoxine/pyrimethamine. *See*  
 Pyrimethamine/sulfadoxine
- Sulfamethizole, 832*t*
- Sulfamethoxazole  
 pharmacokinetics of, 40*t*, 832*t*
- Sulfamylon, 837. *See also* Mafenide
- Sulfanilamide, 832*f*
- Sulfapyridine, 1101*f*  
 ionization constants of, 11*t*  
 pharmacokinetics of, 832*t*
- Sulfasalazine, **646**, 1101
- Sulfathalidine, 832*f*
- Sulfation, 60*t*
- Sulfinpyrazone, 656  
 drug interactions with, 610*t*
- Sulfisoxazole, 832*f*; 837  
 pharmacokinetics of, 832*t*
- Sulfonamides, **831–833**, 837  
 antimicrobial activity of, 831, 832*f*
- Sulfonamides (*Cont.*):  
 oral absorption of  
 in neonates *vs.* older children and  
 adults, 1044*t*
- Sulfonylureas, **754–756**, 755*t*, 766
- Sulfur, for scabies, **1068**
- Sulfur dioxide  
 TLVs of, 1005*t*
- Sulfur dioxide poisoning, **1004**
- Sulindac, **642**, 656  
 properties of, 638*t*
- Sulthiame, 420
- Sumatriptan, 285*f*; 292  
 for migraine, 285  
 pharmacokinetics of, 286*t*
- Sunitinib  
 for cancer, 967*t*, **968**
- Sunscreens, **1069**
- Superoxidized water  
 as antiseptic/disinfectant, **896**
- Supersensitivity  
 denervation, 92
- Supprelin LA, 678. *See also* Histrelin  
 acetate
- Suprane, 446. *See also* Desflurane
- Suprax, 807. *See also* Cefixime
- Suprofen, 656
- Suramin  
 clinical uses of, 933
- Surface area  
 as factor in drug dosage in  
 infants and children, 1047,  
 1049, 1049*t*
- Surgical relaxation  
 neuromuscular blocking drugs for, 476
- Surmontil, 539. *See also* Trimipramine
- Susceptibility testing  
 of pathogens to antimicrobial drugs, 903
- Suspensions  
 in pediatric patients, 1046
- Sustiva, 888. *See also* Efavirenz
- Sweat glands  
 antimuscarinic drug effects on, 120
- Symlin, 766. *See also* Pramlintide
- Symmetrel, 499, 888. *See also* Amantadine
- Sympathetic nervous system  
 function of  
 drugs altering, **174–175**  
 in renin release, 296, 297*f*
- Sympathomimetic drugs, **129–149**, 355  
 actions of  
 molecular pharmacology underlying,  
**130–134**  
 alpha receptors, 131, 131*t*, 132*f*, 137*t*  
 amphetamine-like, 136*f*; **142–143**, 143*t*  
 for anaphylaxis, 145  
 for asthma, **341–344**, 343*f*  
 beta receptors, 131–132,  
 beta<sub>2</sub>-selective drugs, 343–344, 343*f*  
 cardiovascular applications of, 144–145
- Sympathomimetic drugs (*Cont.*):  
 cardiovascular system effects of, 136–138,  
 137*t*, 138*t*, 139*f*, 140*f*  
 catecholamine reuptake inhibitors,  
**143**  
 CNS applications of, 146  
 in congestive heart failure, 225  
 described, 129–130  
 desensitization of, 133  
 direct-acting, 133*t*, 136*f*; **141**  
 dopamine agonists, **143–144**  
 dopamine receptors, 131, 132, 137*t*  
 genitourinary applications of, 145–146  
 indirect-acting, 136*f*; **142–143**, 143*t*  
 mixed-acting, 136*f*; **141–142**  
 noncardiac effects of, 138–140  
 norepinephrine transporter of, 134  
 ophthalmic applications of, 145  
 organ system effects of, **136–140**  
 in OTC products, 1123*t*  
 pulmonary applications of, 145  
 receptors  
 regulation of, 133–134  
 selectivity of, 133, 133*t*  
 subtypes of, 131  
 distribution of, 136, 137*t*  
 physiologic functions of, 133  
 polymorphisms of, 134  
 therapeutic uses for, **144–146**  
 toxicities of, 344  
 types of, 131
- Sympathoplegic drugs, 172, 189  
 as antihypertensive drugs, **174–175**  
 centrally acting, **175–177**  
 mechanisms and sites of action of,  
 175–176
- Synagis, 889. *See also* Palivizumab
- Synapse(s)  
 CNS drugs and, **361–363**, 362*f*, 363*f*
- Synaptic plasticity  
 addiction and, 571
- Synaptic potentials  
 CNS drugs and, **361–363**, 362*f*, 363*f*
- Synaptobrevin, 83
- Synaptosomal nerve-associated proteins  
 (SNAPs), 82–83
- Synaptotagmin, 84
- Synarel, 678. *See also* Nafarelin acetate
- Syndrome of inappropriate ADH (SIADH)  
 secretion  
 ADH antagonists for, 264
- Synercid, 819. *See also*  
 Quinupristin-dalfopristin
- Synergism  
 among antimicrobial drugs, 909–910
- Synergistic killing, 823
- Synergy studies  
 for infections with known etiology, 903
- Syntaxin, 83
- Synthetic estrogens, 718, 718*f*

- Synthetic progestins, 723  
 physiologic effects of, 724, 725*t*
- Synthetic steroids  
 with androgenic and anabolic action, 735, 735*t*
- Synthroid, 695. *See also* Levothyroxine
- Syprine, 499. *See also* Trientine
- Systemic infections  
 antifungal drugs for, **849–855**
- Systolic failure, 211
- T**
- T lymphocytes, 978–981, 979*f*, 980*f*
- t-PA. *See* Tissue plasminogen activator (t-PA)
- Tachykinins  
 as CNS neurotransmitters, 367*t*
- Tachyphylaxis, 32
- Tacrine  
 for Alzheimer's disease, 1054–1055, 112
- Tacrolimus, 999, 1067  
 as immunosuppressive drug, 985*t*, **986**
- Tadalafil  
 for erectile dysfunction, 199
- Taenia* spp.  
 niclosamide for, 942
- Taeniasis  
 praziquantel for, 944
- Tagamet, 1111. *See also* Cimetidine
- Talwin, 562. *See also* Pentazocine
- Tambocor, 249. *See also* Flecainide
- Tamiflu, 889. *See also* Oseltamivir
- Tamoxifen, **731**, 740  
 fetal effects of, 1043*t*
- Tamsulosin, 152*f*, **154–155**, 167
- Tapazole, 695. *See also* Methimazole
- Tapentadol, 559, 562
- Tapeworms  
 drugs used for, 938*t*
- Tar compounds, **1074**
- Tardive akathisia, 496
- Tardive dyskinesia, 496  
 antipsychotic drugs and, 511
- Tardive dystonia, 496
- Target concentration, 45
- Target concentration intervention, **47–49**  
 in designing rational dosage regimen, **45–47**, 47*f*  
 loading dose, 46–47, 47*f*  
 maintenance dose, 46
- Target concentration strategy, 48
- Tasmar, 499. *See also* Tolcapone
- Tavist, 292. *See also* Clemastine
- Taxanes  
 for cancer, 963*t*, **964**
- Tazarotene  
 for acne, 1070  
 for psoriasis, **1071**
- Tazidime, 807. *See also* Ceftazidime
- Tazobactam, 801*f*
- TCAs. *See* Tricyclic antidepressants (TCAs)
- Teeth  
 fluoride effects on, 777  
 tetracyclines effects on, 812
- Teflaro, 807. *See also* Ceftaroline fosamil
- Tegaserod, 286  
 in constipation management, 1094, 1097*f*, 1112
- Tegretol, 427, 519. *See also* Carbamazepine
- Teicoplanin, **803**
- Tekturna, 190. *See also* Aliskiren
- Telaprevir  
 for HCV infection, 886
- Telavancin, 798*t*, **803**, 808  
 pharmacokinetics and dosage of, 798*t*, 803
- Telbivudine  
 for HBV infection, 883*t*, **885**
- Telithromycin, 814–815, 819
- Telmisartan, 190, 225
- Temazepam  
 pharmacokinetic properties of, 377*t*
- Temozolomide  
 clinical activity and toxicities of, 956*t*
- Temperature  
 hyperthermia, 284*t*  
 opioid analgesics effects on, 551, 551*t*
- Temptra, 656. *See also* Acetaminophen
- Tenecteplase  
 pharmacology of, 612
- Tenex, 189. *See also* Guanfacine
- Tenofovir, 863*f*, 871*t*, **875**, 889  
 drug interactions with, 874*t*  
 for HBV infection, 883*t*, **885**
- Tenormin, 167, 189. *See also* Atenolol
- Tensilon, 112. *See also* Edrophonium
- Teratogen(s)  
 defined, 1042  
 FDA risk categories for, 1042, 1043*t*  
 risks associated with  
 counseling women about, 1042–1043
- Teratogenic drug actions  
 during pregnancy, 1041–1043, 1041*f*, 1042*t*–1043*t*
- Terazol 3, 858. *See also* Terconazole
- Terazol 7, 858. *See also* Terconazole
- Terazosin, **154**, 189
- Terbinafine  
 for mucocutaneous infections, **856**  
 oral, **1067**  
 from prescription to OTC status, 1116*t*  
 topical, **1065**
- Terbutaline  
 for asthma, 344  
 ionization constants of, 11*t*  
 pharmacokinetic parameters for, 40*t*  
 in premature labor suppression, 145  
 structure of, 142*f*, 343*f*
- Terconazole, 858
- Teriparatide, 771  
 for osteoporosis, 775, 783
- Terlipressin, 303  
 for variceal hemorrhage, **1108**
- Tertiary amine, 11
- p*-Tertiary amylphenol, 895
- Testicular cancer  
 chemotherapeutic drugs for, **973–974**
- Testis(es), **734–739**
- Testopel, 740. *See also* Testosterone pellets
- Testosterone, **734–737**. *See also* Androgen(s)  
 preparations available, 735*t*, 740
- Tetanus  
 passive immunization for, 1169*t*
- Tetanus-diphtheria-pertussis vaccine, 1166*t*
- Tetanus-diphtheria vaccine, 1165*t*
- Tetrabenazine  
 for Huntington's disease, 494–495  
 preparations available, 499
- Tetracaine, 463, 451*t*
- 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin (TCDD), 1010, 1009*f*
- Tetrachlorodiphenylethane (TDE)  
 toxicity rating for, 1006*t*
- Tetrachloroethylene  
 TLVs of, 1005*t*
- Tetracyclic antidepressants  
 dosage of, 535*t*  
 drug interactions with, 537  
 pharmacodynamics of, 530*t*, 531  
 pharmacokinetics of, 529–530, 529*t*
- Tetracycline(s), **810–813**  
 fetal effects of, 1043*t*  
 during lactation, 1048*t*
- Tetraethylammonium, 124
- Tetrahydrocannabinol  
 abuse of, 572  
 for chronic pain, 550
- Tetrahydrozoline  
 preparations available, 148
- Tetraiodothyronine (T<sub>4</sub>), 681
- Tetrahiomolybdate  
 for Wilson's disease, 497
- Teveten, 190, 225. *See also* Eprosartan
- Tezosentan  
 in heart failure management, 219
- Thalamus  
 circuitry of, 483, 484*f*
- Thalidomide  
 dermatologic uses of, 1078*t*  
 fetal effects of, 1043*t*  
 immunomodulatory derivatives of, **987–988**  
 as immunosuppressive drug, **987–988**
- Thalitone, 270. *See also* Chlorthalidone
- Thalomid, 999. *See also* Thalidomide
- Theo-24, 355. *See also* Theophylline
- Theo-Dur, 355. *See also* Theophylline
- Theobromine, 345*f*
- Theophylline, **344–346**, 355  
 drug interactions with, 1161*t*

- Theophylline (*Cont.*):  
 half-life of  
   in neonates and adults, 1045*t*  
 hepatic clearance of  
   aging effects on, 1052*t*  
 ionization constants of, 11*t*  
 during lactation, 1048*t*  
 overdose of, **1037–1038**  
 pharmacokinetic and pharmacodynamic parameters for, 40*t*
- Therapeutic index, 32
- Thiabendazole, **945**  
 for helminthic infections, 938*t*, **945**
- Thiamine  
 in acute alcohol intoxication management, 395
- Thiazide diuretics, **260–261**  
 in bone mineral homeostasis, 777
- Thiazolidinedione(s)  
 combination therapy with  
   preparations available, 766  
 for diabetes mellitus, **757–759**
- Thiazolidinedione derivatives, 766
- Thienobenzodiazepine antipsychotics  
 advantages and disadvantages of, 509*t*  
 chemical structure effects on potency and toxicity of, 505*t*
- Thimerosal, 897, 898
- Thioamides  
 antithyroid activity of, **688–689**
- 6-Thioguanine  
 clinical activity and toxicities of, 959*t*  
 mechanism of action of, 961, 961*f*
- Thiol(s)  
 nitric oxide interactions with, 332–333
- Thiopental  
 pharmacologic properties of, 439*t*
- 6-Thiopurines  
 for cancer, **961–962**, 961*f*
- Thioridazine  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*  
 ionization constants of, 11*t*
- Thiotepa  
 clinical activity and toxicities of, 956*t*  
 structure of, 954*f*
- Thiothixene  
 advantages and disadvantages of, 509*t*  
 dosage of, 510*t*
- Thioxanthene antipsychotics, 503*f*; 504  
 advantages and disadvantages of, 509*t*  
 chemical structure effects on potency and toxicity of, 505*t*
- Thorazine, 519. *See also* Chlorpromazine
- Threshold limit values (TLVs), 1001  
 of air pollutants and solvents, 1005*t*
- Thrombate III, 617. *See also* Antithrombin III
- Thrombin inhibitors  
 direct, **607–608**. *See also specific drugs*
- Thrombocytopenia, 582  
 heparin-induced, 606
- Thrombolytic drugs  
 for acute myocardial infarction, 611, 612
- Thrombopoietin  
 properties of, 996*t*
- Thrombosis, treatment of  
 arterial, **614**  
 venous, **614**
- Thromboxane(s), 315. *See also* Eicosanoid(s)  
 organ system effects of, 320–322
- Thromboxane A<sub>2</sub>, 315, 320, 601, 612
- Thrombus(i)  
 platelet-rich, 601–602  
 red, 602  
 white, 601–602
- Thymoglobulin, 999. *See also* Antithymocyte globulin
- Thyrogen, 678, 695. *See also* Thyrotropin
- Thyroid. *See also* Antithyroid drugs  
 autoregulation of, 684  
 drug effects on, 684, 685*t*  
 function of  
   lithium effects on, 516  
   physiology of, **681–684**
- Thyroid desiccated, 695
- Thyroid disease, 695
- Thyroid drugs, **681–696**. *See also specific drugs and* Antithyroid drugs
- Thyroid function tests  
 values for, 683–684, 683*t*
- Thyroid hormones, **684–688**
- Thyroid neoplasms, **694**
- Thyroid-pituitary relationships, 683–684, 684*f*
- Thyroid stimulators  
 abnormal, 684
- Thyroid storm, 692–693
- Thyroidectomy  
 for Graves' disease, 692
- Thyroiditis  
 subacute, **692**
- Thyrolar, 695. *See also* Liotrix
- Thyrotoxicosis  
 amiodarone-induced, 693–694  
 manifestations of, 687*t*  
 during pregnancy, 693  
 treatment of, 691–694
- Thyrotropin, 695
- Thyrotropin alfa, 678
- Thyrotropin-releasing hormone (TRH), 661, 661*t*  
 clinical uses of, 661*t*  
 diagnostic uses of, 662*t*
- Thyroxine, 681  
 during lactation, 1048*t*  
 peripheral metabolism of, 682, 682*f*
- Tiagabine, 415*f*; 416  
 for seizures, **415–416**
- Ticar, 807. *See also* Ticarcillin
- Ticarcillin  
 dosage of, 795*t*, 807
- Ticarcillin/clavulanate potassium, 807
- Ticlid, 617. *See also* Ticlopidine
- Ticlopidine  
 as antiplatelet agent, 612–613, 617
- Tics, 495  
 described, 483  
 treatment of, 495
- Tigan, 1112. *See also* Trimethobenzamide
- Tigecycline, 810*f*, 812
- Tikosyn, 249. *See also* Dofetilide
- Tiludronate disodium, 786
- Time-dependent killing, 907
- Timentin, 807. *See also* Ticarcillin/clavulanate potassium
- Timolol, 159*t*, 161, 167, 189
- Tinactin, 858. *See also* Tolnaftate
- Tindamax, 935. *See also* Tinidazole
- Tinidazole, 892  
 adverse effects of, 929  
 for amebiasis, **927–929**, 928*t*
- Tinzaparin, 617
- Tioconazole, 858  
 from prescription to OTC status, 1116*t*
- Tiotropium, 117*f*, 127, 347, 355  
 for COPD, 121
- Tipranavir, 871*t*, **880–881**, 889  
 drug interactions with, 874*t*
- Tirofiban, 613, 617
- Tirosint, 695. *See also* Levothyroxine
- Tissue factor-VIIa complex, 602–604, 603*f*
- Tissue plasminogen activators (t-PAs), 604, 604*f*  
 pharmacology of, 612
- Tissue schizonticides, 915
- Tizanidine, 141, 148, **477–478**, 481  
 as muscle relaxant, 146
- TLVs. *See* Threshold limit values (TLVs)
- TMP-SMZ. *See also* Trimethoprim-sulfamethoxazole (TMP-SMZ)
- TNKase, 617. *See also* Tenecteplase
- Tobramycin, 822*f*, **826**, 828  
 pharmacokinetic and pharmacodynamic parameters for, 40*t*
- Tocainide  
 pharmacokinetic and pharmacodynamic parameters for, 40*t*
- Tocilizumab, **646–647**, **993**
- Tofranil, 539. *See also* Imipramine
- Tolazamide  
 for diabetes mellitus, 754, 755*t*
- Tolazoline  
 cardiovascular effects of, 153*f*
- Tolbutamide  
 for diabetes mellitus, 754, 755*t*  
 hepatic clearance of  
   aging effects on, 1052*t*  
 ionization constants of, 11*t*

- Tolbutamide (*Cont.*):  
 during lactation, 1048*t*  
 pharmacokinetic and pharmacodynamic parameters for, 40*t*
- Tolcapone  
 for parkinsonism, 488*f*, 490, 499
- Tolectin, 656. *See also* Tolmetin
- Tolerance, 66
- Tolinase, 766. *See also* Tolazamide
- Tolmetin, **642**
- Tolnaftate, 858  
 topical, **1066**
- Tolterodine  
 for urinary disorders, 122, 122*t*
- Toluene, 1006  
 TLVs of, 1005*t*
- Tolvaptan, 264, 675  
 in heart failure, 222  
 preparations available, 270, 678
- Tonic-clonic seizures  
 generalized, 421  
 drugs used for, **407–417, 422**
- Topamax, 427, 519. *See also* Topiramate
- Topiramate, 416*f*, 427, 519  
 for seizures, **416**  
 for tremors, 494
- Topotecan  
 clinical activity and toxicities of, 963*t*
- Toprol, 167. *See also* Metoprolol
- Toprol XL, 225. *See also* Metoprolol
- Toradol, 655. *See also* Ketorolac
- Torcetrapib, 631
- Toremifene, 731, 740
- Tornalate, 355. *See also* Bitolterol
- Torseamide  
 dosage of, 259*t*, 270
- Tositumomab, 992
- Tourette's syndrome, **495**  
 antipsychotic drugs for, 509
- Toviaz, 127. *See also* Fesoterodine
- Toxaphenes  
 toxicity rating for, 1006*t*
- Toxic dose  
 median (TD<sub>50</sub>), 31–32
- Toxic multinodular goiter, **692**
- Toxic products  
 metabolism of drugs to,  
 60–61, 61*f*
- Toxic syndromes, **1032–1038**
- Toxic uninodular goiter, **692**
- Toxicodynamics, **1027–1028**
- Toxicokinetics, **1027–1028**
- Toxicology, **1001–1038**  
 chemicals, **1003–1005**, 1005*t*  
 defined, 1, 2*f*  
 environmental, **1001–1003**  
 herbicides, **1008–1010**  
 occupational, 1001  
 pesticides, **1006–1008**, 1006*t*–1008*t*  
 screening tests, 1031, 1031*t*
- Toxicology (*Cont.*):  
 solvents, **1005–1006**, 1005*t*  
 terminology related to, **1002**
- Toxin(s)  
 defined, 4  
 exposure to  
 duration of, 1002  
 routes of, 1002  
 ion channel effects, 360, 360*t*
- Toxoplasma gondii*  
 drugs used for, 932*t*
- Toxoplasmosis  
 drugs used for, 926
- Tracheal intubation  
 neuromuscular blocking drugs for, 476
- Tracleer, 225. *See also* Bosentan
- Trademark, 76
- Tradjenta, 766. *See also* Linagliptin
- Tramadol, 559, 562
- Trandate, 167, 189. *See also* Labetalol
- Trandolapril, 190, 225
- Tranexamic acid  
 for bleeding disorders, 616
- Transderm Scop, 127, 1111, 1112. *See also* Scopolamine
- Transdermal patch  
 opioid analgesic, 554
- Transferrin, 583*f*, 584
- Transient neurologic symptoms  
 of local anesthetics, 459
- Translational research, 70  
 in drug development, 76
- Transmembrane enzymes  
 ligand-regulated, 22–23, 23*f*
- Transmembrane signaling mechanisms,  
 21, 21*f*
- Transplantation  
 autologous stem cell  
 myeloid growth factors in,  
 593, 593*f*  
 bone marrow  
 immunosuppressive drugs in,  
**994–995**  
 organ  
 immunosuppressive drugs in, 985*t*  
 solid organ  
 immunosuppressive drugs in,  
**994–995**
- Transport molecules, 9, 10*t*
- Transport proteins, 16
- Transporter(s)  
 drug, 9, 10*t*
- Tranxene, 387, 427. *See also* Clorazepate
- Tranylcypromine, 528*f*, 539  
 chemistry of, 527–528  
 dosage of, 535*t*  
 pharmacokinetics of, 530
- Trastuzumab, 992  
 preparations available, 999
- Travatan, 328. *See also* Travoprost
- Travelers  
 immunizations recommended for, 1170  
 malaria prevention in  
 drugs used for, 919*t*
- Travoprost, 328
- Trazodone, 155, 529  
 chemistry of, 526, 527*f*  
 dosage of, 535*t*
- Trecator-SC, 848. *See also* Ethionamide
- Trelstar, 678. *See also* Triptorelin pamoate
- Trematodes  
 drugs used for, 938*t*
- Tremor(s), 493–494  
 beta-receptor antagonists for, 164  
 described, 483, 493  
 essential, 493–494  
 intention, 494  
 lithium and, 516  
 rest, 494
- Trental, 209, 355. *See also* Pentoxifylline
- Treprostinil, 326, 328
- Treprostinil sodium, 325*f*
- TRH. *See* Thyrotropin-releasing hormone (TRH)
- Triamcinolone, 700*f*, 712  
 clinical uses and dosage of, 703*t*
- Triamterene, 270
- Triazolam, 374*f*  
 pharmacokinetic properties of, 377*t*
- Tricalcium phosphate  
 preparations available, 786
- Trichlorfon, **942**  
 for helminthic infections, 938*t*, **942**  
 toxicity rating for, 1007*t*
- Trichlormethiazide  
 dosage of, 261*t*
- 1,1,1-Trichloroethane  
 TLVs of, 1005*t*
- Trichloroethylene  
 TLVs of, 1005*t*
- 2,4,5-Trichlorophenoxyacetic acid,  
 1008–1009  
 structure of, 1009*f*
- Trichogenic agents, **1077**
- Trichomonas vaginalis*  
 drugs used for, 932*t*
- Trichomoniasis  
 drugs used for, 928
- Trichuriasis  
 albendazole for, 938–939
- Trichlormethiazide, 270
- Tricor, 633. *See also* Fenofibrate
- Tricyclic antidepressants (TCAs) **526**,  
**527*f***, 539  
 adverse effects of, 535  
 dosage of, 535*t*  
 drug interactions with, 536–537, 1152*t*  
 fetal effects of, 1042*t*  
 overdose of, **1034**  
 pharmacodynamics of, 530*t*, 531

- Tridihexethyl, 127  
 Tridione, 427. *See also* Trimethadione  
 Trientine  
   for Wilson's disease, 497, 499  
 Triethylenemelamine, 954*f*  
 Trifluoperazine, 503*f*  
   dosage of, 510*t*  
 Trifluridine  
   dosage of, 865*t*, 889  
   for HSV and VZV infections, **866**  
 Trihexyphenidyl  
   for parkinsonism, 492*t*, 499  
 Triiodothyronine (T<sub>3</sub>), 681  
 Trileptal, 427. *See also* Oxcarbazepine  
 Trilostane, **710**  
 Trimethadione  
   fetal effects of, 1043*t*  
   for seizures, 419  
 Trimethaphan, 127  
 Trimethobenzamide  
   for nausea and vomiting, 1100  
 Trimethoprim, **833–834**, 837  
   pharmacokinetics of, 40*t*, 832*t*, 834  
 Trimethoprim-sulfamethoxazole  
   (TMP-SMZ), **833–834**  
   drug interactions with, 610*t*  
 Trimipramine  
   pharmacodynamics of, 530*t*  
 Trimipramine maleate  
   dosage of, 535*t*  
 Trimpex, 837. *See also* Trimethoprim  
 Triorthocresyl phosphate (TOCP), 110,  
   1007–1008  
 Trioxsalen, **1069**  
 "Triple response"  
   of histamine, 276  
 Triprolidine, 292  
 Triptan(s), **285–286**  
 Triptorelin pamoate, 678  
 Tronothane, 463. *See also* Pramoxine  
 Tropicamide, 117*f*, 127  
 Trospium, 127  
   for urinary disorders, 122, 122*t*  
 TRPV1, 550  
 Truncal rigidity  
   opioid analgesics and, 551, 551*t*  
 Trusopt, 270. *See also* Dorzolamide  
*Trypanosoma cruzi*  
   drugs used for, 932*t*  
 Trypanosomiasis  
   African  
     drugs used for, **930–934**, 930*f*, 932*t*  
 L-Tryptophan  
   structure of, 281*f*  
 Tuberculin hypersensitivity, 983  
 Tuberculosis  
   drugs used for, **839–845**. *See also specific drugs*  
     adverse reactions to, 843  
     amikacin, 840*t*, 844  
   Tuberculosis, drugs used for (*Cont.*):  
     aminosalicylic acid, 840*t*, 844  
     capreomycin, 840*t*, 844  
     cycloserine, 840*t*, 844  
     dosages of, 840*t*  
     duration of therapy, 840*t*  
     ethambutol, 840*t*, **842**  
     ethionamide, 840*t*, 843–844  
     fluoroquinolones, 840*t*, 844–845  
     isoniazid, **840–841**, 840*t*  
     kanamycin, 840*t*, 844  
     linezolid, 840*t*, 845  
     preparations available, 848  
     pyrazinamide, 840*t*, **842–843**  
     rifabutin, 840*t*, 845  
     rifampin, 840*t*, **841–842**  
     rifapentine, 840*t*, 845  
     second-line drugs, 840*t*, **843–845**  
     streptomycin, 840*t*, **843**  
   Tuberoinfundibular system, 506  
 Tubocurarine, 466–470, 468*f*, 481  
   pharmacokinetics of, 40*t*, 470*t*  
   tissue effects of, 474*t*  
 Tumor(s)  
   neuroendocrine  
     diarrhea due to  
       octreotide for, 1095  
   Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
     properties of, 996*t*  
   Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ )  
     antagonists, **647–649**, 647*f*.  
     *See also specific drugs*  
     for psoriasis, **1071–1072**  
   Tumor suppressor genes  
     cancer related to, 950  
 Tums, 786, 1111. *See also* Calcium  
   carbonate  
 Turner syndrome  
   growth hormone for, 663, 663*t*  
 Tygacil, 819. *See also* Tetracycline  
 Tylenol, 656. *See also* Acetaminophen  
 Tylenol with Codeine, 562. (Oxycodone/  
   acetaminophen)  
 Tylox, 562. (Oxycodone/acetaminophen)  
 Typhoid vaccine, 1166*t*  
 Tyramine, **143**, 143*t*  
 Tyrosine hydroxylase inhibitors, 167  
 Tyrosine nitration  
   nitric oxide interactions with,  
     333, 333*t*  
 Tysabri, 999. *See also* Natalizumab  
 Tyzeka, 889. *See also* Telbivudine
- U**  
 Ularitide, 256  
   in heart failure management, 219  
 Ulcer(s)  
   *H. pylori*  
     proton pump inhibitors for,  
       1087–1088  
   Ulcer(s) (*Cont.*):  
     NSAID-associated  
       proton pump inhibitors for, 1088  
     peptic. *See* Peptic ulcer(s)  
 Uloric, 656. *See also* Febuxostat  
 Ultane, 446. *See also* Sevoflurane  
 Ultiva, 562. *See also* Remifentanyl  
 Ultram, 562. *See also* Tramadol  
 Ultrarapid metabolism, 63–64  
 Unasyn, 807. (Ampicillin/sulbactam)  
 Unicyclic antidepressants  
   effects of, 531, 536  
   chemistry of, 527, 528*f*  
   dosage of, 535*t*  
 Uniphyl, 355. *See also* Theophylline  
 Unipolar depression  
   lithium for, 516  
 United Kingdom Prospective Diabetes  
   Study (UKPDS), 752  
 United Nations Food and Agriculture  
   Organization and the World  
   Health Organization (FAO/  
   WHO) Joint Expert  
   Commission on Food  
   Additives, 1002  
 Unithiol, **1023–1024**  
 Unithroid, 695. *See also* Levothyroxine  
 Univasc, 190, 225. *See also* Moexipril  
 Unstable angina, 193  
   clinical pharmacology of, 207  
   nitrate effects in, 200  
 Uracil, 960*f*  
 Urantide, 309  
 Urapidil, 155  
 Urea as drug, **1075**  
 Urecholine, 112. *See also* Bethanechol  
 Uricosuric drugs  
   for gout, 651*f*, **652–653**  
 Uridine 5'-diphosphate  
   (UDP)-glucuronosyl  
   transferases (UGTs),  
   59–60, 60*f*  
 Urinary alkalization  
   carbonic anhydrase inhibitors for, 257,  
   257*t*  
 Urinary antiseptics, **892–893**  
 Urinary disorders  
   antimuscarinic drugs for, 122,  
   122*t*  
 Urinary obstruction  
   alpha-receptor antagonists for, 156  
 Urinary pH manipulation  
   in decontamination of poisoned patient,  
   1032  
 Urinary tract  
   disorders of  
     cholinomimetic drugs for, 108  
     indirect-acting cholinomimetic drug  
     effects on, 107  
     sulfonamides effects on, 833



- Urine volume  
increase in  
osmotic diuretics for, 263–264
- Urispas, 127. *See also* Flavoxate
- Urofollitropin, 666–667, 678
- Urokinase, 604, 604*f*  
pharmacology of, 611
- Urotensin, **309**
- Ursodiol  
for gallstones, **1107**
- Uroxatral, 167. *See also* Alfuzosin
- Urticaria  
contact  
immunologic  
topical dermatologic medications  
and, 1063*t*  
non-immunologic  
topical dermatologic medications  
and, 1063*t*
- Use-dependent drug action, 235, 236*f*
- Ustekinumab, **993–994**, 999  
for psoriasis, **1072**
- Uterine bleeding  
estrogen and, 722
- Uterine fibroids  
gonadotropins in, 670
- Uterine leiomyomata  
gonadotropins in, 670
- Uterus  
ergot alkaloids effects on, 289  
inhaled anesthetics effects on, 437  
opioid analgesics effects on, 552  
oral contraceptives effects on, 727
- V**
- V-Cillin, 807. *See also* Penicillin V
- Vaccine(s), **1163–1170**. *See also specific types and* Immunization(s)
- Vaccinia  
passive immunization for, 1169*t*
- Vagistat-1, 858. *See also* Tioconazole
- Vagus nerve stimulation (VNS)  
for seizures, 404
- Valacyclovir, 863*f*, 889  
dosage of, 865*t*  
for HSV and VZV infections, **864**  
topical, **1067**
- Valcyte, 889. *See also* Valganciclovir
- Valganciclovir, 863*f*, 889  
for CMV infections, **867–868**
- Valium, 387, 400, 427. *See also* Diazepam
- Valproic acid/valproate, **418**,  
427, 519  
for bipolar disorder, 517  
fetal effects of, 1043*t*  
pharmacokinetics of, 40*t*, 418–419  
for seizures, **418**
- Valsartan  
preparations available, 190, 225
- Valtrex, 889. *See also* Valacyclovir
- VAMPs, 82
- Vancocin, 808. *See also* Vancomycin
- Vancoled, 808. *See also* Vancomycin
- Vancomycin, **802–803**, 808  
dosage of, 798*t*, 802  
mechanisms of action of, 802  
pharmacokinetics of, 40*t*, 798*t*, 802
- Vantas, 678. *See also* Histrelin acetate
- Vantin, 807. *See also* Cefotaxime
- Vaprisol, 270, 678. *See also* Conivaptan
- Vardenafil  
for erectile dysfunction, 199
- Varenicline  
in nicotine addiction, 574–575  
in smoking cessation, 110, 112
- Variant angina, 193  
diagnosis of  
ergot alkaloids in, 290  
nitrate effects in, 200
- Variceal hemorrhage  
drugs used for, **1107–1108**
- Varicella vaccine, 1166*t*
- Varicella-zoster virus (VZV) infection  
drugs used for, **862–866**  
passive immunization for, 1169*t*
- Vascular disorders  
oral contraceptives and, 729  
peripheral  
alpha-receptor antagonists for, 156
- Vascular smooth muscle  
ergot alkaloids effects on, 288*t*, 289, 289*f*  
nitrates/nitrites effects on, 196*f*, 197  
nitroglycerin effects on, 196*f*, 197  
peptides and, **295–312**  
prostaglandins and thromboxanes effects  
on, 320
- Vascular tone  
determinants of, 194–195, 194*t*
- Vasoactive intestinal peptide (VIP),  
**306–307**  
in ANS, ENS, and NANC neurons, 84*t*
- Vasoactive peptides, **295–312**. *See also specific drugs*  
adrenomedullin, **308**  
angiotensin, **295–300**  
CGRP, **308**  
endothelins, **304–306**  
kinins, **300–303**  
natriuretic peptides, **303–304**  
neuropeptide Y, **308–309**  
neurotensin, **307–308**  
substance P, **307**  
urotensin, **309**  
vasopeptidase inhibitors, **304**  
vasopressin, **303**  
VIP, **306–307**
- Vasoconstriction  
induction of  
sympathomimetic drugs for,  
144–145
- Vasodilator(s). *See also specific drugs*  
for angina pectoris, **193–210**  
as antihypertensive drugs, **180–183**  
calcium channel blockers, **183**  
diazoxide, **182–183**  
direct  
described, 172  
fenoldopam, **183**  
in heart failure management, **219, 220**  
hydralazine, **181**  
mechanism and sites of action of, 174*f*,  
180, 181*t*  
minoxidil, **181**  
sodium nitroprusside, **182**
- Vasopeptidase inhibitors, **304**
- Vasopressin, **303, 674–675**  
clinical pharmacology of, 674–675  
contraindications to, 675  
for variceal hemorrhage, **1108**
- Vasopressin agonists, 678
- Vasopressin antagonists, **303, 675**, 678
- Vasopressin receptors, **303**
- Vasospasm(s)  
cerebral  
following subarachnoid hemorrhage  
calcium channel blockers effects on,  
204
- Vasospastic angina, 193  
clinical pharmacology of, 207
- Vasotec, 190, 225. *See also* Enalapril
- Vectibix, 999. *See also* Panitumumab
- Vecuronium  
pharmacokinetic and pharmacodynamic  
properties of, 469*f*, 470*t*, 474*t*
- Venlafaxine, 526*f*, 539  
dosage of, 535*t*  
pharmacodynamics of, 530*t*, 531  
pharmacokinetics of, 528, 529*t*
- Venous thromboembolic disease  
oral contraceptives and, 729
- Venous thrombosis, **614**
- Ventavis, 328. *See also* Iloprost
- Ventilation  
alveolar  
of inhaled anesthetics, 430–432, 432*f*  
control of  
neuromuscular blocking drugs for,  
476
- Ventolin, 355. *See also* Albuterol
- Ventral tegmental area (VTA), 565
- Verapamil  
for angina, **201–205**  
for cardiac arrhythmias, **245**  
clinical pharmacology of, 202*t*  
dosage of, 175*t*, 245  
for hypertension, 183  
membrane actions of, 237*t*  
for migraine, 285  
pharmacokinetics of, 40*t*, 175*t*, 245  
pharmacologic properties of, 238*t*

- Verapamil (*Cont.*):  
 therapeutic use of, 245  
 toxicity of, 245
- Vermox, 946. *See also* Mebendazole
- Vernakalant  
 for cardiac arrhythmias, **243–244**
- Versed, 387, 446. *See also* Midazolam
- Very-low-density lipoproteins (VLDLs),  
 619, 620, 621*f*
- Vesamicol, 82
- Vesicare, 127. *See also* Solifenacin
- Vesicle-associated membrane proteins  
 (VAMPs), 82
- Vesicle-associated transporter, 82, 83*f*
- Vesicular glutamate transporter, 367
- Vesicular monoamine transporter, 85
- Vesicular proteoglycan, 82
- Vestibular disturbances  
 H<sub>1</sub>-receptor antagonists for, 280
- Vfend, 858. *See also* Voriconazole
- Viagra, 209. *See also* Sildenafil
- Vibativ, 808. *See also* Telavancin
- Vibramycin, 819, 935. *See also* Doxycycline
- Vicodin, 562. *See also* Hydrocodone/  
 acetaminophen
- Vicoprofen, 562. *See also* Hydrocodone/  
 ibuprofen
- Victoza, 766. *See also* Liraglutide
- Vigabatrin  
 for seizures, **416–417**
- Viibryd, 539. *See also* Vilazodone
- Vilazodone, 539
- Vimpat, 427. *See also* Lacosamide
- Vinblastine  
 for cancer, **962**, 963*t*  
 as immunosuppressive drug, 989
- Vinca alkaloids  
 for cancer, **962–964**, 963*t*
- Vincristine  
 for cancer, **962–964**, 963*t*  
 as immunosuppressive drug, 989
- Vinorelbine  
 for cancer, 963*t*, **964**
- VIP. *See* Vasoactive intestinal peptide (VIP)
- Viracept, 889. *See also* Nelfinavir
- Viral infections  
 drugs used for, **861–890**. *See also specific  
 drugs, indications, and*  
 Antiviral drugs
- Viral replication, 861–862
- Viramune, 889. *See also* Nevirapine
- Viread, 889. *See also* Tenofovir
- Viroptic, 889. *See also* Trifluridine
- Virus(es)  
 cancer related to, 949–950  
 described, 861
- Visicol, 1112. *See also* Sodium phosphate
- Visine, 148. *See also* Tetrahydrozoline
- Visken, 167, 189. *See also* Pindolol
- Vistaril, 292, 387. *See also* Hydroxyzine
- Vistide, 888. *See also* Cidofovir
- Vitamin B<sub>12</sub>  
 for anemia, 584*t*, **586–588**
- Vitamin D  
 in bone mineral homeostasis, 770, 770*f*,  
 771*f*, **772–773**, 772*f*  
 for chronic kidney disease, 781–782  
 deficiency of  
 nutritional, **781**  
 for hypocalcemia, 780  
 metabolites and analogs of, 772–773,  
 773*t*  
 PTH and FGF23 interactions with,  
**773–774**
- Vitamin D–dependent rickets  
 hereditary, **783–784**  
 types I and II, **783–784**
- Vitamin K  
 for bleeding disorders, 614–615
- Vitamin K<sub>1</sub>, 609*f*
- Vitamin K cycle, 609, 609*f*
- Vivactil, 539. *See also* Protriptyline
- VLDLs. *See* Very-low-density lipoproteins  
 (VLDLs)
- VNS. *See* Vagus nerve stimulation (VNS)
- Voltage-gated channels, 23–24, 24*f*
- Volume of distribution, 38, 39*t*–41*t*, 1027  
 defined, 38  
 in drug concentration measurements, 50  
 in the elderly, 1052, 1052*t*  
 in infants and children, 1044–1045  
 pharmacokinetic mechanisms of, 1149  
 as pharmacokinetic variable, 48
- Vomiting  
 nausea and. *See* Nausea and vomiting  
 prevention of  
 domperidone in, 1092  
 metoclopramide in, 1092
- Voriconazole, 853*f*, 858  
 for systemic infections, **855**
- Vorinostat, 1077  
 dermatologic uses of, 1078*t*
- Vytorin  
 preparations available, 633
- VZV infection. *See* Varicella-zoster virus  
 (VZV) infection
- W**
- Warfarin, **608–611**, 609*f*, 617  
 fetal effects of, 1043*t*  
 ionization constants of, 11*t*  
 during lactation, 1048*t*  
 pharmacokinetics of, 40*t*,  
 608–609, 609*f*
- Water  
 superoxidized  
 as antiseptic/disinfectant, **896**
- Water balance. *See also* Diuretics  
 drugs altering, **172–174**, 174*f*
- Water conjugation, 60*t*
- Water excretion  
 agents altering, **263–265**. *See also  
 specific diuretics*
- Wearing-off reactions, 487
- Weight  
 as factor in drug dosage in infants and  
 children, 1047, 1049, 1049*t*
- Weight loss aids  
 ingredients in, 1122*t*
- WelChol, 633. *See also* Colesevelam
- Wellbutrin, 539. *See also* Bupropion
- Wernicke-Korsakoff syndrome, 393
- Westhroid, 695. *See also* Thyroid desiccated
- White thrombi, 601–602
- Whole bowel irrigation  
 for iron poisoning, 586
- Wilson's disease, 496–497
- Withdrawal syndrome, 549, 565
- Wound(s)  
 classification criteria for  
 of NRC, 911  
*Wuchereria bancrofti*  
 diethylcarbamazine citrate for, 940
- Wyntensin, 189. *See also* Guanabenz
- X**
- X-linked agammaglobulinemia, 984–985
- X-linked hypophosphatemia, **783**
- Xalatan, 328. *See also* Latanoprost
- Xanax, 387. *See also* Alprazolam
- Xanthine, 345*f*
- Xenazine, 499. *See also* Tetrabenazine
- Xenobiotics, 4, 53
- Xenopex, 355. *See also* Levalbuterol
- Xibrom, 655. *See also* Bromfenac
- Xifaxan, 848. *See also* Rifaximin
- Xolair, 355, 999. *See also* Omalizumab
- Xylocaine, 249, 463. *See also* Lidocaine
- Xylometazoline, **141**, 148
- Xyzal, 292. *See also* Levocetirizine
- Y**
- Yellow fever vaccine, 1166*t*
- Yodoxin, 935. *See also* Iodoquinol
- Yohimbine, 155
- Z**
- Zaditor, 292. *See also* Ketotifen
- Zafirlukast, 328, 349, 355
- Zalcitabine, 863*f*, 872*t*, **875**, 889
- Zaleplon  
 biotransformation of, 374, 375*f*, 378,  
 387  
 pharmacokinetic properties of, 377*t*
- Zanaflex, 148, 481. *See also* Tizanidine
- Zanamivir  
 for influenza, **886–887**
- Zantac, 1111. *See also* Ranitidine
- Zarontin, 427. *See also* Ethosuximide
- Zaroxolyn, 270. *See also* Metolazone

- Zebeta, 167, 189, 225. *See also* Bisoprolol
- Zectran  
toxicity rating for, 1008*t*
- Zefazone, 807. *See also* Cefmetazole
- Zegerid, 1111. *See also* Omeprazole
- Zelnorm, 1112. *See also* Tegaserod
- Zemplar, 786. *See also* Paricalcitol
- Zemuron, 481. *See also* Rocuronium
- Zenapax, 999. *See also* Daclizumab
- Zenpep, 1111. *See also* Pancrelipase
- Zephiran, 898. *See also* Benzalkonium
- Zestril, 190, 225. *See also* Lisinopril
- Zetia, 633. *See also* Ezetimibe
- Zevalin, 999. *See also* Ibritumomab tiuxetan
- Ziconotide, 562  
for chronic pain, 550, 562
- Zidovudine, 863*f*, 872*t*, **875–876**,  
889  
pharmacokinetic parameters for, 40*t*  
during pregnancy, 876, 876*t*
- Ziegler's enzyme, 65
- Zileuton, 349, 328, 355
- Zinacef, 807. *See also* Cefuroxime
- Zinc  
for Wilson's disease, 497
- Ziprasidone, 504*f*, 519  
advantages and disadvantages of,  
509*t*  
dosage of, 510*t*
- Zithromax, 819. *See also*  
Azithromycin
- Zocor, 633. *See also* Simvastatin
- Zofran, 1111. *See also* Ondansetron
- Zoladex, 678. *See also* Goserelin acetate
- Zoledronate, zoledronic acid  
for osteoporosis,  
775, 783
- Zolmitriptan  
pharmacokinetics of, 286*t*
- Zolof, 539. *See also* Sertraline
- Zolpidem, 374  
biotransformation of, 377–378  
pharmacokinetic properties of,  
377*t*
- Zometa, 786. *See also* Zoledronic acid
- Zomig, 292. *See also* Zolmitriptan
- Zonegran, 427. *See also* Zonisamide
- Zonisamide  
for seizures, **417**, 427
- Zoster vaccine, 1166*t*
- Zosyn, 807. *See also* Piperacillin  
and tazobactam  
sodium
- Zovirax, 888. *See also* Acyclovir
- Zyflo, 328, 355. *See also* Zileuton
- Zyloprim, 656. *See also* Allopurinol
- Zymine, 292. *See also* Triprolidine
- Zyprexa, 519. *See also* Olanzapine
- Zyrtec, 292. *See also* Cetirizine
- Zyvox, 819. *See also* Linezolid